var title_f20_3_20528="Prenatal ultrasound of unilateral MCDK";
var content_f20_3_20528=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F80361&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F80361&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prenatal ultrasound of unilateral multicystic dysplastic kidney",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 416px; height: 282px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Tulin Ozcan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_3_20528=[""].join("\n");
var outline_f20_3_20528=null;
var title_f20_3_20529="Patient information: Chorioretinitis (The Basics)";
var content_f20_3_20529=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/82974\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29105\">",
"         Parts of the eye",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?26/13/26833\">",
"         Patient information: Uveitis (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Chorioretinitis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/chorioretinitis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H7004196\">",
"      <span class=\"h1\">",
"       What is chorioretinitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Chorioretinitis is an eye condition that can cause dark spots in your vision or vision loss. It involves the back of the eye. In chorioretinitis, structures in the back of the eye called the &ldquo;choroid&rdquo; and &ldquo;retina&rdquo; get inflamed (",
"      <a class=\"graphic graphic_figure graphicRef70420 \" href=\"UTD.htm?28/27/29105\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      Chorioretinitis can be caused by different things. Often, it&rsquo;s caused by an infection.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7004211\">",
"      <span class=\"h1\">",
"       What are the symptoms of chorioretinitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Chorioretinitis is usually painless. Common symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Seeing dark spots (called &ldquo;floaters&rdquo;) in your vision",
"       </li>",
"       <li>",
"        Vision loss",
"       </li>",
"       <li>",
"        Poor vision at night",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Not everyone with these symptoms has chorioretinitis. Different eye conditions can also cause these symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7004243\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. Your doctor or nurse will ask about your symptoms and other medical problems. You will also have a detailed eye exam. This will probably be done by an eye specialist. During the exam, he or she will use a magnifying tool to look in the back of your eye.",
"     </p>",
"     <p>",
"      Your doctor might also do tests to check for an infection that could be causing your chorioretinitis. These tests can include blood tests or a chest X-ray.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7004258\">",
"      <span class=\"h1\">",
"       How is chorioretinitis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Chorioretinitis is usually treated by an eye specialist.",
"     </p>",
"     <p>",
"      Treatment depends, in part, on what&rsquo;s causing your chorioretinitis. If an infection or other medical condition is causing your chorioretinitis, your doctor will treat that infection or condition.",
"     </p>",
"     <p>",
"      Other treatment depends on how mild or severe the inflammation is. If the inflammation is mild, your doctor might not treat it. But he or she will monitor your condition to make sure it doesn&rsquo;t get worse.",
"     </p>",
"     <p>",
"      If the inflammation is more serious, your doctor will treat it. Treatment might involve getting a shot of a medicine called a steroid into your eye or around your eye. Steroids help with inflammation. These steroids are different from the ones athletes take to build muscle.",
"     </p>",
"     <p>",
"      If the steroid shot doesn&rsquo;t help enough, your doctor might prescribe steroid pills or other medicines.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7004273\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/13/26833?source=see_link\">",
"       Patient information: Uveitis (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?20/3/20529?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 82974 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-125.39.66.146-C1CFDD43C6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_3_20529=[""].join("\n");
var outline_f20_3_20529=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7004196\">",
"      What is chorioretinitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7004211\">",
"      What are the symptoms of chorioretinitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7004243\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7004258\">",
"      How is chorioretinitis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7004273\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/82974\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29105\">",
"      Parts of the eye",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/13/26833?source=related_link\">",
"      Patient information: Uveitis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_3_20530="Patient information: Travelersâ€™ diarrhea (The Basics)";
var content_f20_3_20530=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?9/5/9299\">",
"         Patient information: Diarrhea in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?26/42/27298\">",
"         Patient information: Staying healthy when you travel (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?35/29/36308\">",
"         Patient information: Acute diarrhea in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?28/30/29156\">",
"         Patient information: Food poisoning (food-borne illness) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?16/2/16421\">",
"         Patient information: General travel advice (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Travelers&rsquo; diarrhea (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/travelers-diarrhea-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H14951448\">",
"      <span class=\"h1\">",
"       What is travelers&rsquo; diarrhea?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Travelers&rsquo; diarrhea is runny or watery bowel movements in people who are traveling. It is usually caused by bacteria but can also be caused by a virus or parasite. &nbsp;",
"     </p>",
"     <p>",
"      You are more likely to get travelers&rsquo; diarrhea if you travel in: &nbsp;",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Asia (except Singapore and Japan)",
"       </li>",
"       <li>",
"        Africa",
"       </li>",
"       <li>",
"        South America, Central America, and Mexico",
"       </li>",
"       <li>",
"        Countries around the Mediterranean Sea, including Israel",
"       </li>",
"       <li>",
"        Caribbean islands",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14951463\">",
"      <span class=\"h1\">",
"       What are the symptoms of travelers&rsquo; diarrhea?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main symptom is runny or watery bowel movements about 4 to 14 days after arriving. Other symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Feeling sick",
"       </li>",
"       <li>",
"        Loss of appetite",
"       </li>",
"       <li>",
"        Cramps in the lower belly",
"       </li>",
"       <li>",
"        Nausea and vomiting",
"       </li>",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Gas and bloating &ndash; Feeling like the belly is full, with pain in the middle or top of the belly.",
"       </li>",
"       <li>",
"        Blood in the bowel movements",
"       </li>",
"       <li>",
"        Feeling as though you need have a bowel movement even if you just did, or like you need to get to the toilet in a hurry",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Travelers&rsquo; diarrhea usually lasts 1 to 5 days, but some people are sick for a week or longer. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14951478\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your doctor or nurse gave you antibiotics to take for diarrhea, you can take them instead of going to a doctor or nurse in another country. But you might need to see a doctor or nurse if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        You are sick for 10 to 14 days or longer.",
"       </li>",
"       <li>",
"        You have a fever of 102&ordm;F (40&ordm;C) or higher.",
"       </li>",
"       <li>",
"        You have severe belly pain.",
"       </li>",
"       <li>",
"        You have bloody diarrhea or you are vomiting.",
"       </li>",
"       <li>",
"        The antibiotics you took did not help.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14951493\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probably not. If you see a doctor or nurse, he or she will ask where you traveled and what you did. If the doctor thinks a parasite might be causing the diarrhea, he or she might ask for a bowel movement sample. Testing it can show if you have a parasite. But this is not usually needed.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14951510\">",
"      <span class=\"h1\">",
"       How is travelers&rsquo; diarrhea treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most important treatment is getting enough fluid. That&rsquo;s because diarrhea can cause the body to lose fluid. Adults with mild diarrhea can drink lots of fluids with water, salt, and sugar. Soup broth and water mixed with juice are good choices. If you are drinking enough, your urine will look light yellow or almost clear.",
"     </p>",
"     <p>",
"      If you have diarrhea more than 4 times a day, you can drink an &ldquo;oral rehydration solution.&rdquo; You can buy this in a packet at the pharmacy. Mix it with bottled or boiled drinking water.",
"     </p>",
"     <p>",
"      Other treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Antibiotics &ndash; These medicines fight infections.",
"       </li>",
"       <li>",
"        Medicines that ease diarrhea, such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?40/33/41492?source=see_link\">",
"         loperamide",
"        </a>",
"        (brand name: Imodium&reg;)",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?11/39/11892?source=see_link\">",
"         diphenoxylate",
"        </a>",
"        &nbsp;(sample brand name: Lomotil&reg;), or bismuth&nbsp;subsalicylate (sample brand names: Pepto-Bismol&reg; or Kaopectate&reg;) &ndash; These medicines can help, but they can also cause other health problems. Bismuth salicylate might not be safe for pregnant women or people who take",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?6/12/6342?source=see_link\">",
"         aspirin",
"        </a>",
"        for another condition. You should only take loperamide or diphenoxylate if you are also taking antibiotics. &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14951525\">",
"      <span class=\"h1\">",
"       Can travelers&rsquo; diarrhea be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can reduce your chances of getting travelers&rsquo; diarrhea by being careful about what and how you eat and drink. While you are traveling: &nbsp; &nbsp;",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Do not drink tap water. Drink bottled carbonated drinks, beer, wine, or hot tea or coffee instead. Brush your teeth with bottled water.",
"       </li>",
"       <li>",
"        Do not use ice in drinks. Ice is usually made from tap water.",
"       </li>",
"       <li>",
"        Do not eat food from carts or stands in the street.",
"       </li>",
"       <li>",
"        Do not eat sauces set out on restaurant tables. These include salsa and ketchup.",
"       </li>",
"       <li>",
"        Do not eat fresh foods at room temperature. These include guacamole, fruit or chicken salads, and buffet food on a steam table.",
"       </li>",
"       <li>",
"        Do not eat foods or drinks made with unpasteurized milk.",
"       </li>",
"       <li>",
"        Ask for drinks in the bottle, without ice. If you drink from a glass, use a straw.",
"       </li>",
"       <li>",
"        Do not eat fruits unless they have a peel and you have peeled them yourself.",
"       </li>",
"       <li>",
"        Make sure meat and seafood are well done and eggs have a firm yolk.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you can&rsquo;t find bottled water or soft drinks, you can make your drinking water safe by:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Boiling it for 3 minutes (let it cool before drinking)",
"       </li>",
"       <li>",
"        Adding 5 drops of tincture of iodine to 4 cups of water and waiting 30 minutes - Tincture of iodine is a liquid you can buy at most pharmacies or camping goods stores.",
"       </li>",
"       <li>",
"        Using a water treatment filter from a camping or sports store",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Wash your hands after going to the bathroom, changing diapers, blowing your nose, touching animals, or taking out the trash.",
"     </p>",
"     <p>",
"      If you have a serious health condition, travelers&rsquo; diarrhea could cause you to lose too much water. This can be dangerous and even cause death. If you are going on a trip, talk to your doctor or nurse ahead of time. He or she might give you antibiotics to take while you are traveling.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14951540\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/42/27298?source=see_link\">",
"       Patient information: Staying healthy when you travel (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/5/9299?source=see_link\">",
"       Patient information: Diarrhea in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/29/36308?source=see_link\">",
"       Patient information: Acute diarrhea in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/30/29156?source=see_link\">",
"       Patient information: Food poisoning (food-borne illness) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?16/2/16421?source=see_link\">",
"       Patient information: General travel advice (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?20/3/20530?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83761 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-F1BE05E961-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_3_20530=[""].join("\n");
var outline_f20_3_20530=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14951448\">",
"      What is travelers&rsquo; diarrhea?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14951463\">",
"      What are the symptoms of travelers&rsquo; diarrhea?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14951478\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14951493\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14951510\">",
"      How is travelers&rsquo; diarrhea treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14951525\">",
"      Can travelers&rsquo; diarrhea be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14951540\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/29/36308?source=related_link\">",
"      Patient information: Acute diarrhea in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/5/9299?source=related_link\">",
"      Patient information: Diarrhea in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/30/29156?source=related_link\">",
"      Patient information: Food poisoning (food-borne illness) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/2/16421?source=related_link\">",
"      Patient information: General travel advice (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/42/27298?source=related_link\">",
"      Patient information: Staying healthy when you travel (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_3_20531="Rabies immune globulin (human): Patient drug information";
var content_f20_3_20531=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Rabies immune globulin (human): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/22/6500?source=see_link\">",
"     see \"Rabies immune globulin (human): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/29/41427?source=see_link\">",
"     see \"Rabies immune globulin (human): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F216777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      HyperRAB&reg; S/D;",
"     </li>",
"     <li>",
"      Imogam&reg; Rabies-HT",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F216778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      HyperRAB&reg; S/D;",
"     </li>",
"     <li>",
"      Imogam&reg; Rabies Pasteurized",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691548",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop rabies infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702845",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to rabies immune globulin, thimerosal, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697275",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have IgA deficiency, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Short-term pain after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Allergic side effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11848 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-C3286EAA3D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_3_20531=[""].join("\n");
var outline_f20_3_20531=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216777\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216778\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013089\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013088\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013093\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013094\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013096\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013091\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013097\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013098\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/22/6500?source=related_link\">",
"      Rabies immune globulin (human): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/29/41427?source=related_link\">",
"      Rabies immune globulin (human): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_3_20532="Chloramphenicol: Patient drug information";
var content_f20_3_20532=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Chloramphenicol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     see \"Chloramphenicol: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/35/4664?source=see_link\">",
"     see \"Chloramphenicol: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F149436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Chloromycetin&reg;;",
"     </li>",
"     <li>",
"      Chloromycetin&reg; Succinate;",
"     </li>",
"     <li>",
"      Diochloram&reg;;",
"     </li>",
"     <li>",
"      Pentamycetin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10015339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700208",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chloramphenicol may cause blood problems. This may cause more chance of getting an infection, bleeding problems, or slow healing. Be careful when using toothbrushes, floss, or dental picks; bleeding from your gums may happen. Your doctor may need to check your blood work while you are taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691487",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat bacterial infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701764",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to chloramphenicol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703427",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Bone marrow disease, liver disease, low blood cell count, or poor kidney function.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703739",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have G6PD deficiency.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697875",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696430",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A small number of people may have low blood pressure or more acid in the blood.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10015344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10015349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11324 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-219.243.220.100-85C35604D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_3_20532=[""].join("\n");
var outline_f20_3_20532=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149436\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015339\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015341\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015340\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015345\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015346\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015348\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015343\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015344\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015349\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015350\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=related_link\">",
"      Chloramphenicol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/35/4664?source=related_link\">",
"      Chloramphenicol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_3_20533="Ertapenem: Pediatric drug information";
var content_f20_3_20533=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ertapenem: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?40/36/41542?source=see_link\">",
"    see \"Ertapenem: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?9/41/9876?source=see_link\">",
"    see \"Ertapenem: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F166533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      INVanz&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F166534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Invanz&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1047189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Carbapenem",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1047183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/36/41542?source=see_link\">",
"      see \"Ertapenem: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.M., I.V. (",
"     <b>",
"      Note:",
"     </b>",
"     I.V. therapy may be administered for up to 14 days; I.M. for up to 7 days):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 3 months to 12 years: 15 mg/kg/dose every 12 hours; maximum dose: 1 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adolescents and Adults: Treatment guidelines: 1 g once daily. Total antimicrobial treatment duration for pediatric and adult patients:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Complicated intra-abdominal infections: 5-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Complicated skin and skin structure infections (including diabetic foot infections): 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Community-acquired pneumonia: 10-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Complicated UTI/pyelonephritis: 10-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acute pelvic infections: 3-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: Prophylaxis of surgical site infection following colorectal surgery: I.V.: Single 1 g dose administered 1 hour prior to surgical procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Adults: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Decrease dose 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemodialysis: Adults: If daily dose is given within 6 hours prior to hemodialysis, a supplementary dose of 150 mg should be given following hemodialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     Insufficient data exist to recommend specific dosing adjustment in hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F166510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     INVanz&reg;: 1 g [contains sodium ~137 mg (~6 mEq)/g]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F166496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1047192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M. injection: Reconstitute 1 g vial with 3.2 mL of 1% lidocaine immediately prior to administration with a resultant concentration of 312.5 mg/mL. Shake vial well. Administer I.M. injection deep into a large muscle mass such as the gluteus maximus or lateral part of the thigh.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V. intermittent infusion: Reconstitute 1 g vial with 10 mL SWI, NS, or bacteriostatic water for injection with a resultant concentration of 100 mg/mL. Further dilute dose with NS to a final maximum concentration of 20 mg/mL and administer over 30 minutes. Do not coinfuse with other medications.",
"     <b>",
"      Do not infuse with dextrose-containing solutions.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F166563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS; per manufacturer do",
"     <b>",
"      not",
"     </b>",
"     mix with other medications or use diluents containing dextrose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Daptomycin, heparin, hetastarch in NS, potassium chloride, telavancin, tigecycline.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Anidulafungin, caspofungin.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1047186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store lyophilized powder at room temperature not to exceed 25&deg;C (77&deg;F). Reconstituted I.V. ertapenem solution further diluted in NS or following activation of ertapenem in ADD-Vantage&reg; vials with ADD-Vantage&reg; diluent: Stable for 6 hours at room temperature or 24 hours if refrigerated and used within 4 hours after removal from refrigeration; do not freeze. Incompatible with dextrose-containing solutions. Reconstituted I.M. ertapenem solution should be used within 1 hour after preparation.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1047191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of moderate to severe, complicated intra-abdominal infections, acute pelvic infections, complicated skin and skin structure infections (including diabetic foot infections without osteomyelitis), community-acquired pneumonia, and complicated urinary tract infections caused by susceptible",
"     <i>",
"      S. aureus",
"     </i>",
"     (methicillin susceptible strains only),",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     (penicillin-sensitive strains),",
"     <i>",
"      S. agalactiae",
"     </i>",
"     ,",
"     <i>",
"      S. pyogenes",
"     </i>",
"     ,",
"     <i>",
"      E. coli",
"     </i>",
"     ,",
"     <i>",
"      B. fragilis",
"     </i>",
"     ,",
"     <i>",
"      C. clostridioforme",
"     </i>",
"     ,",
"     <i>",
"      Peptostreptococcus",
"     </i>",
"     species,",
"     <i>",
"      H. influenzae",
"     </i>",
"     (beta-lactamase negative strains),",
"     <i>",
"      K. pneumoniae",
"     </i>",
"     , and",
"     <i>",
"      M. catarrhalis",
"     </i>",
"     (FDA approved in ages &ge;3 months and adults); prophylaxis of surgical site infection following colorectal surgery (FDA approved in adults); has also been used for documented or suspected infection due to susceptible organisms for outpatient parenteral therapy",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F166564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ertapenem may be confused with doripenem, imipenem, meropenem",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       INVanz&reg; may be confused with AVINza&reg;, I.V. vancomycin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F166562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain, edema, hyper-/hypotension, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Altered mental status (ie, agitation, confusion, disorientation, mental acuity decreased, somnolence, stupor); anxiety, dizziness, fatigue, fever, headache, hypothermia (infants, children, and adolescents), insomnia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Diaper rash (infants and children), erythema, genital rash (infants, children, and adolescents), pruritus, rash, skin lesions (infants, children, and adolescents)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia, hyper-/hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, acid regurgitation, appetite decreased (infants, children, and adolescents), constipation, diarrhea, dyspepsia, nausea, oral candidiasis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urine RBCs/WBCs increased, vaginitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Eosinophils increased, hematocrit/hemoglobin decreased, leukopenia, neutrophils decreased, prothrombin time increased, thrombocytopenia, thrombocytosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Albumin decreased, alkaline phosphatase increased, bilirubin (total) increased, hepatic enzyme increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Extravasation, infused vein complications, phlebitis/thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (infants, children, and adolescents), leg pain, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Otitis media (infants, children, and adolescents)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Serum creatinine increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, dyspnea, nasopharyngitis (infants, children, and adolescents), pharyngitis, rales/rhonchi, respiratory distress, rhinitis (infants, children, and adolescents), rhinorrhea (infants, children, and adolescents), upper respiratory tract infection (infants, children, and adolescents), wheezing (infants, children, and adolescents)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Anaphylactoid reactions, anaphylaxis, arrhythmia, asthma, asystole, atrial fibrillation, bradycardia, bronchoconstriction,",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea, cardiac arrest, cholelithiasis, delirium, DRESS syndrome, gastrointestinal hemorrhage, gout, heart failure, heart murmur, hemoptysis, hypoxemia, ileus, jaundice, oliguria/anuria, pancreatitis, pleural effusion, renal insufficiency, seizure, septicemia, septic shock, subdural hemorrhage, ventricular tachycardia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1047195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ertapenem, carbapenems, or any component; patients who have had an anaphylactoid reaction to beta-lactams; hypersensitivity to local anesthetics of the amide type for patients receiving I.M. injections",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1047182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with CNS disorders, history of seizures and/or compromised renal function; dosage adjustment required in patients with renal impairment",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1047181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serious and occasionally fatal hypersensitivity reactions have been reported in patients receiving beta-lactam therapy; careful inquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins, or other beta-lactams before initiating ertapenem. Seizures have been reported with ertapenem therapy. Valproic acid (VPA) serum concentrations may be significantly decreased by concurrent carbapenem use leading to breakthrough seizures; VPA dosage adjustment may not adequately compensate for this interaction; concurrent use with valproic acid/divalproex sodium not recommended. Pseudomembranous colitis has been reported in patients receiving ertapenem; prolonged use may result in superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD); CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F166504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: Carbapenems may decrease the serum concentration of Divalproex.  Management: Concurrent use of carbapenem antibiotics with divalproex is generally not recommended.  Alternative antimicrobial agents should be considered, but if a concurrent carbapenem is necessary, consider additional anti-seizure medication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Ertapenem.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Ertapenem may increase the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Carbapenems may decrease the serum concentration of Valproic Acid.  Management: Concurrent use of carbapenem antibiotics with valproic acid is generally not recommended.  Alternative antimicrobial agents should be considered, but if a concurrent carbapenem is necessary, consider additional anti-seizure medication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F166506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F166516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal reproduction studies. Ertapenem is approved for the treatment of postpartum endomyometritis, septic abortion, and postsurgical infections. Information related to use during pregnancy has not been located.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1047188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic renal, hepatic, and hematologic function tests; neurological assessment",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1047180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits cell wall synthesis by binding to penicillin-binding proteins",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1047194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Excreted in breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 3 months to 12 years: &sim;0.2 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 13-17 years: 0.16 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 0.12 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 85% to 95% (concentration-dependent plasma protein binding)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Renal metabolism to an open-ring metabolite",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: I.M.: 90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 3 months to 12 years: 2.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 13-17 years: 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: I.M.: 2.3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 80% of a dose is excreted in the urine (38% as unchanged drug) and 10% in feces; undergoes glomerular filtration and tubular secretion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: 30% removed by hemodialysis",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F4028693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/41/9876?source=see_link\">",
"      see \"Ertapenem: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inform physician if you are taking valproic acid or divalproex sodium since an alternative treatment may be needed; inform physician of prolonged diarrhea, abdominal pain, or vomiting. Report any chest pain, respiratory difficulty, dizziness, or confusion.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1047196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sodium content 1 g: 6 mEq",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Arguedas A, Cespedes J, Botet FA, et al, \"Safety and Tolerability of Ertapenem Versus Ceftriaxone in a Double-Blind Study Performed in Children With Complicated Urinary Tract Infection, Community-Acquired Pneumonia or Skin and Soft-Tissue Infection,\"",
"      <i>",
"       Int J Antimicrob Agents",
"      </i>",
"      , 2009, 33(2):163-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/3/20533/abstract-text/18945594/pubmed\" id=\"18945594\" target=\"_blank\">",
"        18945594",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Curran M, Simpson D, and Perry C, &ldquo;Ertapenem: A Review of Its Use in the Management of Bacterial Infections,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 2003, 63(17):1855-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/3/20533/abstract-text/12921489/pubmed\" id=\"12921489\" target=\"_blank\">",
"        12921489",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Keating GM and Perry CM, \"Ertapenem: A Review of Its Use in the Treatment of Bacterial Infections,\"  Drugs, 2005, 65(15):2151-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/3/20533/abstract-text/16225376 /pubmed\" id=\"16225376 \" target=\"_blank\">",
"        16225376",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nix DE, Majumdar AK, and DiNubile MJ, &ldquo;Pharmacokinetics and Pharmacodynamics of Ertapenem: An Overview for Clinicians,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 2004, 53(Suppl 2):ii23-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/3/20533/abstract-text/15150180/pubmed\" id=\"15150180\" target=\"_blank\">",
"        15150180",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12903 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-D795AC79FE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_3_20533=[""].join("\n");
var outline_f20_3_20533=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166533\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166534\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047189\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047183\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166510\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166496\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047192\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166563\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047186\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047191\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166564\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166562\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047195\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047182\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047181\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299280\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166504\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166506\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166516\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047188\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047180\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047194\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4028693\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047196\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12903\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12903|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/36/41542?source=related_link\">",
"      Ertapenem: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/41/9876?source=related_link\">",
"      Ertapenem: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_3_20534="HLA-B27 peptide presentation";
var content_f20_3_20534=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F68628&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F68628&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    HLA-B27 peptide presentation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 566px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Top panel (A): The three-dimensional structure of the alpha1 and alpha 2 domains of HLA-B*2705. Numbers identify polymorphic residues among B27 subtypes. A peptide (green) intimately interacts with the groove through hydrogen bonds. Each of six pockets (A-F) can bind the side chain of an individual amino acid. Lower panel: (B) Schematic diagram showing binding of antigenic peptides to HLA-B27 and recognition by the T-cell receptor. The side-chains of peptide \"anchor\" residues P2, P3 and P9 (C-terminal) are bound in pockets. The side-chains of P1, P4 and P8, which extend out of the peptide-binding groove, are critical for T-cell recognition.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     (A) Reproduced with permission from: Lopez-Larrea, C, Gonzalez, S, Martinez-Borra, J. The role of HLA-B27 polymorphism and molecular mimicry in spondylarthropathy. Molecular Medicine Today 1998; 4:540. Copyright &copy; 1998 Elsevier Science.",
"     <br>",
"      (B) Reproduced with permission from: Bowness, P, Zaccai, N, Bird, J, Jones, FY. HLA-B27 and disease pathogenesis: new structural and functional insights. Exp Rev Mol Med. Cambridge University Press 1999. Copyright &copy; 1999 Cambridge University Press.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_3_20534=[""].join("\n");
var outline_f20_3_20534=null;
var title_f20_3_20535="Lidocaine (topical): Drug information";
var content_f20_3_20535=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lidocaine (topical): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?28/46/29413?source=see_link\">",
"    see \"Lidocaine (topical): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/50/33574?source=see_link\">",
"    see \"Lidocaine (topical): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8768584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      AneCream&reg; [OTC];",
"     </li>",
"     <li>",
"      Anestafoam&trade; [OTC] [DSC];",
"     </li>",
"     <li>",
"      Band-Aid&reg; Hurt Free&trade; Antiseptic Wash [OTC];",
"     </li>",
"     <li>",
"      Burn Jel Plus [OTC];",
"     </li>",
"     <li>",
"      Burn Jel&reg; [OTC];",
"     </li>",
"     <li>",
"      L-M-X&reg; 4 [OTC];",
"     </li>",
"     <li>",
"      L-M-X&reg; 5 [OTC];",
"     </li>",
"     <li>",
"      LidaMantle&reg; [DSC];",
"     </li>",
"     <li>",
"      Lidoderm&reg;;",
"     </li>",
"     <li>",
"      LidoPatch&trade; [OTC];",
"     </li>",
"     <li>",
"      LTA&reg; 360;",
"     </li>",
"     <li>",
"      Premjact&reg;;",
"     </li>",
"     <li>",
"      RectiCare&trade; [OTC];",
"     </li>",
"     <li>",
"      Regenecare&reg;;",
"     </li>",
"     <li>",
"      Regenecare&reg; HA [OTC];",
"     </li>",
"     <li>",
"      Solarcaine&reg; cool aloe Burn Relief [OTC];",
"     </li>",
"     <li>",
"      Topicaine&reg; [OTC];",
"     </li>",
"     <li>",
"      Unburn&reg; [OTC];",
"     </li>",
"     <li>",
"      Xylocaine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8768585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Betacaine&reg;;",
"     </li>",
"     <li>",
"      Lidodan&trade;;",
"     </li>",
"     <li>",
"      Lidoderm&reg;;",
"     </li>",
"     <li>",
"      Maxilene&reg;;",
"     </li>",
"     <li>",
"      Xylocaine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8768604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic, Topical;",
"     </li>",
"     <li>",
"      Local Anesthetic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8768792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;text-align:justify;display:inline\">",
"     <b>",
"      Anesthesia, topical:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Cream:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LidaMantle&reg;: Skin irritation: Apply a thin film to affected area 2-3 times/day as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     L-M-X&reg; 4: Skin irritation: Apply up to 3-4 times daily to intact skin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     L-M-X&reg; 5: Relief of anorectal pain and itching: Apply to affected area up to 6 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Gel, ointment:",
"     </i>",
"     Apply to affected area &le;4 times/day as needed (maximum dose: 4.5 mg/kg, not to exceed 300 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Topical solution:",
"     </i>",
"     Apply 1-5 mL (40-200 mg) to affected area",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Jelly:",
"     </i>",
"     Maximum dose: 30 mL (600 mg) in any 12-hour period:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anesthesia of male urethra: 5-30 mL (100-600 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anesthesia of female urethra: 3-5 mL (60-100 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Oral topical solution (viscous):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anesthesia of the mouth: 15 mL swished in the mouth and spit out no more frequently than every 3 hours (maximum: 8 doses per 24-hour period)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anesthesia of the pharynx: 15 mL gargled no more frequently than every 3 hours (maximum: 8 doses per 24-hour period); may be swallowed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Patch:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lidoderm&reg;: Postherpetic neuralgia: Apply patch to most painful area. Up to 3 patches may be applied in a single application. Patch(es) may remain in place for up to 12 hours in any 24-hour period.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LidoPatch&trade;: Pain (localized): Apply patch to painful area. Patch may remain in place for up to 12 hours in any 24-hour period. No more than 1 patch should be used in a 24-hour period.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F8768791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/50/33574?source=see_link\">",
"      see \"Lidocaine (topical): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Anesthesia, topical:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Cream:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LidaMantle&reg;: Skin irritation: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     L-M-X&reg; 4: Skin irritation: Children &ge;2 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     L-M-X&reg; 5: Relief of anorectal pain and itching: Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Jelly:",
"     </i>",
"     Children: Dose varies with age and weight (maximum dose: 4.5 mg/kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Oral topical solution (viscous):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children &lt;3 years: 1.25 mL applied to area with a cotton-tipped applicator no more frequently than every 3 hours (maximum: 4 doses per 12-hour period)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;3 years: Should not exceed 4.5 mg/kg/dose (or 300 mg/dose); swished in the mouth and spit out no more frequently than every 3 hours (maximum: 4 doses per 12-hour period)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8768793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8768875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, foam, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anestafoam&trade;: 4% (30 g [DSC]) [contains benzalkonium chloride, benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, spray, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Solarcaine&reg; cool aloe Burn Relief: 0.5% (127 g) [contains aloe, vitamin E]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, rectal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     L-M-X&reg; 5: 5% (15 g, 30 g) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AneCream&reg;: 4% (5 g, 15 g, 30 g) [contains benzyl alcohol, soybean lecithin]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     L-M-X&reg; 4: 4% (5 g, 15 g, 30 g) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     RectiCare&trade;: 5% (30 g) [contains benzyl alcohol, natural rubber/natural latex in packaging, propylene glycol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as hydrochloride: 0.5% (0.9 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LidaMantle&reg;: 3% (85 g [DSC])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Topicaine&reg;: 4% (10 g, 30 g, 113 g); 5% (10 g, 30 g, 113 g) [contains aloe, benzyl alcohol, ethanol 35%, jojoba]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Burn Jel Plus: 2.5% (118 mL) [contains vitamin E]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Burn Jel&reg;: 2% (59 mL, 118 mL); 2% (3.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Regenecare&reg;: 2% (14 g, 85 g) [contains aloe; contains calcium alginate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Regenecare&reg; HA: 2% (85 g) [contains aloe; contains hyaluronic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Solarcaine&reg; cool aloe Burn Relief: 0.5% (113 g, 226 g) [contains aloe, isopropyl alcohol, menthol, tartrazine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Unburn&reg;: 2.5% (59 mL) [contains vitamin E]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Jelly, topical, as hydrochloride: 2% (5 mL, 30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Jelly, topical, as hydrochloride [preservative free]: 2% (5 mL, 10 mL, 20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical: 5% (35.4 g, 50 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patch, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lidoderm&reg;: 5% (30s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LidoPatch&trade;: 3.99% (3s) [contains menthol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical [spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Premjact&reg;: 9.6% (13 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical, as hydrochloride: 4% [40 mg/mL] (50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Band-Aid&reg; Hurt Free&trade; Antiseptic Wash: 2% [20 mg/mL] (177 mL) [contains aloe, benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LTA&reg; 360: 4% [40 mg/mL] (4 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Xylocaine&reg;: 4% [40 mg/mL] (50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical, as hydrochloride [preservative free]: 4% [40 mg/mL] (4 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, viscous, oral topical, as hydrochloride: 2% [20 mg/mL] (20 mL, 100 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8768595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Hydrochloride cream, jelly, ointment, solution",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8768819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel (Topicaine&reg;): Apply a moderately thick layer to affected area (~",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      8",
"     </sub>",
"     inch thick). Allow time for numbness to develop (~20-60 minutes after application). When used prior to laser surgery, avoid mucous membranes and remove prior to laser treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral topical solution (viscous): Have patient swish medication around mouth and then spit it out; for pharyngeal anesthesia, patient should gargle and may swallow medication.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patch:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lidoderm&reg;: Apply to most painful area of skin immediately after removal from protective envelope. May be cut (with scissors, prior to removal of release liner) to appropriate size. Clothing may be worn over application area. After removal from skin, fold used patches so the adhesive side sticks to itself; avoid contact with eyes. Remove immediately if burning sensation occurs. Wash hands after application. Avoid exposing application site to external heat sources (eg, heating pad, electric blanket, heat lamp, hot tub).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LidoPatch&trade;: Remove protective film and apply to painful area. Avoid contact with eyes or mucous membranes. Wash hands after application. Avoid exposing application site to external heat sources (eg, heating pad, electric blanket, heat lamp, hot tub).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8768625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rectal: Temporary relief of pain and itching due to anorectal disorders",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical: Local anesthetic for oral mucous membrane; use in laser/cosmetic surgeries; minor burns, cuts, and abrasions of the skin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral topical solution (viscous): Topical anesthesia of irritated oral mucous membranes and pharyngeal tissue",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patch (Lidoderm&reg;): Relief of allodynia (painful hypersensitivity) and chronic pain in postherpetic neuralgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patch (LidoPatch&trade;): Temporary relief of localized pain",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8768637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Frequency not defined.",
"     <b>",
"      Note:",
"     </b>",
"     Adverse effects vary with formulation and extent of systemic absorption; children may be at increased risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cyanosis, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, confusion, dizziness, lethargy, lightheadedness, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioedema, bruising (topical patch), contact dermatitis, depigmentation (topical patch), edema of the skin, itching, petechia (topical patch), pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Methemoglobinemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Irritation (topical patch)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Pain exacerbation (topical patch), paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Hypoxia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8768633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to lidocaine or any component of the formulation; hypersensitivity to another local anesthetic of the amide type",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8768634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic adverse effects: Potentially life-threatening side effects (eg, irregular heart beat, seizures, coma, respiratory depression, death) have occurred when used prior to cosmetic procedures. Excessive dosing (application to large areas, application to denuded skin, or wearing of device for longer than recommended) may lead to increased absorption and systemic toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dermal integrity reduced: Application to broken or inflamed skin may lead to increased systemic absorption; use caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use caution in patients with severe hepatic disease due to diminished ability to metabolize systemically-absorbed lidocaine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Topical cream, liquid, gel, and ointment: Do not leave on large body areas for &gt;2 hours. Not for ophthalmic use. Some products are not recommended for use on mucous membranes; consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Topical patch: To avoid accidental ingestion by children, store and dispose of products out of the reach of children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Topical application: When topical anesthetics are used prior to cosmetic or medical procedures, the lowest amount of anesthetic necessary for pain relief should be applied. High systemic levels and toxic effects (eg, methemoglobinemia, irregular heart beats, respiratory depression, seizures, death) have been reported in patients who (without supervision of a trained professional) have applied topical anesthetics in large amounts (or to large areas of the skin), left these products on for prolonged periods of time, or have used wraps/dressings to  cover the skin following application.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8768676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major), CYP2A6 (minor), CYP2B6 (minor), CYP2C9 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8768677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antiarrhythmic Agents (Class III): Lidocaine (Topical) may enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III). Antiarrhythmic Agents (Class III) may increase the serum concentration of Lidocaine (Topical). This mechanism specifically applies to amiodarone and dronedarone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May increase the serum concentration of Lidocaine (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May increase the metabolism of CYP1A2 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of Lidocaine (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: May enhance the arrhythmogenic effect of Lidocaine (Topical). Disopyramide may increase the serum concentration of Lidocaine (Topical). Specifically, the unbound/free fraction of lidocaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8768628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8768629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies with systemic lidocaine have not shown teratogenic effects. Lidocaine and the MEGX metabolite cross the placenta. Topical lidocaine is used locally to provide analgesia prior to episiotomy and during repair of obstetric lacerations. Cumulative exposure from all routes of administration should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8768631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F8768632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When administered topically at recommended doses, the amount of lidocaine available to the nursing infant would not be expected to cause adverse events. Cumulative exposure from all routes of administration should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8768877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (AneCream External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4% (15 g): $16.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (AneCream5 External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (15 g): $24.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Lidocaine HCl External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3% (28.35 g): $35.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Lidocream External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4% (15 g): $16.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (LMX 4 External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4% (15 g): $25.03",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (LMX 5 External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (15 g): $30.53",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (RectiCare External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (30 g): $21.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Lidocaine HCl External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (5 mL): $7.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Regenecare External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (14 g): $3.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Regenecare HA External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (4 mL): $2.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (85 g): $19.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Solarcaine Aloe Extra External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (120 mL): $3.59",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Topicaine 5 External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (30 g): $19.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Topicaine External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4% (30 g): $15.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (AneCream External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4% (1): $30.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Lidocream External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4% (1): $32.81",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (LMX 4 Plus External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4% (1): $48.07",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Zilactin-L Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5% (7.5 mL): $5.69",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Lidocaine HCl External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3% (177 mL): $69.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Lidocaine External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (35.44 g): $72.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Patch",
"     </b>",
"     (Lidoderm External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (30): $283.91",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Bactine External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5-0.133% (120 mL): $3.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Lidocaine HCl External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4% (50 mL): $15.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Lidocaine HCl Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4% (4 mL): $8.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (LTA 360 Kit Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4% (4 mL): $6.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Xylocaine External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4% (50 mL): $21.64",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F11390233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Betacaine (IL);",
"     </li>",
"     <li>",
"      Dermomax (BR);",
"     </li>",
"     <li>",
"      Dimecaina (CN);",
"     </li>",
"     <li>",
"      Dynexan (CH, FR);",
"     </li>",
"     <li>",
"      Esracain Jelly (IL);",
"     </li>",
"     <li>",
"      Gesicain Jelly (IN);",
"     </li>",
"     <li>",
"      Gesicain Ointment (IN);",
"     </li>",
"     <li>",
"      Gesicain Viscous (IN);",
"     </li>",
"     <li>",
"      Kenergon (CH);",
"     </li>",
"     <li>",
"      Leostesin Jelly (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Leostesin Ointment (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Lidocain Gel (FI);",
"     </li>",
"     <li>",
"      Lidocain Spray (BG);",
"     </li>",
"     <li>",
"      Lidoderm (GR, NO);",
"     </li>",
"     <li>",
"      Lidotop Cataplasma (KP);",
"     </li>",
"     <li>",
"      Lignocaine Gel (AU);",
"     </li>",
"     <li>",
"      Lignopad (MY);",
"     </li>",
"     <li>",
"      Peterkaien (ZA);",
"     </li>",
"     <li>",
"      Pisacaina (EC);",
"     </li>",
"     <li>",
"      Power Gel (KP);",
"     </li>",
"     <li>",
"      Prolong 1000 (CN, PE);",
"     </li>",
"     <li>",
"      Roxicaina (CO);",
"     </li>",
"     <li>",
"      Solarcaine (HK);",
"     </li>",
"     <li>",
"      Stud 100 (AU, IL);",
"     </li>",
"     <li>",
"      Versatis (BE, CN, CO, CR, DO, EE, GT, HN, NI, PA, PE, RU, SE, SV);",
"     </li>",
"     <li>",
"      Versatis Plaster (GB, IE);",
"     </li>",
"     <li>",
"      Xilonest (PE);",
"     </li>",
"     <li>",
"      Xilotane Oral (PT);",
"     </li>",
"     <li>",
"      Xylocain Aerosol (DK, SE);",
"     </li>",
"     <li>",
"      Xylocain Gel (AT, CH, DE, DK, FI, NO, SE);",
"     </li>",
"     <li>",
"      Xylocain Liniment (DK);",
"     </li>",
"     <li>",
"      Xylocain Ointment (AT, CH, DE, FI);",
"     </li>",
"     <li>",
"      Xylocain Salve (DK);",
"     </li>",
"     <li>",
"      Xylocain Spray (AT, CH, DE, NO);",
"     </li>",
"     <li>",
"      Xylocain Viscous (AT, CH);",
"     </li>",
"     <li>",
"      Xylocain Viskos (DE, SE);",
"     </li>",
"     <li>",
"      Xylocain Visks (FI);",
"     </li>",
"     <li>",
"      Xylocaina Ointment (IT);",
"     </li>",
"     <li>",
"      Xylocaina Pomada (AR);",
"     </li>",
"     <li>",
"      Xylocaina Spray (CO, IT);",
"     </li>",
"     <li>",
"      Xylocaine Aerosol (AU, HK, NL);",
"     </li>",
"     <li>",
"      Xylocaine Gel (AE, BE, BH, CY, EG, FR, GR, IE, IQ, IR, JO, KW, LB, LY, OM, PK, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Xylocaine Jalea (UY);",
"     </li>",
"     <li>",
"      Xylocaine Jelly (BF, BJ, CI, ET, GH, GM, GN, HK, ID, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, NZ, PH, SC, SD, SG, SL, SN, TH, TN, TW, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Xylocaine Ointment (AE, AU, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, GR, IN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MY, NE, NG, NL, NZ, OM, PH, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Xylocaine Pump Spray (AU, EE);",
"     </li>",
"     <li>",
"      Xylocaine Spray (BE, BF, BJ, CI, ET, GB, GH, GM, GN, GR, HK, ID, IL, KE, LR, MA, ML, MR, MU, MW, MY, NE, NG, NL, PH, PL, SC, SD, SG, SL, SN, TH, TN, TW, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Xylocaine Topical Solution (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Xylocaine Viscosa (PY);",
"     </li>",
"     <li>",
"      Xylocaine Viscous (GB, IE, IN, MY, TH);",
"     </li>",
"     <li>",
"      Xylocaine Viscous Topical Solution (AU, GB);",
"     </li>",
"     <li>",
"      Xylocaine Viscus (GR);",
"     </li>",
"     <li>",
"      Xylocaine Viskeus Topical Solution (NL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8768728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions, which results in inhibition of depolarization with resultant blockade of conduction",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F14294120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset: Transdermal: ~4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Transdermal (5%): ~3% (following application of 3 patches), extent and rate variable; dependent upon concentration, dose, application site, and duration of exposure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: 90% hepatic; active metabolites monoethylglycinexylidide (MEGX) and glycinexylidide (GX)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: Transdermal (5%): 11 hours (following application of 3 patches)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (&lt;10% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/3/20535/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Benitz WE and Tatro DS,",
"      <i>",
"       The Pediatric Drug Handbook",
"      </i>",
"      , 2nd ed, Chicago, IL: Year Book Medical Publishers Inc, 1988.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bril V, England J, Franklin GM, et al, \"Evidence-Based Guideline: Treatment of Painful Diabetic Neuropathy: Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 2011, 76(20):1758-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/3/20535/abstract-text/21482920/pubmed\" id=\"21482920\" target=\"_blank\">",
"        21482920",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Davies PS and Galer BS, &ldquo;Review of Lidocaine Patch 5% Studies in the Treatment of Postherpetic Neuralgia,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 2004, 64(9):937-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/3/20535/abstract-text/15101784/pubmed\" id=\"15101784\" target=\"_blank\">",
"        15101784",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9478 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.181.191-9843F0D5B8-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_3_20535=[""].join("\n");
var outline_f20_3_20535=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768584\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768585\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768604\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768792\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768791\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768793\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768875\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768595\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768819\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768625\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768637\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768633\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768634\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768676\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768677\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768628\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768629\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768631\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768632\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768877\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390233\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768728\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14294120\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9478\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9478|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/30/4579?source=related_link\">",
"      Lidocaine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/39/12915?source=related_link\">",
"      Lidocaine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/59/30642?source=related_link\">",
"      Lidocaine (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?13/54/14184?source=related_link\">",
"      Lidocaine (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/58/36772?source=related_link\">",
"      Lidocaine (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/11/20663?source=related_link\">",
"      Lidocaine (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/46/29413?source=related_link\">",
"      Lidocaine (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/50/33574?source=related_link\">",
"      Lidocaine (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_3_20536="ERCP for biliary disease in children";
var content_f20_3_20536=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   ERCP for biliary disease in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/3/20536/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/3/20536/contributors\">",
"     Moises Guelrud, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/3/20536/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/3/20536/contributors\">",
"     George D Ferry, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/3/20536/contributors\">",
"     Elizabeth B Rand, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/3/20536/contributors\">",
"     Douglas A Howell, MD, FASGE, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/3/20536/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/3/20536/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/3/20536/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic retrograde cholangiopancreatography (ERCP) has an important role in the care of children with a variety of biliary tract disorders, which can be divided broadly as congenital or acquired (",
"    <a class=\"graphic graphic_table graphicRef64323 \" href=\"UTD.htm?16/3/16443\">",
"     table 1",
"    </a>",
"    ). This topic review will summarize indications for ERCP in children with biliary diseases, focusing on some of the more common disorders. Most of these disorders are discussed in further detail in their corresponding topic reviews. The technical aspects of performing ERCP in children, including complications, and for the use of ERCP for pancreatic disorders, are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4822?source=see_link\">",
"     \"ERCP in children: Technique, success and complications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24088?source=see_link\">",
"     \"ERCP for pancreatic disease in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16613333\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic retrograde cholangiopancreatography (ERCP) is an important diagnostic and therapeutic tool for biliary disease in infants and children, as it is in adults. With the advent of new diagnostic imaging techniques such as magnetic resonance cholangiopancreatography (MRCP), ERCP is evolving into a predominantly therapeutic procedure. The usefulness and safety of ERCP in the pediatric age group depends in large part on the experience of the endoscopist. If the necessary experience and equipment are available at an institution, the following are appropriate biliary indications for ERCP:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12866817\">",
"    <span class=\"h2\">",
"     Diagnostic indications",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Neonatal cholestasis (especially known or suspected biliary atresia or biliary cysts)",
"     </li>",
"     <li>",
"      Investigation of inconclusive abnormal findings on other examinations (eg, MRCP or CT scan)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12866824\">",
"    <span class=\"h2\">",
"     Therapeutic indications",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Biliary obstruction (eg, due to known or suspected choledocholithiasis, bile plug syndrome, parasitic infestation, biliary strictures, or primary sclerosing cholangitis)",
"     </li>",
"     <li>",
"      Biliary obstruction or leaks after liver transplant",
"     </li>",
"     <li>",
"      Postoperative complications after laparoscopic cholecystectomy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following techniques can be used during therapeutic ERCP:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sphincterotomy",
"     </li>",
"     <li>",
"      Sphincteroplasty (balloon dilation)",
"     </li>",
"     <li>",
"      Stone extraction",
"     </li>",
"     <li>",
"      Stricture dilation",
"     </li>",
"     <li>",
"      Stent placement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Considerations relevant to specific disorders for which ERCP may be indicated, including alternate approaches to the evaluation if ERCP is not available, are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NEONATAL CHOLESTASIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal cholestasis is defined as prolonged conjugated hyperbilirubinemia that occurs in the newborn period. It results from diminished bile flow",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    excretion. Although it can be caused by a large number of disorders, relatively few diagnoses account for the majority of cases. Biliary atresia, which typically occurs in term infants, accounts for about 30 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20536/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Biliary atresia is characterized by inflammation of the bile ducts leading to progressive obliteration of the extrahepatic biliary tract. As diagnostic techniques improve, specific entities that result in a pathologic picture of neonatal hepatitis have been identified. As an example, alpha-1 antitrypsin (AAT) deficiency, now recognized as a distinct condition, was formally included in the broad category of neonatal hepatitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/50/16169?source=see_link\">",
"     \"Causes of neonatal cholestasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/63/39929?source=see_link\">",
"     \"Biliary atresia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evaluation of an infant with neonatal cholestasis should be undertaken in a staged approach (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24519?source=see_link\">",
"     \"Approach to neonatal cholestasis\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initial step is rapid diagnosis and early initiation of therapy of treatable disorders. Conditions such as sepsis, hypothyroidism, panhypopituitarism, and inborn errors of metabolism (eg, galactosemia) must be recognized and treated promptly to avoid progression of the illness.",
"     </li>",
"     <li>",
"      Extrahepatic biliary atresia must be promptly diagnosed or excluded. Infants should be evaluated as rapidly as possible because the success of the surgical intervention (Kasai hepatoportoenterostomy) diminishes progressively with older age at surgery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15737325\">",
"    <span class=\"h2\">",
"     Biliary atresia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of biliary atresia is made with a series of imaging and laboratory tests and liver biopsy to exclude other causes of cholestasis. The definitive diagnosis is made by performing a cholangiogram. This is typically performed intraoperatively (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/63/39929?source=see_link&amp;anchor=H19845794#H19845794\">",
"     \"Biliary atresia\", section on 'Cholangiogram'",
"    </a>",
"    ). However, imaging of the biliary system with endoscopic retrograde cholangiopancreatography (ERCP) is an alternative approach at centers where the necessary expertise and equipment are available. Multiple reports have demonstrated that ERCP can distinguish biliary atresia from other causes of neonatal cholestasis in most patients and thus, assists in avoiding unnecessary surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20536/abstract/3-11\">",
"     3-11",
"    </a>",
"    ]. In one report of 140 infants with suspected biliary atresia, ERCP was successfully performed in 87 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20536/abstract/10\">",
"     10",
"    </a>",
"    ]. If the ERCP findings were compatible with biliary atresia, subsequent intraoperative cholangiogram confirmed biliary atresia in approximately 80 percent. In another series, ERCP was 86 percent sensitive and 94 percent sensitive for detecting biliary atresia, and 100 percent sensitive and 90 percent specific for detecting choledochal cysts [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20536/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Biliary atresia was classified by Kasai into three main types depending on the level of biliary obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20536/abstract/12\">",
"     12",
"    </a>",
"    ]. In Kasai type I the common bile duct is obliterated. In Kasai type IIa, the common hepatic duct is obliterated; in type IIb, there is atresia of the common bile duct, common hepatic duct, and cystic duct. In Kasai type III, the entire extrahepatic biliary tree is obstructed. Kasai types I, IIb, and III are indistinguishable based on ERCP findings because the obstructed common bile duct prevents visualization of the remainder of the biliary tree.",
"   </p>",
"   <p>",
"    A separate classification is used to describe ERCP findings (",
"    <a class=\"graphic graphic_figure graphicRef51768 \" href=\"UTD.htm?9/28/9667\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20536/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      ERCP type 1 &ndash; nonvisualization of the biliary tree (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef63360 \" href=\"UTD.htm?6/14/6383\">",
"       image 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      ERCP type 2 &ndash; visualization of the distal common duct and gallbladder (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef76215 \" href=\"UTD.htm?19/53/20319\">",
"       image 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      ERCP type 3 &ndash; visualization of the gallbladder and the complete common duct, with both hepatic ducts or visualization of biliary lakes at the porta hepatis (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef54117 \" href=\"UTD.htm?42/36/43599\">",
"       image 3",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Successful evaluation of the biliary tree by ERCP depends upon the experience of the endoscopist. In particular, the endoscopist must have confidence that nonvisualization of the common bile duct was not related to technical problems, such as positioning of the catheter. When a skilled endoscopist is available, ERCP may be considered as a first-line test in distinguishing between intra- and extra-hepatic biliary obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Alagille syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alagille syndrome is characterized by the paucity of interlobular bile ducts and the following associated features (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8314?source=see_link\">",
"     \"Inherited disorders associated with conjugated hyperbilirubinemia\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chronic cholestasis (91 percent)",
"     </li>",
"     <li>",
"      Cardiac anomalies, most commonly peripheral pulmonic stenosis (85 percent)",
"     </li>",
"     <li>",
"      Butterfly vertebrae (87 percent)",
"     </li>",
"     <li>",
"      Posterior embryotoxon (prominent Schwalbe line) of the eye (88 percent)",
"     </li>",
"     <li>",
"      Dysmorphic facies, consisting of broad nasal bridge, triangular facies, and deep-set eyes (95 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    ERCP generally is not performed as part of the evaluation for Alagille syndrome, although the diagnosis may be suggested in children undergoing ERCP for evaluation of neonatal cholestasis. In children with Alagille syndrome, the ERCP typically shows normal extrahepatic ducts (although hypoplasia is also reported). In contrast, the intrahepatic ducts are diffusely narrowed and demonstrate reduced arborization [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20536/abstract/7,14\">",
"     7,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Caroli disease and congenital hepatic fibrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Caroli disease is a congenital disorder characterized by multifocal, segmental dilatation of large intrahepatic bile ducts. The condition usually is associated with renal cystic disease of varying severity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/53/2902?source=see_link\">",
"     \"Caroli disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Caroli initially described two variants, which has led to some confusion in terminology.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Caroli disease is the less common form and is characterized by bile ductular ectasia without other apparent hepatic abnormalities.",
"     </li>",
"     <li>",
"      The more common variant is Caroli syndrome, in which bile duct dilatation is associated with congenital hepatic fibrosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis is established by imaging studies that demonstrate bile duct ectasia and irregular, cystic dilation of the large proximal intrahepatic bile ducts with a normal common bile duct. These findings can be seen readily with ultrasonography, magnetic resonance cholangiography, or ERCP. Because ERCP is the most invasive of these tests, it is generally not required for diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     BILIARY CYSTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biliary cysts are cystic dilatations, which may occur singly or in multiples throughout the bile ducts. They originally were termed choledochal cysts (involving the extrahepatic bile duct), but the clinical classification was revised in 1977 to include intrahepatic cysts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/47/9977?source=see_link\">",
"     \"Biliary cysts\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several theories of biliary cyst formation have been proposed, and it seems likely that no one mechanism accounts for all biliary cysts. Cysts may be congenital or acquired and have been associated with a variety of anatomic abnormalities. Familial occurrence of cysts has been described. The increased incidence in some Asian countries suggests a genetic or environmental predisposition.",
"   </p>",
"   <p>",
"    The diagnosis of biliary cysts can be made by abdominal ultrasound, computed tomography (CT), or magnetic resonance cholangiopancreatography (MRCP). Endoscopic retrograde cholangiopancreatography (ERCP) can be used as a supplementary test to confirm the diagnosis and categorize the type of cyst (",
"    <a class=\"graphic graphic_figure graphicRef80937 \" href=\"UTD.htm?26/27/27056\">",
"     figure 2",
"    </a>",
"    ) to facilitate surgical planning. The cysts may be fusiform (spindle-like, ie, wider in the middle and tapering towards the ends), or cystic (spherical). A type III cyst is an intraluminal duodenal duplication and is also known as a choledochocele. An overall approach is discussed separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/47/9977?source=see_link\">",
"     \"Biliary cysts\"",
"    </a>",
"    ); a few technical points that are particularly relevant in children are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6402731\">",
"    <span class=\"h2\">",
"     Anomalous pancreaticobiliary junction",
"    </span>",
"    &nbsp;&mdash;&nbsp;An anomalous pancreaticobiliary junction (APBJ, also known as anomalous pancreaticobiliary union, APBU) is present in about 70 percent of patients with biliary cysts. It is characterized by a junction of the bile duct and pancreatic duct outside the duodenal wall with a long common duct channel (",
"    <a class=\"graphic graphic_figure graphicRef51092 \" href=\"UTD.htm?36/24/37249\">",
"     figure 3",
"    </a>",
"    ). In children, the maximum length of the common channel in healthy neonates and infants younger than one year is 3 mm. It increases with age to a maximum of 5 mm in children and adolescents between 13 and 15 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20536/abstract/15\">",
"     15",
"    </a>",
"    ]. In adults, a common channel longer than 8 mm is considered abnormal [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20536/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three types of anomalous ductal union have been described. All three types are characterized by a long common channel, and this is dilated in the first two types (Kimura classification) (",
"    <a class=\"graphic graphic_figure graphicRef62147 \" href=\"UTD.htm?23/16/23812\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20536/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type B-P &ndash; Common bile duct joining the main pancreatic duct (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef70896 \" href=\"UTD.htm?7/40/7808\">",
"       image 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Type P-B &ndash; Pancreatic duct joining the common bile duct; this type is more likely to be associated with recurrent pancreatitis than the B-P type [",
"      <a class=\"abstract\" href=\"UTD.htm?20/3/20536/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Long Y type &ndash; A long common channel, without common bile duct dilatation (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef65676 \" href=\"UTD.htm?36/29/37329\">",
"       image 5",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6402745\">",
"    <span class=\"h2\">",
"     Sphincterotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine endoscopic sphincterotomy is not indicated for most cysts. Possible exceptions include the following types of cysts:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fusiform bile duct dilation with a widely dilated common channel [",
"      <a class=\"abstract\" href=\"UTD.htm?20/3/20536/abstract/17\">",
"       17",
"      </a>",
"      ]. In contrast to cystic dilation, fusiform dilation is more commonly associated with low-grade, short strictures located at or distal to the pancreaticobiliary junction [",
"      <a class=\"abstract\" href=\"UTD.htm?20/3/20536/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Distal bile duct stricture, which typically occurs at the point of connection with the pancreatic duct. Up to eight percent of such patients develop cystolithiasis (which may be multiple) involving intrahepatic and extrahepatic ducts [",
"      <a class=\"abstract\" href=\"UTD.htm?20/3/20536/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Choledochocele (type III cyst, in which the cyst is located within the duodenal wall) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef77426 \" href=\"UTD.htm?6/54/7008\">",
"       image 6",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/47/9977?source=see_link&amp;anchor=H1466518#H1466518\">",
"       \"Biliary cysts\", section on 'Type III cysts'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6402768\">",
"    <span class=\"h2\">",
"     Malignancy risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Types I, II, and IV biliary cysts are associated with an increased risk of malignancy. As a result, their surgical excision generally is recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/47/9977?source=see_link&amp;anchor=H1466497#H1466497\">",
"     \"Biliary cysts\", section on 'Type I, II, and IV cysts'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SCLEROSING CHOLANGITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sclerosing cholangitis in children typically is associated with an underlying disorder, including histiocytosis X [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20536/abstract/20,21\">",
"     20,21",
"    </a>",
"    ], immune deficiency states [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20536/abstract/21,22\">",
"     21,22",
"    </a>",
"    ], autoimmune hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20536/abstract/21,23-25\">",
"     21,23-25",
"    </a>",
"    ], and, less frequently, reticular cell sarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20536/abstract/26\">",
"     26",
"    </a>",
"    ] and sickle cell anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20536/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Approximately 14 percent of children with sclerosing cholangitis have underlying inflammatory bowel disease; inflammatory bowel disease is a more common predisposing factor in adults with primary sclerosing cholangitis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20536/abstract/21,29\">",
"     21,29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35334?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology and pathogenesis of primary sclerosing cholangitis\", section on 'PSC and inflammatory bowel disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of sclerosing cholangitis can be established by endoscopic retrograde cholangiopancreatography (ERCP) or magnetic resonance cholangiopancreatography (MRCP) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20536/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. The cholangiogram demonstrates pruning of the peripheral biliary tree and areas of stenosis and ectasia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20536/abstract/7,29\">",
"     7,29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22521?source=see_link\">",
"     \"Clinical manifestations and diagnosis of primary sclerosing cholangitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An advantage of ERCP over MRCP is that it permits therapeutic intervention for those children with obstructive symptoms. Patients with dominant ductal strictures are candidates for endoscopic treatment with sphincterotomy and balloon dilation to relieve the obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20536/abstract/32-35\">",
"     32-35",
"    </a>",
"    ]. Most of the data on the risks and benefits of therapeutic endoscopic intervention are from adult patients; indications and individual considerations are discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41097?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of primary sclerosing cholangitis\", section on 'Endoscopic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ASCARIASIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ascaris infestation can produce acute biliary obstruction with cholangitis, and is a common problem in endemic areas [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20536/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. During endoscopic retrograde cholangiopancreatography (ERCP), the worm can be identified (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68876 \" href=\"UTD.htm?21/8/21647\">",
"     image 7",
"    </a>",
"    ), and removed with a tripod basket [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20536/abstract/7,37\">",
"     7,37",
"    </a>",
"    ]. Patients are also treated with anthelminthic therapy to eradicate the remaining worms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/6/42087?source=see_link\">",
"     \"Endoscopic diagnosis and management of biliary parasitosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/8/16520?source=see_link\">",
"     \"Ascariasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CHOLEDOCHOLITHIASIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Choledocholithiasis is rare in infants and children [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20536/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. When it occurs, it is usually associated with hemolysis, chronic liver disease, biliary tract malformations, such as choledochal cyst (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53940 \" href=\"UTD.htm?15/9/15519\">",
"     image 8",
"    </a>",
"    ), or infection. In a review of 382 infants and children with gallstones, approximately half had recognized risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20536/abstract/40\">",
"     40",
"    </a>",
"    ]. The most common risk factors identified were sickle cell disease, parenteral nutrition, and cardiac surgery. The highest frequency of gallstones was in infants, 80 percent of whom were asymptomatic. In this age group, the most common risk factors were parenteral nutrition (with or without short bowel syndrome), diuretic use, cephalosporins, and cardiac surgery. The incidence of gallstones rises sharply in girls during puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20536/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=see_link\">",
"     \"Overview of the clinical manifestations of sickle cell disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/45/29400?source=see_link\">",
"     \"Chronic complications of the short bowel syndrome in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/60/43977?source=see_link\">",
"     \"Overview of hemolytic anemias in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ultrasonography does not always identify small stones in the biliary system. Thus, magnetic resonance cholangiopancreatography (MRCP) or endoscopic retrograde cholangiopancreatography (ERCP) usually is required to evaluate symptomatic children in whom there is high clinical suspicion of choledocholithiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20536/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of ERCP and the benefit of endoscopic sphincterotomy in children with choledocholithiasis have not been fully established. However, where appropriate expertise is available, we suggest ERCP for stone extraction in young infants as well as children and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20536/abstract/39,44-50\">",
"     39,44-50",
"    </a>",
"    ]. Infants and children who are asymptomatic but have small common bile duct stones on an imaging study should usually be managed conservatively, since the stones (or sludge) are likely to pass spontaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20536/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Sphincterotomy generally should be reserved for symptomatic patients or those with underlying lithogenic disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     BILE PLUG SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bile plug syndrome refers to obstruction of the extrahepatic bile ducts by bile sludge in patients with normal biliary tract and is generally correctable. The diagnosis is suspected by ultrasonography and confirmed by ERCP. Irrigation during the ERCP may relieve the obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20536/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MALIGNANT STRICTURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant strictures of extrahepatic ducts are rare in children. However, they have been described in case reports in which successful relief of obstruction was achieved with stenting [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20536/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     BILE DUCT COMPLICATIONS AFTER LIVER TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bile duct complications are common after liver transplantation. These include bile duct strictures, leaks, and stones, and may occur either early (within four weeks) or late after transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/51/826?source=see_link&amp;anchor=H2#H2\">",
"     \"The role of endoscopy in biliary complications after liver transplantation\", section on 'Types of complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In many cases, patients are evaluated with magnetic resonance cholangiopancreatography (MRCP) before embarking on more invasive procedures. In patients requiring further evaluation, endoscopic retrograde cholangiopancreatography (ERCP) offers an alternative to percutaneous or transhepatic cholangiography. ERCP is the procedure of choice in those who have a coagulopathy and usually is preferred over percutaneous cholangiography in patients with a duct-to-duct anastomosis. ERCP also permits therapeutic interventions, such as stenting for bile leaks and dilation and stenting of postoperative strictures [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20536/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/51/826?source=see_link\">",
"     \"The role of endoscopy in biliary complications after liver transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     HEPATOBILIARY TRAUMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic retrograde cholangiopancreatography (ERCP) can be safely performed in patients with liver trauma and may permit endoscopic therapy, or may be helpful in identifying the need for surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20536/abstract/57\">",
"     57",
"    </a>",
"    ]. Hemodynamically stable patients with a biliary leak can be treated with nasobiliary drainage with or without sphincterotomy or with a transpapillary stent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20536/abstract/58\">",
"     58",
"    </a>",
"    ]. Surgery is generally reserved for those in whom stenting is unsuccessful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15737208\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endoscopic retrograde cholangiopancreatography (ERCP) has an important role in the evaluation and treatment of a variety of biliary tract disorders in children if the special expertise and equipment that is needed to perform ERCP in this age group is available. ERCP is particularly helpful in the evaluation of neonatal cholestasis (to exclude or support a diagnosis of biliary atresia) and a variety of other causes of biliary obstruction including choledocholithiasis (",
"      <a class=\"graphic graphic_table graphicRef64323 \" href=\"UTD.htm?16/3/16443\">",
"       table 1",
"      </a>",
"      ). Therapeutic maneuvers that can be accomplished during ERCP include sphincterotomy, sphincteroplasty (balloon dilation), extraction of stones from the biliary tree, stricture dilation, and stent placement. (See",
"      <a class=\"local\" href=\"#H16613333\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infants with suspected biliary atresia are evaluated with a series of imaging and laboratory tests and liver biopsy to exclude other causes of cholestasis. A cholangiogram is the final step in the diagnostic process. This is done by intraoperative cholangiogram at many centers, but ERCP is a reasonable alternative at centers in which special expertise and equipment is available. Nonvisualization of the common bile duct is highly suggestive of biliary atresia, provided that this was not caused by technical problems, such as positioning of the catheter. Findings consistent with biliary atresia should be followed by surgical exploration for presumed hepatoportoenterostomy (Kasai procedure). (See",
"      <a class=\"local\" href=\"#H15737325\">",
"       'Biliary atresia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ERCP is generally not needed for the diagnosis of other causes of neonatal cholestasis, including Alagille syndrome and Caroli disease. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Alagille syndrome'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Caroli disease and congenital hepatic fibrosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Biliary cysts are cystic dilatations, which may occur singly or in multiples throughout the bile ducts. The diagnosis can be made by abdominal ultrasound, computerized tomography, or magnetic resonance cholangiopancreatography (MRCP). ERCP confirms the diagnosis and categorizes the type of cyst (",
"      <a class=\"graphic graphic_figure graphicRef80937 \" href=\"UTD.htm?26/27/27056\">",
"       figure 2",
"      </a>",
"      ) to facilitate surgical planning. An abnormal pancreaticobiliary junction (APBJ) is present in about 70 percent of patients with biliary cysts. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Biliary cysts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sclerosing cholangitis in children typically is associated with an underlying disorder, including histiocytosis X, immune deficiency states, reticular cell sarcoma, or sickle cell anemia. Approximately 14 percent of children with primary sclerosing cholangitis have underlying inflammatory bowel disease. The diagnosis of sclerosing cholangitis can be established by ERCP or MRCP. Patients with symptomatic dominant ductal strictures are candidates for endoscopic treatment to relieve the obstruction. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Sclerosing cholangitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ERCP is indicated for relief of biliary obstruction by ascariasis and other parasites, and is used in combination with anthelminthic therapy to eradicate the remaining worms. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Ascariasis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among infants and children with choledocholithiasis, about half of affected patients have underlying risk factors, which include hemolytic disease (eg, sickle cell disease), chronic liver disease (eg, parenteral nutrition associated liver disease), cardiac surgery, or biliary tract malformations. The role of therapeutic ERCP for choledocholithiasis in children has not been fully established. Infants and children who are asymptomatic but have small common bile duct stones can be managed conservatively. We suggest sphincterotomy and stone removal for symptomatic patients or those with underlying lithogenic disorders (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Choledocholithiasis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bile duct complications are common after liver transplantation. These include bile duct strictures, leaks, and stones, and may occur either early (within four weeks) or late after transplantation. Most patients are initially evaluated with MRCP. ERCP can be used for therapeutic intervention for most of patients with these complications. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Bile duct complications after liver transplantation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/51/826?source=see_link\">",
"       \"The role of endoscopy in biliary complications after liver transplantation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/1\">",
"      el-Youssef M, Whitington PF. Diagnostic approach to the child with hepatobiliary disease. Semin Liver Dis 1998; 18:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/2\">",
"      Schreiber RA, Kleinman RE. Biliary atresia. J Pediatr Gastroenterol Nutr 2002; 35 Suppl 1:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/3\">",
"      Derkx HH, Huibregtse K, Taminiau JA. The role of endoscopic retrograde cholangiopancreatography in cholestatic infants. Endoscopy 1994; 26:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/4\">",
"      Iinuma Y, Narisawa R, Iwafuchi M, et al. The role of endoscopic retrograde cholangiopancreatography in infants with cholestasis. J Pediatr Surg 2000; 35:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/5\">",
"      Mitchell SA, Wilkinson ML. The role of ERCP in the diagnosis of neonatal conjugated hyperbilirubinemia. Gastrointest Endosc 1994; 40:A55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/6\">",
"      Ohnuma N, Takahashi T, Tanabe M, et al. The role of ERCP in biliary atresia. Gastrointest Endosc 1997; 45:365.",
"     </a>",
"    </li>",
"    <li>",
"     Guelrud M, Carrl Locke DL, Fox VL. ERCP in Pediatric Practice: Diagnosis and Treatment, Isis Medical Media Ltd, Oxford 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/8\">",
"      Aabakken L, Aagenaes I, Sanengen T, et al. Utility of ERCP in neonatal and infant cholestasis. J Laparoendosc Adv Surg Tech A 2009; 19:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/9\">",
"      Shanmugam NP, Harrison PM, Devlin J, et al. Selective use of endoscopic retrograde cholangiopancreatography in the diagnosis of biliary atresia in infants younger than 100 days. J Pediatr Gastroenterol Nutr 2009; 49:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/10\">",
"      Petersen C, Meier PN, Schneider A, et al. Endoscopic retrograde cholangiopancreaticography prior to explorative laparotomy avoids unnecessary surgery in patients suspected for biliary atresia. J Hepatol 2009; 51:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/11\">",
"      Keil R, Snajdauf J, Rygl M, et al. Diagnostic efficacy of ERCP in cholestatic infants and neonates--a retrospective study on a large series. Endoscopy 2010; 42:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/12\">",
"      Kasai M, Suzuki H, Ohashi E, et al. Technique and results of operative management of biliary atresia. World J Surg 1978; 2:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/13\">",
"      Guelrud M, Jaen D, Mendoza S, et al. ERCP in the diagnosis of extrahepatic biliary atresia. Gastrointest Endosc 1991; 37:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/14\">",
"      Morelli A, Pelli MA, Vedovelli A, et al. Endoscopic retrograde cholangiopancreatography study in Alagille's syndrome: first report. Am J Gastroenterol 1983; 78:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/15\">",
"      Guelrud M, Morera C, Rodriguez M, et al. Normal and anomalous pancreaticobiliary union in children and adolescents. Gastrointest Endosc 1999; 50:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/16\">",
"      Misra SP, Dwivedi M. Pancreaticobiliary ductal union. Gut 1990; 31:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/17\">",
"      Ng WD, Liu K, Wong MK, et al. Endoscopic sphincterotomy in young patients with choledochal dilatation and a long common channel: a preliminary report. Br J Surg 1992; 79:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/18\">",
"      Ito T, Ando H, Nagaya M, Sugito T. Congenital dilatation of the common bile duct in children.--The etiologic significance of the narrow segment distal to the dilated common bile duct. Z Kinderchir 1984; 39:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/19\">",
"      Yamaguchi M. Congenital choledochal cyst. Analysis of 1,433 patients in the Japanese literature. Am J Surg 1980; 140:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/20\">",
"      Leblanc A, Hadchouel M, Jehan P, et al. Obstructive jaundice in children with histiocytosis X. Gastroenterology 1981; 80:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/21\">",
"      Debray D, Pariente D, Urvoas E, et al. Sclerosing cholangitis in children. J Pediatr 1994; 124:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/22\">",
"      DiPalma JA, Strobel CT, Farrow JG. Primary sclerosing cholangitis associated with hyperimmunoglobulin M immunodeficiency (dysgammaglobulinemia). Gastroenterology 1986; 91:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/23\">",
"      Vergani D, Mieli-Vergani G. Autoimmune Hepatitis and PSC Connection. Clin Liver Dis 2008; 12:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/24\">",
"      Miloh T, Arnon R, Shneider B, et al. A retrospective single-center review of primary sclerosing cholangitis in children. Clin Gastroenterol Hepatol 2009; 7:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/25\">",
"      Hiejima E, Komatsu H, Sogo T, et al. Utility of simplified criteria for the diagnosis of autoimmune hepatitis in children. J Pediatr Gastroenterol Nutr 2011; 52:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/26\">",
"      Alpert LI, Jindrak K. Idiopathic retroperitoneal fibrosis and sclerosing cholangitis associated with a reticulum cell sarcoma. Report of a case. Gastroenterology 1972; 62:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/27\">",
"      Werlin SL, Glicklich M, Jona J, Starshak RJ. Sclerosing cholangitis in childhood. J Pediatr 1980; 96:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/28\">",
"      Mieli-Vergani G, Vergani D. Sclerosing cholangitis in the paediatric patient. Best Pract Res Clin Gastroenterol 2001; 15:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/29\">",
"      Classen M, G&ouml;tze H, Richter HJ, Bender S. Primary sclerosing cholangitis in children. J Pediatr Gastroenterol Nutr 1987; 6:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/30\">",
"      Ferrara C, Valeri G, Salvolini L, Giovagnoni A. Magnetic resonance cholangiopancreatography in primary sclerosing cholangitis in children. Pediatr Radiol 2002; 32:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/31\">",
"      Chavhan GB, Roberts E, Moineddin R, et al. Primary sclerosing cholangitis in children: utility of magnetic resonance cholangiopancreatography. Pediatr Radiol 2008; 38:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/32\">",
"      Kerkar N, Miloh T. Sclerosing cholangitis: pediatric perspective. Curr Gastroenterol Rep 2010; 12:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/33\">",
"      Stoker J, Lam&eacute;ris JS, Robben SG, et al. Primary sclerosing cholangitis in a child treated by nonsurgical balloon dilatation and stenting. J Pediatr Gastroenterol Nutr 1993; 17:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/34\">",
"      Siegel JH, Guelrud M. Endoscopic cholangiopancreatoplasty: hydrostatic balloon dilation in the bile duct and pancreas. Gastrointest Endosc 1983; 29:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/35\">",
"      Guelrud M, Mendoza S, Gelrud A. A tapered balloon with hydrophilic coating to dilate difficult hilar biliary strictures. Gastrointest Endosc 1995; 41:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/36\">",
"      Malik AH, Saima BD, Wani MY. Management of hepatobiliary and pancreatic ascariasis in children of an endemic area. Pediatr Surg Int 2006; 22:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/37\">",
"      Baba AA, Shera AH, Bhat MA, et al. Management of biliary ascariasis in children living in an endemic area. Eur J Pediatr Surg 2010; 20:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/38\">",
"      Shaw PJ, Spitz L, Watson JG. Extrahepatic biliary obstruction due to stone. Arch Dis Child 1984; 59:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/39\">",
"      Guelrud M, Mendoza S, Jaen D, et al. ERCP and endoscopic sphincterotomy in infants and children with jaundice due to common bile duct stones. Gastrointest Endosc 1992; 38:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/40\">",
"      Bogue CO, Murphy AJ, Gerstle JT, et al. Risk factors, complications, and outcomes of gallstones in children: a single-center review. J Pediatr Gastroenterol Nutr 2010; 50:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/41\">",
"      Nilsson S. Gallbladder disease and sex hormones. A statistical study. Acta Chir Scand 1966; 132:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/42\">",
"      Arcement CM, Meza MP, Arumanla S, Towbin RB. MRCP in the evaluation of pancreaticobiliary disease in children. Pediatr Radiol 2001; 31:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/43\">",
"      Topal B, Van de Moortel M, Fieuws S, et al. The value of magnetic resonance cholangiopancreatography in predicting common bile duct stones in patients with gallstone disease. Br J Surg 2003; 90:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/44\">",
"      Guelrud M, Daoud G, Mendoza S, et al. Endoscopic sphincterotomy in a 6-month-old infant with choledocholithiasis and double gallbladder. Am J Gastroenterol 1994; 89:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/45\">",
"      Buckley A, Connon JJ. The role of ERCP in children and adolescents. Gastrointest Endosc 1990; 36:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/46\">",
"      Brown K. Use of ERCP with pancreatic and biliary sphincterotomy for treatment of familial pancreatitis in a 2 year old pediatric patient. Gastrointest Endosc 1993; 39:A309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/47\">",
"      Man DW, Spitz L. Choledocholithiasis in infancy. J Pediatr Surg 1985; 20:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/48\">",
"      Tarnasky PR, Tagge EP, Hebra A, et al. Minimally invasive therapy for choledocholithiasis in children. Gastrointest Endosc 1998; 47:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/49\">",
"      Sandoval C, Stringel G, Ozkaynak MF, et al. Perioperative management in children with sickle cell disease undergoing laparoscopic surgery. JSLS 2002; 6:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/50\">",
"      Komatsu Y, Kawabe T, Toda N, et al. Endoscopic papillary balloon dilation for the management of common bile duct stones: experience of 226 cases. Endoscopy 1998; 30:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/51\">",
"      Wesdorp I, Bosman D, de Graaff A, et al. Clinical presentations and predisposing factors of cholelithiasis and sludge in children. J Pediatr Gastroenterol Nutr 2000; 31:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/52\">",
"      Vrochides DV, Sorrells DL Jr, Kurkchubasche AG, et al. Is there a role for routine preoperative endoscopic retrograde cholangiopancreatography for suspected choledocholithiasis in children? Arch Surg 2005; 140:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/53\">",
"      Bickerstaff KI, Britton BJ, Gough MH. Endoscopic palliation of malignant biliary obstruction in a child. Br J Surg 1989; 76:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/54\">",
"      Guelrud M, Mendoza S, Zager A, Noguera C. Biliary stenting in an infant with malignant obstructive jaundice. Gastrointest Endosc 1989; 35:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/55\">",
"      Pfau PR, Kochman ML, Lewis JD, et al. Endoscopic management of postoperative biliary complications in orthotopic liver transplantation. Gastrointest Endosc 2000; 52:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/56\">",
"      Rerknimitr R, Sherman S, Fogel EL, et al. Biliary tract complications after orthotopic liver transplantation with choledochocholedochostomy anastomosis: endoscopic findings and results of therapy. Gastrointest Endosc 2002; 55:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/57\">",
"      Singh V, Narasimhan KL, Verma GR, Singh G. Endoscopic management of traumatic hepatobiliary injuries. J Gastroenterol Hepatol 2007; 22:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20536/abstract/58\">",
"      Ulitsky A, Werlin S, Dua KS. Role of ERCP in the management of non-iatrogenic traumatic bile duct injuries in the pediatric population. Gastrointest Endosc 2011; 73:823.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5867 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-47BF19C4B0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_3_20536=[""].join("\n");
var outline_f20_3_20536=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15737208\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16613333\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12866817\">",
"      Diagnostic indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12866824\">",
"      Therapeutic indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NEONATAL CHOLESTASIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15737325\">",
"      Biliary atresia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Alagille syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Caroli disease and congenital hepatic fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      BILIARY CYSTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6402731\">",
"      Anomalous pancreaticobiliary junction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6402745\">",
"      Sphincterotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6402768\">",
"      Malignancy risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SCLEROSING CHOLANGITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ASCARIASIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CHOLEDOCHOLITHIASIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      BILE PLUG SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MALIGNANT STRICTURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      BILE DUCT COMPLICATIONS AFTER LIVER TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      HEPATOBILIARY TRAUMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15737208\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5867\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5867|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?6/14/6383\" title=\"diagnostic image 1\">",
"      Biliary atresia type 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?19/53/20319\" title=\"diagnostic image 2\">",
"      Biliary atresia type 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/36/43599\" title=\"diagnostic image 3\">",
"      Biliary atresia type 3a",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?7/40/7808\" title=\"diagnostic image 4\">",
"      Anomalous pancreaticobiliary union type B-P",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?36/29/37329\" title=\"diagnostic image 5\">",
"      Anomalous pancreaticobiliary union long Y",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?6/54/7008\" title=\"diagnostic image 6\">",
"      Choledochocele",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/8/21647\" title=\"diagnostic image 7\">",
"      Biliary ascariasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/9/15519\" title=\"diagnostic image 8\">",
"      Choledochal cyst type 1-C",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5867|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/28/9667\" title=\"figure 1\">",
"      Endoscopic classification of biliary atresia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/27/27056\" title=\"figure 2\">",
"      Classification of biliary cysts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/24/37249\" title=\"figure 3\">",
"      Normal versus anomalous pancreaticobiliary junction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/16/23812\" title=\"figure 4\">",
"      Types of APBJ",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5867|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/3/16443\" title=\"table 1\">",
"      Biliary disorders evaluated by ERCP",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24519?source=related_link\">",
"      Approach to neonatal cholestasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/8/16520?source=related_link\">",
"      Ascariasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/63/39929?source=related_link\">",
"      Biliary atresia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/47/9977?source=related_link\">",
"      Biliary cysts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/53/2902?source=related_link\">",
"      Caroli disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/50/16169?source=related_link\">",
"      Causes of neonatal cholestasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/45/29400?source=related_link\">",
"      Chronic complications of the short bowel syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22521?source=related_link\">",
"      Clinical manifestations and diagnosis of primary sclerosing cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24088?source=related_link\">",
"      ERCP for pancreatic disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4822?source=related_link\">",
"      ERCP in children: Technique, success and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/6/42087?source=related_link\">",
"      Endoscopic diagnosis and management of biliary parasitosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35334?source=related_link\">",
"      Epidemiology and pathogenesis of primary sclerosing cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8314?source=related_link\">",
"      Inherited disorders associated with conjugated hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/60/43977?source=related_link\">",
"      Overview of hemolytic anemias in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=related_link\">",
"      Overview of the clinical manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/51/826?source=related_link\">",
"      The role of endoscopy in biliary complications after liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41097?source=related_link\">",
"      Treatment of primary sclerosing cholangitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_3_20537="Evaluation and management of fever in children with non-chemotherapy-induced neutropenia";
var content_f20_3_20537=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation and management of fever in children with non-chemotherapy-induced neutropenia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/3/20537/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/3/20537/contributors\">",
"     Nabil M Ahmed, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/3/20537/contributors\">",
"     Debra L Palazzi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/3/20537/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/3/20537/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/3/20537/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/3/20537/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/3/20537/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/3/20537/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever and neutropenia are common in children with primary hematologic diseases. The risk of developing an infection and the types of pathogens isolated during infection differ depending upon the underlying disorder (",
"    <a class=\"graphic graphic_table graphicRef65091 \" href=\"UTD.htm?40/8/41100\">",
"     table 1",
"    </a>",
"    ). The management of children with fever and chronic neutropenic disorders is reviewed here. The conditions (other than chemotherapy) that cause neutropenia in children, the risk of infection in children with non-chemotherapy-induced neutropenia, and fever in children with chemotherapy-induced neutropenia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/20/30022?source=see_link\">",
"     \"Risk of infection in children with fever and non-chemotherapy-induced neutropenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15898?source=see_link\">",
"     \"Fever in children with chemotherapy-induced neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6211742\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6211916\">",
"    <span class=\"h2\">",
"     Neutropenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutropenia generally is defined as an absolute neutrophil count (ANC) &lt;1500",
"    <span class=\"nowrap\">",
"     cells/microL.",
"    </span>",
"    The ANC is calculated using the following formula:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; ANC = total white blood cell count",
"    <span class=\"nowrap\">",
"     (cells/microL)",
"    </span>",
"    x (percent neutrophils + percent bands) &divide; 100",
"   </p>",
"   <p>",
"    The degree of neutropenia is classified as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mild &ndash; ANC 1000 to",
"      <span class=\"nowrap\">",
"       1500/microL",
"      </span>",
"     </li>",
"     <li>",
"      Moderate &ndash; ANC 500 to",
"      <span class=\"nowrap\">",
"       1000/microL",
"      </span>",
"     </li>",
"     <li>",
"      Severe &ndash; ANC",
"      <span class=\"nowrap\">",
"       &lt;500/microL.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children of African (and to a lesser degree Asian) descent could have up to 15 percent lower mean total leukocyte count, largely due to an up to 25 percent lower mean neutrophil count at baseline. This difference is not seen in children with bacteremia, suggesting an intact leukocytic response [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20537/abstract/1\">",
"     1",
"    </a>",
"    ]. Most studies evaluating the significance of the degree of neutropenia on the risk of infection have been in cancer patients, in whom an increased risk of infection becomes apparent at an ANC",
"    <span class=\"nowrap\">",
"     &lt;1000/microL,",
"    </span>",
"    is greater at",
"    <span class=\"nowrap\">",
"     &lt;500/microL,",
"    </span>",
"    and greatest at",
"    <span class=\"nowrap\">",
"     &lt;100/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20537/abstract/2\">",
"     2",
"    </a>",
"    ]. The risk of infection in children with fever and non-chemotherapy induced neutropenia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/20/30022?source=see_link\">",
"     \"Risk of infection in children with fever and non-chemotherapy-induced neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever in neutropenic patients generally is defined as a single oral or axillary temperature &ge;38.3&ordm;C (101&ordm;F) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20537/abstract/3\">",
"     3",
"    </a>",
"    ]. A temperature &ge;38&ordm;C (100.4&ordm;F) for longer than 1 hour or two elevations &ge;38&ordm;C during a 12-hour period are definitions of fever that also are used [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20537/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fever often is the sole sign of occult infection in the neutropenic host. However, this sign may be absent in some infected patients who instead may be hypothermic, hypotensive, listless, or confused. Thus, infection must be considered and treated empirically if any signs of clinical deterioration are present in a neutropenic child, regardless of the recorded temperature.",
"   </p>",
"   <p>",
"    Measuring the temperature orally is preferred, although an axillary temperature is acceptable if the patient is unable to use an oral thermometer. Generally, no adjustment is made when comparing axillary and oral temperatures. However, more conservative guidelines suggest that adding 0.5&ordm;F (0.3&ordm;C) to the axillary temperature reading may be warranted. Because of associated risks of mucosal trauma and bacteremia, measurement of rectal temperature should be avoided in neutropenic patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6211924\">",
"    <span class=\"h2\">",
"     Risk category",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of infection among children with non-chemotherapy-induced neutropenia can be categorized as low, low to moderate, and high, based upon the clinical appearance and underlying disorder (",
"    <a class=\"graphic graphic_table graphicRef65091 \" href=\"UTD.htm?40/8/41100\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low risk &ndash; Otherwise healthy, well-appearing child with transient, isolated neutropenia",
"     </li>",
"     <li>",
"      Low to moderate risk &ndash; Well-appearing child with chronic benign neutropenia or cyclic neutropenia",
"     </li>",
"     <li>",
"      High risk &ndash; Ill-appearing child with neutropenia (of any etiology); well- or ill-appearing child with severe congenital neutropenia (Kostmann syndrome) or aplastic anemia; children with a previous episode of complicated febrile illness or life-threatening infection",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with fever and neutropenia should be evaluated promptly because they may be at substantial risk of developing a life-threatening infection. In ill-appearing patients or those at highest risk of infection (",
"    <a class=\"graphic graphic_table graphicRef65091 \" href=\"UTD.htm?40/8/41100\">",
"     table 1",
"    </a>",
"    ), the evaluation ideally should occur at a hospital with subspecialty services or at a facility that can arrange for transport to such a facility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H736498159\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important aspects of the history in a child with fever and neutropenia include [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20537/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      New site-specific symptoms",
"     </li>",
"     <li>",
"      Antimicrobial prophylaxis",
"     </li>",
"     <li>",
"      Infection exposures, including illness (eg, cough, influenza, etc) in family members",
"     </li>",
"     <li>",
"      History of documented infections or colonization",
"     </li>",
"     <li>",
"      Concomitant noninfectious cause of fever (eg, receipt of blood products)",
"     </li>",
"     <li>",
"      Underlying comorbid conditions (eg, diabetes, recent surgery)",
"     </li>",
"     <li>",
"      Presence of intravascular catheters or other devices",
"     </li>",
"     <li>",
"      Immunization history (deficient immunizations or questionable immunization history)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete physical examination should be performed, with particular attention to common sites of infection, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Skin, especially folds, areas surrounding nail beds, and central venous catheter sites including the subcutaneous tunnel, if present",
"     </li>",
"     <li>",
"      Sinuses; sinus tenderness should be evaluated",
"     </li>",
"     <li>",
"      Oropharynx, especially the gingival line and buccal mucosa",
"     </li>",
"     <li>",
"      Lungs",
"     </li>",
"     <li>",
"      Abdomen",
"     </li>",
"     <li>",
"      Perineum, especially the perianal and labial regions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mild erythema or tenderness should not be ignored because signs of inflammation in the neutropenic patient may be subtle.",
"    <strong>",
"     Periodic repeated physical examinations are essential",
"    </strong>",
"    . Visual signs of inflammation may become evident only when neutrophil counts are recovering.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;A blood culture should be obtained in all children with neutropenia. It is particularly important that blood cultures be obtained without delay in ill-appearing patients and those at highest risk of serious bacterial infection (",
"    <a class=\"graphic graphic_table graphicRef65091 \" href=\"UTD.htm?40/8/41100\">",
"     table 1",
"    </a>",
"    ). Blood cultures should be obtained from central catheter ports when such access is available. Opinions vary as to whether blood should also be cultured from peripheral sites in these patients and practices vary from institution to institution [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20537/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. The rationale for culturing both peripheral and central sites is to differentiate a catheter-related infection from bacteremia from another source.",
"   </p>",
"   <p>",
"    In addition to providing information necessary for diagnosing catheter-related blood stream infection, obtaining more than one blood culture can be helpful in distinguishing between blood culture contamination and true blood stream infection. As an example, true bacteremia is more likely when coagulase-negative staphylococci are isolated from two or more blood cultures than from a single culture, which may be reflective of a contaminated specimen.",
"   </p>",
"   <p>",
"    The only other site that may be useful to culture routinely is urine in febrile neutropenic girls, especially those younger than three years. In one study, urinary tract infections accounted for 11 percent of all documented infections in febrile neutropenic patients, and 76 percent of these occurred in girls [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20537/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Additional studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional studies should be obtained",
"    <strong>",
"     as clinically indicated",
"    </strong>",
"    . Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rapid and sensitive viral diagnostic tests (for example, for influenza, respiratory syncytial virus [RSV] and adenovirus, as clinically appropriate), and culture of nasopharyngeal secretions for viruses.",
"     </li>",
"     <li>",
"      Serum galactomannan testing twice weekly in high risk patients with ongoing fever and neutropenia; galactomannan can also be sent from cerebrospinal fluid or bronchoalveolar lavage fluid, as clinically appropriate [",
"      <a class=\"abstract\" href=\"UTD.htm?20/3/20537/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chest radiographs in children with respiratory signs and symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?20/3/20537/abstract/11\">",
"       11",
"      </a>",
"      ]. A chest radiograph that is negative for infiltrates should be interpreted with caution since infiltrates may not appear until neutrophil counts are recovering. Patients with ongoing signs and symptoms may require further imaging with magnetic resonance imaging or computed tomography scanning.",
"     </li>",
"     <li>",
"      Abdominal radiographs",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ultrasonography in children with abdominal signs and symptoms, particularly abdominal pain [",
"      <a class=\"abstract\" href=\"UTD.htm?20/3/20537/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lumbar puncture in children with altered mental status or meningeal signs; platelet transfusion may be necessary before lumbar puncture in patients with thrombocytopenia as well as neutropenia.",
"     </li>",
"     <li>",
"      Stool bacterial culture,",
"      <em>",
"       Clostridium difficile",
"      </em>",
"      toxin assay, and viral cultures in children with diarrhea; assay for ova and parasites may be indicated in those with significant exposure history, prolonged neutropenia or persistent diarrhea.",
"     </li>",
"     <li>",
"      Gram stain and bacterial culture, fungal stain and culture, acid-fast bacilli stain and culture, and possibly fluorescent antibody stains or polymerase chain reaction tests to identify pathogens from abscesses or sites with drainage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H736498253\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6211957\">",
"    <span class=\"h2\">",
"     Guidelines for treatment of fever and neutropenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines for the management of fever and neutropenia in the cancer patient have been derived from controlled clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20537/abstract/5,10\">",
"     5,10",
"    </a>",
"    ]. Similar validated therapeutic approaches to fever in the patient with other forms of neutropenia have not been developed because of the rarity of the primary neutropenic disorders. Thus, management of the high-risk patient with chronic neutropenia generally is extrapolated from the care of the patient with chemotherapy-induced neutropenia. However, the risk for viral, fungal, and parasitic infections differs depending upon the cause and severity of neutropenia (",
"    <a class=\"graphic graphic_table graphicRef65091 \" href=\"UTD.htm?40/8/41100\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6213838\">",
"    <span class=\"h2\">",
"     Treatment setting",
"    </span>",
"    &nbsp;&mdash;&nbsp;The appropriate treatment setting for children with fever and non-chemotherapy induced neutropenia depends upon their risk of infection (",
"    <a class=\"graphic graphic_table graphicRef65091 \" href=\"UTD.htm?40/8/41100\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children at high risk for infection generally are initially treated in the hospital with broad-spectrum parenteral antibiotics. In selected cases, empiric antibiotic therapy may be transferred to an ambulatory setting after an initial period of 48 hours, when blood cultures are negative [",
"      <a class=\"abstract\" href=\"UTD.htm?20/3/20537/abstract/5,10,13\">",
"       5,10,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Children at low or moderate risk who have superficial or upper respiratory infections may be treated in the outpatient setting with oral antibiotics and close outpatient follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?20/3/20537/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Empiric antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initiation of empiric broad-spectrum parenteral antibiotic therapy for fever and neutropenia is required for any ill-appearing patient and for patients with underlying severe congenital neutropenia or aplastic anemia. Patients with chronic neutropenia or cyclic neutropenia who have abdominal pain, pneumonia, significant localized infection, or who have experienced life-threatening or recurrent infections also may require hospitalization for parenteral antibiotic therapy.",
"   </p>",
"   <p>",
"    The cornerstone of treatment for the febrile, neutropenic patient at high risk for infection (",
"    <a class=\"graphic graphic_table graphicRef65091 \" href=\"UTD.htm?40/8/41100\">",
"     table 1",
"    </a>",
"    ) is prompt initiation of empiric broad-spectrum antibiotic therapy. Specific sites of infection, if present, will guide the choice of antibiotics. When choosing empiric therapy, the practitioner should consider:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The types of bacterial isolates found in the institution and the community",
"     </li>",
"     <li>",
"      Local antibiotic susceptibility patterns",
"     </li>",
"     <li>",
"      The patient's drug allergies (if any)",
"     </li>",
"     <li>",
"      Presence of organ dysfunction, particularly renal and hepatic",
"     </li>",
"     <li>",
"      History and etiology of previous life-threatening infections",
"     </li>",
"     <li>",
"      Whether the patient was receiving prophylactic antimicrobials",
"     </li>",
"     <li>",
"      Previous colonization with resistant bacteria (eg, methicillin-resistant",
"      <em>",
"       Staphyloccocus aureus",
"      </em>",
"      ;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"       vancomycin",
"      </a>",
"      -resistant",
"      <em>",
"       Enterococcus",
"      </em>",
"      ; extended-spectrum beta-lactamase producing gram-negative organism, including",
"      <em>",
"       Klebsiella pneumoniae",
"      </em>",
"      carbapenemase)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Suggested initial regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Care for the high-risk hematology patient with neutropenia (",
"    <a class=\"graphic graphic_table graphicRef65091 \" href=\"UTD.htm?40/8/41100\">",
"     table 1",
"    </a>",
"    ) is extrapolated from the care of the cancer patient with chemotherapy-induced neutropenia. Both groups of patients are at risk for infections caused by gram-positive and gram-negative organisms. Thus, empiric antibiotic therapy should be active against a broad spectrum of potential pathogens. Although gram-positive organisms typically represent the majority of isolates in febrile neutropenic patients, empiric antibiotic therapy should ensure adequate gram-negative coverage because of the potential for a life-threatening infection with gram-negative organisms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84649247\">",
"    <span class=\"h4\">",
"     Uncomplicated fever episodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever episodes in children with neutropenia may be considered uncomplicated if they are not associated with [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20537/abstract/5,14\">",
"     5,14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemodynamic instability",
"     </li>",
"     <li>",
"      Gastrointestinal symptoms, including abdominal pain, nausea, vomiting, or diarrhea",
"     </li>",
"     <li>",
"      New-onset neurologic signs or mental status changes",
"     </li>",
"     <li>",
"      Intravascular catheter infection (especially catheter tunnel infection)",
"     </li>",
"     <li>",
"      New pulmonary infiltrate or hypoxemia or underlying chronic lung disease",
"     </li>",
"     <li>",
"      Skin or soft tissue infection at any site",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We suggest monotherapy with a broad-spectrum antipseudomonal agent for the empiric treatment of uncomplicated fever episodes in children with non-chemotherapy-induced neutropenia who are at high risk of infection (",
"    <a class=\"graphic graphic_table graphicRef65091 \" href=\"UTD.htm?40/8/41100\">",
"     table 1",
"    </a>",
"    ). Broad-spectrum antipseudomonal agents include",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/27/28086?source=see_link\">",
"     piperacillin-tazobactam",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/9/12438?source=see_link\">",
"     cefepime",
"    </a>",
"    , and carbapenems (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/24/2439?source=see_link\">",
"     meropenem",
"    </a>",
"    and imipenem-cilastin). Among the carbapenems, we prefer meropenem to imipenem-cilastin because of the risk of seizures with imipenem-cilastin.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/4/14405?source=see_link\">",
"     Ceftazidime",
"    </a>",
"    is no longer recommended for empiric monotherapy in high-risk patients because of its decreasing activity against many gram-negative pathogens and weak activity against",
"    <em>",
"     Streptococcus viridans",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20537/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple randomized trials and a meta-analysis have demonstrated that monotherapy with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/27/28086?source=see_link\">",
"     piperacillin-tazobactam",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/9/12438?source=see_link\">",
"     cefepime",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/24/2439?source=see_link\">",
"     meropenem",
"    </a>",
"    , or imipenem-cilastin is as efficacious as combination therapy for the empiric treatment of most febrile neutropenic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20537/abstract/5,10,15-17\">",
"     5,10,15-17",
"    </a>",
"    ]. Monotherapy is considered standard therapy for patients with uncomplicated episodes of fever [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20537/abstract/5,10,14\">",
"     5,10,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acceptable monotherapy regimens include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/27/28086?source=see_link\">",
"       Piperacillin-tazobactam",
"      </a>",
"      &ndash; For infants &lt;9 months: 80",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/10/33956?source=see_link\">",
"       piperacillin",
"      </a>",
"      component intravenously [IV] every 8 hours; for infants and children &ge;9 months and &le;40 kg: 100",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of piperacillin component IV every 8 hours; for children &gt;40 kg: 3 g of piperacillin component IV every 6 hours or 4 g of piperacillin component IV every 6 to 8 hours; the maximum daily dose of the piperacillin component is 16",
"      <span class=\"nowrap\">",
"       g/day;",
"      </span>",
"      the dose should be adjusted for renal dysfunction (see",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/27/28086?source=see_link\">",
"       \"Piperacillin and tazobactam sodium: Pediatric drug information\"",
"      </a>",
"      );",
"      <strong>",
"       OR",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/9/12438?source=see_link\">",
"       Cefepime",
"      </a>",
"      &ndash; 50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (to a maximum of 2 g per dose) IV every 8 hours (see",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/9/12438?source=see_link\">",
"       \"Cefepime: Pediatric drug information\"",
"      </a>",
"      );",
"      <strong>",
"       OR",
"      </strong>",
"     </li>",
"     <li>",
"      A carbapenem (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/24/2439?source=see_link\">",
"       meropenem",
"      </a>",
"      or imipenem-cilastin):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/24/2439?source=see_link\">",
"       Meropenem",
"      </a>",
"      &ndash; For children &ge;3 months of age with non-central nervous system infection: 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV (to a maximum of 1 g per dose every 8 hours); for children &ge;3 months of age with central nervous system infection: 40",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV (to a maximum of 2 g per dose) every 8 hours; the dose must be adjusted for renal dysfunction (see",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/24/2439?source=see_link\">",
"       \"Meropenem: Pediatric drug information\"",
"      </a>",
"      );",
"      <strong>",
"       OR",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/39/11896?source=see_link\">",
"       Imipenem-cilastatin",
"      </a>",
"      &ndash; For infants older than one month of age and children: 25",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV (to a maximum of 1 g per dose) every 6 hours; the dose must be adjusted for renal dysfunction (see",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/39/11896?source=see_link\">",
"       \"Imipenem and cilastatin: Pediatric drug information\"",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      If a carbapenem (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/24/2439?source=see_link\">",
"       meropenem",
"      </a>",
"      or imipenem-cilastin) is to be used, meropenem is preferred because of the risk of seizures with imipenem-cilastin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/4/14405?source=see_link\">",
"     Ceftazidime",
"    </a>",
"    is an alternate monotherapy regimen for low-risk patients (",
"    <a class=\"graphic graphic_table graphicRef65091 \" href=\"UTD.htm?40/8/41100\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/4/14405?source=see_link\">",
"       Ceftazidime",
"      </a>",
"      &ndash; 50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (to a maximum of 2 g per dose) IV every 8 hours; the dose must be adjusted for renal dysfunction (see",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/4/14405?source=see_link\">",
"       \"Ceftazidime: Pediatric drug information\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84649024\">",
"    <span class=\"h4\">",
"     Hemodynamic instability",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest combination therapy with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    <strong>",
"     plus",
"    </strong>",
"    an aminoglycoside (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/48/37632?source=see_link\">",
"     gentamicin",
"    </a>",
"    )",
"    <strong>",
"     plus",
"    </strong>",
"    a broad-spectrum antipseudomonal agent for hemodynamically unstable children with fever and non-chemotherapy-induced neutropenia who are at high risk of infection (",
"    <a class=\"graphic graphic_table graphicRef65091 \" href=\"UTD.htm?40/8/41100\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20537/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The addition of an aminoglycoside broadens coverage of for life-threatening gram-negative sepsis. The major disadvantage of combination therapy is the toxicity of aminoglycosides, particularly nephrotoxicity.",
"   </p>",
"   <p>",
"    A sample combination therapy regimen is",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    <strong>",
"     plus",
"    </strong>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/48/37632?source=see_link\">",
"     gentamicin",
"    </a>",
"    &nbsp;",
"    <strong>",
"     plus",
"    </strong>",
"    &nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/27/28086?source=see_link\">",
"     piperacillin-tazobactam",
"    </a>",
"    as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"       Vancomycin",
"      </a>",
"      (15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per dose IV every 6 to 8 hours; maximum 1 g per dose); the dose and dosing interval should be adjusted according to serum concentration for renal dysfunction (see",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"       \"Vancomycin: Pediatric drug information\"",
"      </a>",
"      ),",
"      <strong>",
"       plus &nbsp;",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/48/37632?source=see_link\">",
"       Gentamicin",
"      </a>",
"      (for patients &lt;50 kg: 2.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per dose IV every 8 hours; for patients &ge;50 kg: 1.5 to 2.0",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV [to a maximum of 120 mg per dose] IV every 8 hours); the dose and dosing interval should be adjusted according to serum concentrations for renal dysfunction (see",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/48/37632?source=see_link\">",
"       \"Gentamicin: Pediatric drug information\"",
"      </a>",
"      ),",
"      <strong>",
"       plus",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/27/28086?source=see_link\">",
"       Piperacillin-tazobactam",
"      </a>",
"      (for infants &lt;9 months: 80",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/10/33956?source=see_link\">",
"       piperacillin",
"      </a>",
"      component IV every 8 hours; for infants and children &ge;9 months and &le;40 kg: 100",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of piperacillin component IV every 8 hours; for children &gt;40 kg: 3 g of piperacillin component IV every 6 hours or 4 g of piperacillin component IV every 6 to 8 hours); the maximum daily dose of the piperacillin component is 16",
"      <span class=\"nowrap\">",
"       g/day;",
"      </span>",
"      the dose should be adjusted for renal dysfunction (see",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/27/28086?source=see_link\">",
"       \"Piperacillin and tazobactam sodium: Pediatric drug information\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other broad-spectrum anti-pseudomonal agents, such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/9/12438?source=see_link\">",
"     cefepime",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/24/2439?source=see_link\">",
"     meropenem",
"    </a>",
"    , may be substituted for",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/27/28086?source=see_link\">",
"     piperacillin-tazobactam",
"    </a>",
"    . Dosing for these agents is provided above (see",
"    <a class=\"local\" href=\"#H84649247\">",
"     'Uncomplicated fever episodes'",
"    </a>",
"    above). If a multiply-drug-resistant gram-negative pathogen is suspected, meropenem should be initiated while the results of cultures are pending.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h4\">",
"     Vancomycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The routine use of empiric",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    for febrile neutropenia is discouraged to decrease colonization or infection with multidrug-resistant organisms such as vancomycin-resistant enterococci (VRE) and to prevent complications of overuse such as",
"    <em>",
"     C. difficile",
"    </em>",
"    colitis. Moreover, although up to two-thirds of bacterial bloodstream isolates in febrile neutropenic cancer patients are gram-positive cocci (frequently coagulase-negative staphylococci resistant to extended-spectrum penicillins or third-generation cephalosporins), the morbidity and mortality are similar for patients treated with and without vancomycin in the initial antibiotic regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20537/abstract/18-22\">",
"     18-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Extrapolating from the guidelines of the Infectious Diseases Society of America (IDSA) for febrile neutropenia in cancer patients and the Hospital Infection Control Practices Advisory Committee of the Centers for Disease Control and Prevention (CDC) for the use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    , we suggest that the use of vancomycin for patients with non-chemotherapy-induced neutropenia be limited to the following clinical scenarios [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20537/abstract/5,23\">",
"     5,23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypotension or other signs of cardiopulmonary deterioration",
"     </li>",
"     <li>",
"      Radiographically documented pneumonia",
"     </li>",
"     <li>",
"      Evidence of meningitis or new onset of neurologic signs and symptoms suggestive of meningitis",
"     </li>",
"     <li>",
"      Clinically suspected central venous catheter site infection (eg, chills or rigors with infusion through the catheter and cellulitis around the catheter entry or exit site)",
"     </li>",
"     <li>",
"      Skin or soft tissue infection at any site",
"     </li>",
"     <li>",
"      Known colonization with methicillin-resistant",
"      <em>",
"       S. aureus",
"      </em>",
"      (MRSA), or penicillin- and cephalosporin-resistant",
"      <em>",
"       Streptococcus pneumoniae",
"      </em>",
"     </li>",
"     <li>",
"      A blood culture reportedly growing gram-positive bacteria with identification and susceptibility testing pending",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional indications for",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    may include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prior use of quinolone prophylaxis during afebrile neutropenia",
"     </li>",
"     <li>",
"      Previous history of infection with penicillin-resistant streptococci [",
"      <a class=\"abstract\" href=\"UTD.htm?20/3/20537/abstract/21\">",
"       21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      High incidence of methicillin-resistant staphylococcal infections in the community",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Renal function and serum troughs should be monitored in children receiving",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    , especially those with targeted troughs &ge;15",
"    <span class=\"nowrap\">",
"     mcg/mL,",
"    </span>",
"    those in intensive care, and those receiving",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/26/5544?source=see_link\">",
"     furosemide",
"    </a>",
"    . Nephrotoxicity is observed more often in children who attain high average vancomycin troughs (&ge;15",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    than in those who attain low average vancomycin troughs (&lt;15",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20537/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    is administered empirically, it should be discontinued if no obvious indication for ongoing treatment is found (eg, no pathogens have been identified in cultures and no focus of infection is obvious) after 48 to 72 hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25528788\">",
"    <span class=\"h4\">",
"     Gastrointestinal symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the patient with neutropenia and abdominal symptoms, particularly abdominal pain or blood per rectum, we suggest the use of an antibiotic with activity against anaerobes (eg, monotherapy with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/27/28086?source=see_link\">",
"     piperacillin-tazobactam",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/24/2439?source=see_link\">",
"     meropenem",
"    </a>",
"    ; as an alternative,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/59/21425?source=see_link\">",
"     metronidazole",
"    </a>",
"    may be added to other broad-spectrum coverage to provide activity against anaerobes) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20537/abstract/5,25\">",
"     5,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7428430\">",
"    <span class=\"h3\">",
"     Modifications to initial regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regardless of the initial empiric choice, modification of the regimen must be considered in the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Change in clinical status or vital signs",
"     </li>",
"     <li>",
"      Persistent fever for &gt;48 hours",
"     </li>",
"     <li>",
"      Isolation of an organism from the blood or other infection site",
"     </li>",
"     <li>",
"      Development of signs or symptoms of a localized infection",
"     </li>",
"     <li>",
"      Recurrent fever after initial defervescence",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For those patients in whom a site of infection has been defined and who are afebrile, therapy can be adjusted to the most appropriate treatment for the particular infection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20537/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Antifungal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that patients with non-chemotherapy-induced neutropenia who have remained febrile and profoundly neutropenic after four to seven days of broad-spectrum antibiotics or who have a positive serum galactomannan test be treated with antifungal therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20537/abstract/4,5,10\">",
"     4,5,10",
"    </a>",
"    ]. Patients with persistent fever and neutropenia despite empiric antibacterial therapy could have a clinically occult fungal infection. This is a particularly important consideration for patients with severe aplastic anemia, for whom invasive fungal infections are a major cause of death [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20537/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/12/201?source=see_link\">",
"     Amphotericin B",
"    </a>",
"    is active against a broad spectrum of fungi, and is a reasonable first-line antifungal agent in infants and young children and those without underlying renal insufficiency. Despite the potential benefits of empiric amphotericin B therapy, the substantial toxicity, particularly nephrotoxicity, which may accompany its administration, limits its use in many patients, especially older children. Less toxic alternatives, including lipid formulations of amphotericin B,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/60/12234?source=see_link\">",
"     voriconazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/47/21237?source=see_link\">",
"     caspofungin",
"    </a>",
"    are being studied for efficacy, safety, and appropriate dosing in pediatric cancer patients, with promising results. These studies and their results are discussed separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15898?source=see_link&amp;anchor=H23804813#H23804813\">",
"     \"Fever in children with chemotherapy-induced neutropenia\", section on 'Antifungal therapy'",
"    </a>",
"    ). Whether similar results would be observed in a population of exclusively neutropenic hematology patients is unclear, particularly among patients with severe aplastic anemia, in whom",
"    <em>",
"     Aspergillus",
"    </em>",
"    spp are frequent pathogens as compared with cancer patients in whom",
"    <em>",
"     Candida",
"    </em>",
"    spp predominate (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/20/30022?source=see_link&amp;anchor=H8#H8\">",
"     \"Risk of infection in children with fever and non-chemotherapy-induced neutropenia\", section on 'Aplastic anemia'",
"    </a>",
"    ). In general, the data comparing antifungal agents in children with suspected invasive fungal infection are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20537/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26297?source=see_link\">",
"     Fluconazole",
"    </a>",
"    is not active against",
"    <em>",
"     Aspergillus",
"    </em>",
"    species. It is therefore a less desirable choice for empiric antifungal therapy for the hematology patient with neutropenia and prolonged fever.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of antimicrobial therapy is determined by the site of infection (eg, pneumonia, cellulitis), the clinical response (including resolution of fever) and the pathogen identified. When the source of the fever remains unknown, empiric antibiotic therapy (with the exception of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    ) usually is continued until clinical response and, preferably, until bone marrow production of granulocytes has recovered. When vancomycin is administered empirically, it should be discontinued if no obvious indication for ongoing treatment is found (eg, no pathogens have been identified in cultures and no focus of infection is obvious) after 48 to 72 hours. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Vancomycin'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The duration of neutropenia in the patient with aplastic anemia and other forms of stable chronic neutropenia is indeterminate, complicating the decision about the duration of empiric therapy when no source of infection is identified. Results of a sentinel study of infection in patients with aplastic anemia suggest that empiric antibiotic therapy should continue for 10 to 14 days, followed by careful observation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20537/abstract/27\">",
"     27",
"    </a>",
"    ]. However, the duration of antifungal therapy, if initiated, is more difficult to determine and requires careful consideration as these patients are at high risk of infection due to",
"    <em>",
"     Aspergillus",
"    </em>",
"    species. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Granulocyte-colony stimulating factor (G-CSF)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefits of initiating granulocyte-colony stimulating factor (G-CSF,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/27/44470?source=see_link\">",
"     filgrastim",
"    </a>",
"    , lenograstim) in neutropenic hematology patients with established fever remain anecdotal. However, there are data on the use of G-CSF to increase neutrophil counts and reduce episodes of fever and infection in patients with various types of chronic neutropenia, as illustrated below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial in patients with idiopathic chronic neutropenia, cyclic neutropenia, and congenital neutropenia demonstrated that G-CSF increased neutrophil counts and reduced episodes of fever, infection, and hospitalization [",
"      <a class=\"abstract\" href=\"UTD.htm?20/3/20537/abstract/30\">",
"       30",
"      </a>",
"      ]. Virtually all of the patients with idiopathic chronic neutropenia and cyclic neutropenia responded, whereas only 83 percent of those with congenital neutropenia did. In addition, higher doses of G-CSF were required to achieve a response in patients with congenital neutropenia than in those with idiopathic chronic neutropenia or cyclic neutropenia (up to 15",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per day versus 1 to 5",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per day).",
"     </li>",
"     <li>",
"      A report of 853 patients from the Severe Chronic Neutropenia International Registry included 429 children with idiopathic, cyclic, and congenital neutropenia, almost all of whom were treated with G-CSF [",
"      <a class=\"abstract\" href=\"UTD.htm?20/3/20537/abstract/31\">",
"       31",
"      </a>",
"      ]. Ninety-two percent of all treated patients (including adults) responded to G-CSF at doses &lt;30",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per day with an increase in mean neutrophil count to",
"      <span class=\"nowrap\">",
"       &gt;1500/microL.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of G-CSF in the treatment of each of these disorders is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/33/42520?source=see_link&amp;anchor=H9#H9\">",
"     \"Immune neutropenia\", section on 'Chronic idiopathic neutropenia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/61/42966?source=see_link&amp;anchor=H7#H7\">",
"     \"Cyclic neutropenia\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24937?source=see_link&amp;anchor=H2#H2\">",
"     \"Congenital neutropenia\", section on 'Severe congenital neutropenia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For those children not routinely receiving G-CSF, interventional G-CSF may be indicated for complicated febrile episodes requiring hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20537/abstract/13\">",
"     13",
"    </a>",
"    ]. Such children should be treated in specialized centers by clinicians with expertise in the use of G-CSF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/31/16890?source=see_link\">",
"     \"Introduction to recombinant hematopoietic growth factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12680?source=see_link\">",
"     \"Recombinant hematopoietic growth factors in inherited bone marrow failure syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6213993\">",
"    <span class=\"h2\">",
"     Environmental precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Environmental precautions may reduce the risk of hospital-acquired infection in neutropenic patients who are admitted to the hospital for treatment of fever. Environmental precautions may include [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20537/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All persons should perform hand hygiene before entering and after leaving the patient&rsquo;s room",
"     </li>",
"     <li>",
"      &ldquo;Neutropenic diet&rdquo; (ie, well-cooked foods; avoidance of prepared luncheon meats)",
"     </li>",
"     <li>",
"      Oral hygiene (toothbrushing at least twice per day; oral rinses at least four times per day; dental flossing once per day if it can be performed without trauma)",
"     </li>",
"     <li>",
"      Daily showers or baths",
"     </li>",
"     <li>",
"      Daily inspection of skin sites that may be portals of infection (eg, perineum, sites of intravascular access)",
"     </li>",
"     <li>",
"      Perineal hygiene (gentle but thorough cleaning after bowel movements; thorough drying of the perineum after urination)",
"     </li>",
"     <li>",
"      Avoidance of tampons",
"     </li>",
"     <li>",
"      Avoidance of rectal procedures (eg, thermometry, enemas, suppositories, examinations)",
"     </li>",
"     <li>",
"      Prohibition of plants and dried or fresh flowers in the patient&rsquo;s room (may contain molds)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fever and neutropenia (absolute neutrophil count &lt;1500",
"      <span class=\"nowrap\">",
"       cells/microL)",
"      </span>",
"      are common in children with primary hematologic diseases. The risk of developing an infection and the types of pathogens isolated differ depending upon the underlying disorder (",
"      <a class=\"graphic graphic_table graphicRef65091 \" href=\"UTD.htm?40/8/41100\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fever in the neutropenic patient may be defined as a single oral or axillary temperature &ge;38.3&ordm;C (101&ordm;F), a temperature &ge;38&ordm;C (100.4&ordm;F) for longer than one hour, or two elevations &ge;38&ordm;C during a 12-hour period. Measuring the temperature orally is preferred in neutropenic patients; rectal thermometry should be avoided. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Fever'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with fever and neutropenia should be evaluated promptly because they may be at substantial risk of developing a life-threatening infection. Serial examination of the most common sites of infection (eg, skin, sinuses, oropharynx, lungs, abdomen, and perineum) is essential. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Initial evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A blood culture should be obtained without delay. We also suggest that a urine culture be obtained in febrile girls with neutropenia. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Cultures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Additional studies (eg, chest radiograph, viral studies, stool studies, serum galactomannan) should be obtained as clinically indicated. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Additional studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The approach to the treatment of fever in the high-risk child with non-chemotherapy-induced neutropenia typically parallels that for the child with chemotherapy-induced neutropenia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15898?source=see_link\">",
"       \"Fever in children with chemotherapy-induced neutropenia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with fever and non-chemotherapy-induced neutropenia who are at high risk for bacterial infection (",
"      <a class=\"graphic graphic_table graphicRef65091 \" href=\"UTD.htm?40/8/41100\">",
"       table 1",
"      </a>",
"      ), we recommend prompt initiation of empiric broad-spectrum antibiotic therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Empiric therapy should ensure both gram-negative and gram-positive coverage. The choice of antibiotic is guided by the site of infection if a specific infection is present. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Suggested initial regimens'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For uncomplicated fever episodes (ie, fever without hemodynamic instability, gastrointestinal symptoms, neurologic or mental status changes, concern for catheter infection, pneumonia, or skin or soft tissue infection), we suggest monotherapy with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/27/28086?source=see_link\">",
"       piperacillin-tazobactam",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/9/12438?source=see_link\">",
"       cefepime",
"      </a>",
"      , or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/24/2439?source=see_link\">",
"       meropenem",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H84649247\">",
"       'Uncomplicated fever episodes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For hemodynamically unstable children, we suggest combination therapy with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"       vancomycin",
"      </a>",
"      , an aminoglycoside (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/48/37632?source=see_link\">",
"       gentamicin",
"      </a>",
"      ), and a broad-spectrum antipseudomonal agent (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/27/28086?source=see_link\">",
"       piperacillin-tazobactam",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/9/12438?source=see_link\">",
"       cefepime",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/24/2439?source=see_link\">",
"       meropenem",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). If a multiply-drug-resistant gram-negative infection is suspected, meropenem should be initiated while the results of cultures are pending. (See",
"      <a class=\"local\" href=\"#H84649024\">",
"       'Hemodynamic instability'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For children with abdominal symptoms, particularly abdominal pain or blood per rectum, we suggest the use of an antibiotic with activity against anaerobes (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Acceptable regimens include monotherapy with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/27/28086?source=see_link\">",
"       piperacillin-tazobactam",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/24/2439?source=see_link\">",
"       meropenem",
"      </a>",
"      ; as an alternative,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/59/21425?source=see_link\">",
"       metronidazole",
"      </a>",
"      may be added to other broad-spectrum coverage to provide activity against anaerobes. (See",
"      <a class=\"local\" href=\"#H25528788\">",
"       'Gastrointestinal symptoms'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The use of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"       vancomycin",
"      </a>",
"      should be reserved for febrile neutropenic patients with (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Vancomycin'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hypotension or other signs of cardiopulmonary deterioration",
"     </li>",
"     <li>",
"      Radiographically documented pneumonia",
"     </li>",
"     <li>",
"      Evidence of meningitis or new onset of neurologic signs and symptoms suggestive of meningitis",
"     </li>",
"     <li>",
"      Clinically suspected central venous catheter site infection (eg, chills or rigors with infusion through the catheter and cellulitis around the catheter entry or exit site)",
"     </li>",
"     <li>",
"      Skin or soft tissue infection at any site",
"     </li>",
"     <li>",
"      Known colonization with methicillin-resistant",
"      <em>",
"       Staphylococcus aureus",
"      </em>",
"      (MRSA), or penicillin- and cephalosporin-resistant",
"      <em>",
"       Streptococcus pneumoniae",
"      </em>",
"     </li>",
"     <li>",
"      When a blood culture is reported to be growing gram-positive bacteria, and identification and susceptibility testing are pending",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initial empiric regimen should be modified if there is a change in clinical status or vital signs, fever persists for &gt;48 hours, an organism is isolated from the blood, the patient develops signs or symptoms of a localized infection, or there is recurrent fever after initial defervescence. In addition, for those patients in whom a site of infection has been defined and in whom fever has resolved, therapy can be adjusted to the most appropriate treatment for the particular infection. (See",
"      <a class=\"local\" href=\"#H7428430\">",
"       'Modifications to initial regimen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that antifungal therapy be administered to patients who remain febrile and profoundly neutropenic after four to seven days of broad-spectrum antibiotics and patients who have a positive serum galactomannan test (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Antifungal therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The duration of antimicrobial therapy is determined by the site of infection (eg, pneumonia, cellulitis), the clinical response (including resolution of fever) and the pathogen identified. When the source of the fever remains unknown, empiric antibiotic therapy (with the exception of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"       vancomycin",
"      </a>",
"      ) usually is continued until clinical response and, preferably, until bone marrow production of granulocytes has recovered. Empiric vancomycin should be discontinued after 48 to 72 hours if there continues to be no clinical focus of infection and no pathogens have been identified in cultures. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20537/abstract/1\">",
"      Kline MW, Lorin MI. Similarity in white blood cell counts between white and black children with bacteremia. Pediatr Infect Dis 1986; 5:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20537/abstract/2\">",
"      Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64:328.",
"     </a>",
"    </li>",
"    <li>",
"     Wolff LJ, Ablin AR, Altman AJ, Johnson FL. The management of fever. In: Supportive care of children with cancer: Current therapy and guidelines from the Children's Cancer Group, 2nd ed, Ablin AR (Ed), Johns Hopkins University Press, Baltimore 1997. p.23.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20537/abstract/4\">",
"      Weinberger M. Approach to management of fever and infection in patients with primary bone marrow failure and hemoglobinopathies. Hematol Oncol Clin North Am 1993; 7:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20537/abstract/5\">",
"      Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011; 52:e56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20537/abstract/6\">",
"      Adamkiewicz TV, Lorenzana A, Doyle J, Richardson S. Peripheral vs. central blood cultures in patients admitted to a pediatric oncology ward. Pediatr Infect Dis J 1999; 18:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20537/abstract/7\">",
"      Alexander SW, Pizzo PA. Current considerations in the management of fever and neutropenia. Curr Clin Top Infect Dis 1999; 19:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20537/abstract/8\">",
"      Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20537/abstract/9\">",
"      Auletta JJ, O'Riordan MA, Nieder ML. Infections in children with cancer: a continued need for the comprehensive physical examination. J Pediatr Hematol Oncol 1999; 21:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20537/abstract/10\">",
"      Lehrnbecher T, Phillips R, Alexander S, et al. Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation. J Clin Oncol 2012; 30:4427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20537/abstract/11\">",
"      Korones DN. Is routine chest radiography necessary for the initial evaluation of fever in neutropenic children with cancer? Pediatr Blood Cancer 2004; 43:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20537/abstract/12\">",
"      McCarville MB, Adelman CS, Li C, et al. Typhlitis in childhood cancer. Cancer 2005; 104:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20537/abstract/13\">",
"      Donadieu J, Fenneteau O, Beaupain B, et al. Congenital neutropenia: diagnosis, molecular bases and patient management. Orphanet J Rare Dis 2011; 6:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20537/abstract/14\">",
"      Alexander SW, Wade KC, Hibberd PL, Parsons SK. Evaluation of risk prediction criteria for episodes of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol 2002; 24:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20537/abstract/15\">",
"      Paul M, Yahav D, Bivas A, et al. Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams. Cochrane Database Syst Rev 2010; :CD005197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20537/abstract/16\">",
"      Viscoli C, Cometta A, Kern WV, et al. Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients. Clin Microbiol Infect 2006; 12:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20537/abstract/17\">",
"      Simon A, Lehrnbecher T, Bode U, et al. Piperacillin-tazobactam in pediatric cancer patients younger than 25 months: a retrospective multicenter survey. Eur J Clin Microbiol Infect Dis 2007; 26:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20537/abstract/18\">",
"      Paul M, Borok S, Fraser A, et al. Additional anti-Gram-positive antibiotic treatment for febrile neutropenic cancer patients. Cochrane Database Syst Rev 2005; :CD003914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20537/abstract/19\">",
"      Ramphal R, Bolger M, Oblon DJ, et al. Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study. Antimicrob Agents Chemother 1992; 36:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20537/abstract/20\">",
"      Feld R. Vancomycin as part of initial empirical antibiotic therapy for febrile neutropenia in patients with cancer: pros and cons. Clin Infect Dis 1999; 29:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20537/abstract/21\">",
"      Elting LS, Rubenstein EB, Rolston KV, Bodey GP. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 1997; 25:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20537/abstract/22\">",
"      Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trials Group. J Infect Dis 1991; 163:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20537/abstract/23\">",
"      Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). Am J Infect Control 1995; 23:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20537/abstract/24\">",
"      McKamy S, Hernandez E, Jahng M, et al. Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children. J Pediatr 2011; 158:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20537/abstract/25\">",
"      Smith-Slatas CL, Bourque M, Salazar JC. Clostridium septicum infections in children: a case report and review of the literature. Pediatrics 2006; 117:e796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20537/abstract/26\">",
"      Torres HA, Bodey GP, Rolston KV, et al. Infections in patients with aplastic anemia: experience at a tertiary care cancer center. Cancer 2003; 98:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20537/abstract/27\">",
"      Weinberger M, Elattar I, Marshall D, et al. Patterns of infection in patients with aplastic anemia and the emergence of Aspergillus as a major cause of death. Medicine (Baltimore) 1992; 71:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20537/abstract/28\">",
"      Maertens JA, Madero L, Reilly AF, et al. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J 2010; 29:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20537/abstract/29\">",
"      Blyth CC, Hale K, Palasanthiran P, et al. Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections. Cochrane Database Syst Rev 2010; :CD006343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20537/abstract/30\">",
"      Dale DC, Bonilla MA, Davis MW, et al. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood 1993; 81:2496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20537/abstract/31\">",
"      Dale DC, Cottle TE, Fier CJ, et al. Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry. Am J Hematol 2003; 72:82.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6059 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-558F5CFEDC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_3_20537=[""].join("\n");
var outline_f20_3_20537=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6211742\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6211916\">",
"      Neutropenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6211924\">",
"      Risk category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      INITIAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H736498159\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cultures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Additional studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H736498253\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6211957\">",
"      Guidelines for treatment of fever and neutropenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6213838\">",
"      Treatment setting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Empiric antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Suggested initial regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H84649247\">",
"      Uncomplicated fever episodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H84649024\">",
"      Hemodynamic instability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Vancomycin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H25528788\">",
"      Gastrointestinal symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7428430\">",
"      - Modifications to initial regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Antifungal therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Granulocyte-colony stimulating factor (G-CSF)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6213993\">",
"      Environmental precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6059\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6059|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/8/41100\" title=\"table 1\">",
"      Neutropenic children infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/9/12438?source=related_link\">",
"      Cefepime: Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/4/14405?source=related_link\">",
"      Ceftazidime: Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24937?source=related_link\">",
"      Congenital neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/61/42966?source=related_link\">",
"      Cyclic neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15898?source=related_link\">",
"      Fever in children with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/48/37632?source=related_link\">",
"      Gentamicin: Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/39/11896?source=related_link\">",
"      Imipenem and cilastatin: Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/33/42520?source=related_link\">",
"      Immune neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/31/16890?source=related_link\">",
"      Introduction to recombinant hematopoietic growth factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/24/2439?source=related_link\">",
"      Meropenem: Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/27/28086?source=related_link\">",
"      Piperacillin and tazobactam sodium: Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12680?source=related_link\">",
"      Recombinant hematopoietic growth factors in inherited bone marrow failure syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/20/30022?source=related_link\">",
"      Risk of infection in children with fever and non-chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=related_link\">",
"      Vancomycin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_3_20538="Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders";
var content_f20_3_20538=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/3/20538/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/3/20538/contributors\">",
"     Michael J Wright, MBChB, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/3/20538/contributors\">",
"     Heidi M Connolly, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/3/20538/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/3/20538/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/3/20538/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/3/20538/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/3/20538/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the most common inherited disorders of connective tissue, Marfan syndrome (MFS, MIM #154700) is an autosomal dominant condition with a reported incidence of 1 in 3000 to 5000 individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. There is a broad range of clinical severity associated with MFS and related disorders, ranging from isolated features of MFS to neonatal presentation of severe and rapidly progressive disease involving multiple organ systems [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/3\">",
"     3",
"    </a>",
"    ]. Although many clinicians view the disorder in terms of classic ocular, cardiovascular, and musculoskeletal abnormalities, manifestations include involvement of the lung, skin, and central nervous system.",
"   </p>",
"   <p>",
"    The genetics, pathogenesis, clinical manifestations, and diagnosis of MFS and related disorders will be reviewed here. The management of patients with MFS and related disorders and issues related to pregnancy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/51/5945?source=see_link\">",
"     \"Management of Marfan syndrome and related disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20262?source=see_link\">",
"     \"Pregnancy and Marfan syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;MFS is a highly variable systemic tissue disorder with clinical characteristics similar to a variety of other hereditary disorders from which it should be distinguished. MFS is almost exclusively inherited in an autosomal dominant manner, although case reports have described rare recessive FBN1 mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/4\">",
"     4",
"    </a>",
"    ]. While most individuals with MFS have an affected parent, 25 percent or more of probands have MFS as the result of a de novo mutation.",
"   </p>",
"   <p>",
"    Most patients with the typical Marfan phenotype harbor various mutations involving the Fibrillin-1 (FBN1) gene [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. However, FBN1 mutations also occur across a wide range of milder phenotypes that overlap the classic Marfan phenotype. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'FBN phenotypes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In a minority of cases (less than 10 percent) with typical Marfan phenotype, no mutation in FBN1 is identified [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/3\">",
"     3",
"    </a>",
"    ]. In some of these individuals, an inactivating mutation in a gene encoding for transforming growth factor-beta receptor (TGFBR) may be responsible. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'TGFBR mutations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     FBN1 mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;FBN1 is a large gene (65 exons) located at chromosome 15q-21.1. FBN1 protein contains many cysteine-rich sequences homologous to epidermal growth factor (EGF) and to the latent transforming growth factor beta binding protein (LTBP) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. FBN1 protein is an important component of both elastic and nonelastic connective tissues. It is the main protein of a group of connective tissue microfibrils that are essential to normal elastic fibrillogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since the first report of an FBN1 mutation in 1991, more than 600 different mutations involving this protein have been registered for MFS and associated disorders in the Universal Mutation Database for FBN1 (",
"    <a class=\"external\" href=\"file://www.umd.be/FBN1/\">",
"     UMD-FBN1",
"    </a>",
"    ). The majority of the mutations are nonrecurrent and distributed throughout the gene, with exceptions including clustering of mutations between exons 24 and exon 32 associated with cases of severe rapidly progressive MFS (previously known as &ldquo;neonatal MFS&rdquo;) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/12\">",
"     12",
"    </a>",
"    ]. However, some patients with severe MFS lack mutations in this region and many patients with mutations in this region have classic or mild variants of MFS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of note, mutations in FBN1 have been identified in some patients with isolated features of the Marfan phenotype who do not have MFS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'FBN phenotypes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Mutations involving a second fibrillin protein, fibrillin-2, a product of the FBN2 gene located on chromosome 5, have been described and are associated with a phenotype different from the Marfan phenotype. (See",
"    <a class=\"local\" href=\"#H1949862\">",
"     'Congenital contractural arachnodactyly'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14548416\">",
"    <span class=\"h3\">",
"     Causal FBN1 mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Criteria have been developed to identify a FBN1 mutation that is likely causal and thus strong evidence of MFS to be used together with other revised Ghent criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/14\">",
"     14",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H559172\">",
"     'Revised Ghent nosology'",
"    </a>",
"    below):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A mutation previously shown to segregate in a Marfan family",
"     </li>",
"     <li>",
"      De novo mutation (proven paternity and absence of disease in parents) in one of five categories:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In frame and out of frame",
"      <span class=\"nowrap\">",
"       deletion/insertion",
"      </span>",
"     </li>",
"     <li>",
"      Splice site mutations affecting canonical splice sequence or shown to alter splicing on",
"      <span class=\"nowrap\">",
"       mRNA/cDNA",
"      </span>",
"      level",
"     </li>",
"     <li>",
"      Missense",
"      <span class=\"nowrap\">",
"       affecting/creating",
"      </span>",
"      cysteine residues",
"     </li>",
"     <li>",
"      Missense affecting conserved residues of the EGF consensus sequence",
"      <span class=\"nowrap\">",
"       (D/N)X(D/N)(E/Q)Xm(D/N)Xn(Y/F)",
"      </span>",
"      with m and n representing variable numbers of residues; D aspartic acid, N asparagine, E glutamic acid, Q glutamine, Y tyrosine, and F phenylalanine.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Other missense mutations absent in 400 ethnically matched control chromosomes (with segregation in family, if possible to determine)",
"     </li>",
"     <li>",
"      Linkage of haplotype for n&ge;6 meioses to the FBN1 locus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     TGFBR mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A minority of patients with the Marfan phenotype have no identifiable mutation in the FBN1 gene. Mutations in TGF-beta receptor 2 (TGFBR2) and TGFBR1 genes have been linked to the Marfan phenotype in some patients and may be responsible for up to 10 percent of cases with the Marfan phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/7,15,16\">",
"     7,15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some individuals with TGFBR1 or TGFBR2 mutations have clinical features wholly consistent with MFS, while others have features of one of two other syndromes: Loeys-Dietz syndrome (LDS) or familial thoracic aortic aneurysm (FTAA) syndrome. Autosomal dominant inheritance with variable penetrance has been observed in families with a variety of TGFBR mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/17\">",
"     17",
"    </a>",
"    ]. The clinical characteristics of these syndromes are discussed below. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'TGFBR phenotypes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Some experts have proposed that patients with the Marfan phenotype and TGFBR1 or TGFBR2 mutations be classified as having LDS2 (rather than as MFS or Marfan syndrome 2) as a means of highlighting the potential for more aggressive vascular disease than seen in MFS with an FBN1 mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/3,14\">",
"     3,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Prenatal genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prenatal diagnostic testing is feasible if a disease causing mutation has been identified in the family. However, the severity of disease in a child who inherits a mutant FBN1 (or",
"    <span class=\"nowrap\">",
"     TGFBR1/2)",
"    </span>",
"    gene is unpredictable. Linkage analysis and direct sequencing of the FBN1 (or",
"    <span class=\"nowrap\">",
"     TGFBR1/2)",
"    </span>",
"    genes from cells or tissue obtained by amniocentesis or chorionic villus sampling can be informative. Resources for genetic testing are discussed in more detail elsewhere. However, such analyses are time consuming and planning for them should ideally be done prior to conception. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24602?source=see_link\">",
"     \"Genetic counseling and testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18272484\">",
"    <span class=\"h2\">",
"     Role of genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are currently limited outcome data on genetic testing in patients with suspected Marfan syndrome. Not all patients with suspected Marfan syndrome require genetic testing given the cost and potential limitations. Mutation analysis of 93 patients with MFS found FBN1 mutations in 86 (93 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/18\">",
"     18",
"    </a>",
"    ]. Even in the presence of an FBN1 mutation the diagnosis of MFS relies on fulfillment of clinical diagnostic criteria.",
"   </p>",
"   <p>",
"    Genetic testing, however, may be beneficial in the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Identification of FBN1 mutation will change medical management of the affected patient",
"     </li>",
"     <li>",
"      Identification of FBN1 mutation will change follow-up frequency of the affected patient",
"     </li>",
"     <li>",
"      Identification of FBN1 mutation will help identify potentially affected family members",
"     </li>",
"     <li>",
"      Identification of FBN1 mutation will facilitate prenatal diagnostic testing",
"     </li>",
"     <li>",
"      Identification of another disorder (eg, Loeys-Dietz or familial aortic aneurysmal disease) will change medical management or follow-up for the affected patient",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     HISTOPATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologic features of the ascending aorta media in patients with MFS include fragmentation of elastic lamellae, cystic medial necrosis, fibrosis, and loss of smooth muscle cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/19-23\">",
"     19-23",
"    </a>",
"    ]. The term cystic medial necrosis was coined by Erdheim to describe the lacunar appearance of medial degeneration in Marfan syndrome; however no actual cysts or overt necrosis is present [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Cystic medial necrosis and the other histologic findings are not specific for MFS, although greater elastin fragmentation is seen in patients with ascending aortic aneurysms with MFS compared to those with ascending aortic aneurysms without MFS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/19,20,23\">",
"     19,20,23",
"    </a>",
"    ]. The histologic changes are thought to reflect injury and repair [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;How FBN1 or TGFBR mutations lead to disease is not well understood at a molecular level. Among the proposed mechanisms are alterations in:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Calcium binding to EGF-like domains (supported by the loci of some FBN1 mutations) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/24\">",
"       24",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Increased bioavailability of transforming growth factor (TGF)-beta [",
"      <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Support for the importance of TGF-beta signaling comes from animal models of FBN1 Marfan syndrome and preliminary clinical data in which inhibition of TGF-beta attenuates the clinical manifestations of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/26-29\">",
"     26-29",
"    </a>",
"    ]. The administration of the angiotensin II type 1 (AT1) receptor blocker",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    (an antagonist of TGF-beta signaling) in one of these animal models prevented aortic dilation and improved disease manifestations in the aortic wall and the lungs [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/26\">",
"     26",
"    </a>",
"    ]. This effect was not due to altered hemodynamics since a similar benefit was not seen with a beta blocker, which is used clinically to slow the rate of aortic growth. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/51/5945?source=see_link&amp;anchor=H8#H8\">",
"     \"Management of Marfan syndrome and related disorders\", section on 'Beta blockers'",
"    </a>",
"    .) Preliminary clinical data was provided by a cohort study of 18 pediatric patients in which losartan reduced the rate of aortic dilation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/27\">",
"     27",
"    </a>",
"    ]. Additional clinical evidence for this mechanism was provided by a preliminary report in which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/32/22024?source=see_link\">",
"     perindopril",
"    </a>",
"    reduced aortic dilation as well as latent and active TGF-beta [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/28,30\">",
"     28,30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/51/5945?source=see_link&amp;anchor=H10#H10\">",
"     \"Management of Marfan syndrome and related disorders\", section on 'Other drug therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5437793\">",
"    <span class=\"h1\">",
"     CRITERIA FOR DIAGNOSIS OF MFS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Older criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is variable phenotypic expression of MFS, aortic root dilatation and ectopia lentis are cardinal features of the disease and various systemic features support the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/14\">",
"     14",
"    </a>",
"    ]. Other symptoms and signs of MFS, such as joint hypermobility, are much more commonly seen in patients without the disease. Previous reliance on less specific features led to a tendency to over diagnose MFS in index cases or family members. As a result, stringent criteria for the diagnosis of MFS (Ghent nosology) were proposed in 1996 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/31\">",
"     31",
"    </a>",
"    ]. These criteria relied on the recognition of both \"major\" and \"minor\" clinical manifestations involving the skeletal, cardiovascular, and ocular systems, and the dura [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/31\">",
"     31",
"    </a>",
"    ]. Major criteria included: ectopia lentis, aortic root dilatation involving the sinuses of Valsalva or aortic dissection, and lumbosacral dural ectasia by CT or MRI, family or genetic history, and four of eight typical skeletal manifestations.",
"   </p>",
"   <p>",
"    Limitations of some of the 1996 Ghent criteria included insufficient validation, inapplicability to children, and requirement of expensive and specialized evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H559172\">",
"    <span class=\"h2\">",
"     Revised Ghent nosology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2010 revised Ghent nosology puts greater weight on aortic root",
"    <span class=\"nowrap\">",
"     aneurysm/dissection",
"    </span>",
"    and ectopia lentis as the cardinal clinical features of MFS and on testing for mutations in FBN1 and other relevant genes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the absence of family history of MFS, the presence of one of any of the following criteria is diagnostic for MFS:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Aortic criterion (aortic diameter Z&ge;2 or aortic root dissection)",
"      <strong>",
"       and",
"      </strong>",
"      ectopia lentis* (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Ocular abnormalities'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Aortic criterion (aortic diameter Z&ge;2 or aortic root dissection)",
"      <strong>",
"       and",
"      </strong>",
"      a causal FBN1 mutation as defined above (see",
"      <a class=\"local\" href=\"#H14548416\">",
"       'Causal FBN1 mutations'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Aortic criterion (aortic diameter Z&ge;2 or aortic root dissection)",
"      <strong>",
"       and",
"      </strong>",
"      a systemic score &ge;7 (see",
"      <a class=\"local\" href=\"#H14548408\">",
"       'Systemic score'",
"      </a>",
"      below)*",
"     </li>",
"     <li>",
"      Ectopia lentis",
"      <strong>",
"       and",
"      </strong>",
"      a causal FBN1 mutation as defined above (see",
"      <a class=\"local\" href=\"#H14548416\">",
"       'Causal FBN1 mutations'",
"      </a>",
"      above) that has been identified in an individual with aortic aneurysm",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the presence of family history of MFS (as defined by the above criteria), the presence of one of any of the following criteria is diagnostic for MFS:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Ectopia lentis",
"     </li>",
"     <li>",
"      Systemic score &ge;7 points*",
"     </li>",
"     <li>",
"      Aortic criterion (aortic diameter Z&ge;2 above 20 years old, Z&ge;3 below 20 years, or aortic root dissection)*",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For criteria with an asterisk (*), the diagnosis of MFS can be made only in the absence of discriminating features of Shprintzen-Goldberg syndrome (SGS), Loeys-Dietz syndrome (LDS), or vascular Ehlers-Danlos syndrome (vEDS) (",
"    <a class=\"graphic graphic_table graphicRef59476 \" href=\"UTD.htm?40/50/41773\">",
"     table 1",
"    </a>",
"    )",
"    <strong>",
"     and",
"    </strong>",
"    after",
"    <span class=\"nowrap\">",
"     TGFBR1/2,",
"    </span>",
"    collagen biochemistry, or COL3A1 testing if indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14548408\">",
"    <span class=\"h3\">",
"     Systemic score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The revised Ghent nosology includes the following scoring system for systemic features [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Wrist (",
"      <a class=\"graphic graphic_picture graphicRef86854 \" href=\"UTD.htm?26/2/26659\">",
"       picture 1",
"      </a>",
"      ) AND thumb sign (",
"      <a class=\"graphic graphic_picture graphicRef86853 \" href=\"UTD.htm?35/17/36127\">",
"       picture 2",
"      </a>",
"      ): 3 points (wrist OR thumb sign: 1 point) (See",
"      <a class=\"local\" href=\"#H5438518\">",
"       'Arachnodactyly'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Pectus carinatum deformity: 2 (pectus excavatum or chest asymmetry: 1 point) (See",
"      <a class=\"local\" href=\"#H5438657\">",
"       'Pectus deformity'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Hindfoot deformity: 2 points (plain pes planus:1 point) (See",
"      <a class=\"local\" href=\"#H5438665\">",
"       'Hindfoot valgus'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Pneumothorax: 2 points (See",
"      <a class=\"local\" href=\"#H5438685\">",
"       'Pneumothorax'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Dural ectasia: 2 points (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Dural ectasia'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Protrusio acetabuli: 2 points (See",
"      <a class=\"local\" href=\"#H5438612\">",
"       'Protrusio acetabuli'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Reduced upper",
"      <span class=\"nowrap\">",
"       segment/lower",
"      </span>",
"      segment ratio",
"      <span class=\"nowrap\">",
"       (US/LS)",
"      </span>",
"      AND increased arm",
"      <span class=\"nowrap\">",
"       span/height",
"      </span>",
"      AND no severe scoliosis: 1 point (See",
"      <a class=\"local\" href=\"#H5438598\">",
"       'Abnormal US/LS and arm span/height'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Scoliosis or thoracolumbar kyphosis: 1 point (See",
"      <a class=\"local\" href=\"#H5438605\">",
"       'Scoliosis and kyphosis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Reduced elbow extension (&le;170 degrees with full extension): 1 point (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Skeletal findings'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Facial features (at least 3 of the following 5 features: dolichocephaly [reduced cephalic index or head",
"      <span class=\"nowrap\">",
"       width/length",
"      </span>",
"      ratio], enophthalmos, downslanting palpebral fissures, malar hypoplasia, retrognathia): 1 point (See",
"      <a class=\"local\" href=\"#H3616747\">",
"       'Facial features'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Skin striae: 1 point (See",
"      <a class=\"local\" href=\"#H3616954\">",
"       'Skin striae'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Myopia &gt;3 diopters: 1 point (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Ocular abnormalities'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Mitral valve prolapse (all types): 1 point (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Cardiac disease'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A systemic score &ge;7 indicates systemic involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3616818\">",
"    <span class=\"h3\">",
"     Diagnosis in the young",
"    </span>",
"    &nbsp;&mdash;&nbsp;Application of diagnostic criteria to individuals &lt;20 years old, particularly those with sporadic disease, requires special care since additional clinical features may subsequently emerge.",
"   </p>",
"   <p>",
"    The revised Ghent nosology recommends the following categories for individuals &lt;20 years old with features of MFS who do not meet diagnostic criteria for MFS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      &ldquo;Nonspecific connective tissue disorder&rdquo; applies if the systemic score is less than 7",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      aortic root measurements are borderline (Z&lt;3) in the absence of an FBN1 mutation.",
"     </li>",
"     <li>",
"      &ldquo;Potential MFS&rdquo; applies if an FBN1 mutation is identified in a sporadic or familial cases but the aortic root Z-score is less than 3.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Individuals under 20 years of age with systemic findings suggestive of MFS but without cardiovascular involvement should also have annual echocardiograms due to the potential risk of rapid development of aortic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3616851\">",
"    <span class=\"h2\">",
"     Critique of the revised Ghent nosology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among 180 adult patients with MFS according to the original Ghent criteria, 164 (91 percent) met criteria for MFS using the revised Ghent criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/32\">",
"     32",
"    </a>",
"    ]. In 13 of the 16 patients in which the diagnosis of MFS was rejected using the revised criteria, the reason for rejection was a Z-score of the aortic root &lt;2, although the aortic diameter was greater than 40 mm in six of them. Although Z-score data are based on assuming a linear relationship between body surface area (BSA) and aortic root size [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/33\">",
"     33",
"    </a>",
"    ], subsequent data suggest that all aortic roots with diameter &ge; 40 mm are dilated [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/32\">",
"     32",
"    </a>",
"    ]. Thus, Z-score criteria for aortic dilatation may underestimate aortic enlargement, especially in patients with large BSAs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1393404\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS OF MFS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Aortic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aortic root disease, leading to aneurysmal dilatation, aortic regurgitation, and dissection, is the main cause of morbidity and mortality in the MFS (",
"    <a class=\"graphic graphic_movie graphicRef79876 \" href=\"UTD.htm?31/57/32656\">",
"     movie 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef87118 \" href=\"UTD.htm?21/9/21648\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50641 \" href=\"UTD.htm?32/38/33378\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86855 \" href=\"UTD.htm?33/55/34674\">",
"     image 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef87119 \" href=\"UTD.htm?28/55/29553\">",
"     image 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/34\">",
"     34",
"    </a>",
"    ]. There is generally little correlation between the severity of the cardiovascular and the ocular or skeletal manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/35\">",
"     35",
"    </a>",
"    ]. Although dilated, the aorta in MFS tends to be stiffer and less distensible than in controls, and these changes increase with age [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/36-39\">",
"     36-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dilatation of the aorta is found in approximately 50 percent of children with MFS and progresses with time. Approximately 60 to 80 percent of adult patients with MFS have dilatation of the aortic root (with normal range adjusted for patient body surface area and age) by echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/40\">",
"     40",
"    </a>",
"    ], often accompanied by aortic regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/35\">",
"     35",
"    </a>",
"    ]. Dilatation may also involve other segments of the thoracic aorta, the abdominal aorta, the root of the pulmonary artery or even the carotid and intracranial arteries.",
"   </p>",
"   <p>",
"    As recommended in the 2010 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/American",
"    </span>",
"    Association for Thoracic Surgery",
"    <span class=\"nowrap\">",
"     (ACC/AHA/AATS)",
"    </span>",
"    thoracic aorta guidelines, echocardiography is recommended at initial diagnosis and at six months to assess the aortic root and ascending aorta in patients with MFS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/41\">",
"     41",
"    </a>",
"    ]. The normal range for aortic diameter varies with body size and age so nomograms and Z-scores are used to identify aortic dilatation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/14,33\">",
"     14,33",
"    </a>",
"    ]. Monitoring should be performed at least annually as discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/51/5945?source=see_link&amp;anchor=H5#H5\">",
"     \"Management of Marfan syndrome and related disorders\", section on 'Monitoring MFS'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A limitation of using the Z-score to identify aortic dilatation is that it may underestimate aortic enlargement, especially in patients with large body surface area [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/32\">",
"     32",
"    </a>",
"    ]. As noted above, although Z-score data are based on assuming a linear relationship between BSA and aortic root size [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/33\">",
"     33",
"    </a>",
"    ], subsequent data suggest that all aortic roots with diameter &ge;40 mm are dilated [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3616851\">",
"     'Critique of the revised Ghent nosology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Untreated MFS is frequently associated with aortic dissection, which begins just above the coronary ostia and extends the entire length of the aorta; it is a type I dissection in the DeBakey classification or a type A in the Dailey scheme. Approximately 10 percent of dissections begin distal to the left subclavian (type III or type B) but dissection is rarely limited to just the abdominal aorta. Many patients with MFS and aortic dissection have a family history of dissection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of aortic dissection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The frequency with which MFS is responsible for aortic dissection was addressed in a review from the International Registry of Aortic Dissection (IRAD) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/42\">",
"     42",
"    </a>",
"    ]. The frequency varied importantly with age. MFS was present in 50 percent of those under age 40, compared to only 2 percent of older patients with aortic dissection and, in another report from IRAD, no patient over age 70 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The degree of aortic disease also has implications for women who would like to become pregnant and for management during pregnancy. These issues are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20262?source=see_link\">",
"     \"Pregnancy and Marfan syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cardiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitral valve prolapse (MVP) is frequently identified in patients with MFS (eg, 40 and 54 percent in two series of MFS patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]). However, only one point in the systemic score is assigned for MVP since it is a nonspecific feature and most patients with mitral valve prolapse do not have MFS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/40\">",
"     40",
"    </a>",
"    ]. The frequency of MVP in MFS increases with age and is greater in women. Tricuspid valve prolapse may also occur.",
"   </p>",
"   <p>",
"    On echocardiography, the mitral leaflets have an elongated and redundant appearance and either or both leaflets may prolapse. Patients with MFS and MVP have no to severe mitral regurgitation with most having mild or less regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/44\">",
"     44",
"    </a>",
"    ]. Approximately 25 percent of patients with MVP have progressive disease as defined by the appearance or worsening of clinical symptoms of mitral regurgitation or worsening on echocardiography. In some of these cases, worsening of mitral regurgitation is due to spontaneous rupture of the chordae tendineae or the result of infective endocarditis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6649?source=see_link&amp;anchor=H2#H2\">",
"     \"Natural history of chronic mitral regurgitation in mitral valve prolapse and flail mitral leaflet\", section on 'Natural history of mitral valve prolapse'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Care should be taken to distinguish MFS from mitral valve prolapse syndrome, which is defined as mitral valve prolapse associated with a limited systemic features score (&lt;5), as discussed below (see",
"    <a class=\"local\" href=\"#H1950373\">",
"     'Mitral valve prolapse syndrome'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    A preliminary report suggested that some patients with MFS may have a cardiomyopathy with biventricular enlargement and generally asymptomatic mild systolic function unrelated to valvular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Skeletal findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with MFS have excess linear growth of the long bones and joint laxity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/3\">",
"     3",
"    </a>",
"    ]. Individuals with MFS are taller than predicted by their genetic background (aside from the FBN1 mutation) (",
"    <a class=\"graphic graphic_picture graphicRef86852 \" href=\"UTD.htm?30/42/31398\">",
"     picture 3",
"    </a>",
"    ), which is generally, but not necessarily, tall compared to general population standards [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Paradoxically, some individuals with MFS have reduced joint mobility, particularly of the elbow and digits [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/3\">",
"     3",
"    </a>",
"    ]. The presence of reduced elbow extension (&le;170 degrees with full extension) contributes one point to the systemic score [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5438518\">",
"    <span class=\"h3\">",
"     Arachnodactyly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with MFS typically have arachnodactyly with positive thumb and wrist signs. A positive thumb sign indicates that the entire distal phalanx protrudes beyond the ulnar border of a clenched fist with or without the assistance of the patient or examiner to achieve maximum adduction (",
"    <a class=\"graphic graphic_picture graphicRef86853 \" href=\"UTD.htm?35/17/36127\">",
"     picture 2",
"    </a>",
"    ). A positive wrist sign means that the top of the thumb covers the entire fingernail of the fifth finger when wrapped around the contralateral wrist (",
"    <a class=\"graphic graphic_picture graphicRef86854 \" href=\"UTD.htm?26/2/26659\">",
"     picture 1",
"    </a>",
"    ). Three points are assigned if both thumb and wrist signs are positive; only one point is assigned if only one of these signs is positive.",
"   </p>",
"   <p>",
"    Generalized joint hypermobility also may occur, producing findings that overlap with the much more common benign joint hypermobility syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/56/2953?source=see_link\">",
"     \"Clinical manifestations and treatment of the hypermobility syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5438657\">",
"    <span class=\"h3\">",
"     Pectus deformity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pectus carinatum (",
"    <a class=\"graphic graphic_picture graphicRef86852 \" href=\"UTD.htm?30/42/31398\">",
"     picture 3",
"    </a>",
"    ) is assigned two points since it is thought to be more specific for MFS than pectus excavatum or chest asymmetry, which is assigned one point [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25207?source=see_link\">",
"     \"Pectus carinatum\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18071?source=see_link\">",
"     \"Pectus excavatum: Etiology and evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5438665\">",
"    <span class=\"h3\">",
"     Hindfoot valgus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hindfoot valgus is assigned two points. It occurs with forefoot abduction and lowering of the midfoot and should be evaluated from anterior and posterior view. Pes planus (flat foot) without hindfoot valgus is assigned one point.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5438598\">",
"    <span class=\"h3\">",
"     Abnormal US/LS and arm span/height",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with MFS have disproportionately long extremities in comparison to the length of the trunk (dolichostenomelia), so the upper segment to lower segment",
"    <span class=\"nowrap\">",
"     (US/LS)",
"    </span>",
"    ratio is decreased and the arm span to height ratio is increased. In determining the upper",
"    <span class=\"nowrap\">",
"     segment/lower",
"    </span>",
"    segment",
"    <span class=\"nowrap\">",
"     (US/LS)",
"    </span>",
"    ratio, the lower segment is defined as the distance from the top of the symphysis pubis to the floor in the standing position and the upper segment is the height minus the lower segment [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/14\">",
"     14",
"    </a>",
"    ]. Thresholds for abnormal",
"    <span class=\"nowrap\">",
"     US/LS",
"    </span>",
"    and arm",
"    <span class=\"nowrap\">",
"     span/height",
"    </span>",
"    vary with age and ethnicity. Reduced",
"    <span class=\"nowrap\">",
"     US/LS",
"    </span>",
"    is &lt;0.85 for white adults and &lt;0.78 for black adults. For children, reduced",
"    <span class=\"nowrap\">",
"     US/LS",
"    </span>",
"    is &lt;1 for age 0 to 5 years, &lt;0.95 for 6 to 7 years, &lt;0.9 for 8 to 9 years and &lt;0.85 above age 10 years. Increased arm span to height ratio is &gt;1.05 for white adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5438605\">",
"    <span class=\"h3\">",
"     Scoliosis and kyphosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Presence of either of the following findings is diagnostic for scoliosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With the patient bending forward, observation of a vertical difference of &ge;1.5 cm between the ribs of the left and right hemithorax.",
"     </li>",
"     <li>",
"      A Cobb&rsquo;s angle (on an anterior-posterior radiographic view of the spine, the angle between a line drawn along the superior end plate of the superior end vertebra and a second line drawn along the inferior end plate of the inferior end vertebra of the scoliosis) of at least 20 degrees.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If scoliosis is absent, one point can be attributed to kyphosis if there is exaggerated kyphotic thoracolumbar spinal curvature.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5438612\">",
"    <span class=\"h3\">",
"     Protrusio acetabuli",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acetabular protrusion can be diagnosed by plain x-ray, CT or MRI. On an anterior-posterior (AP) pelvic film, medial protrusion of the acetabulum &ge;3 mm beyond the ilio-ischial (Kohler) line is diagnostic. Criteria on CT or MRI are not as precisely defined but involve loss of the normal oval shape of the pelvic inlet at the level of the acetabulum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3616747\">",
"    <span class=\"h3\">",
"     Facial features",
"    </span>",
"    &nbsp;&mdash;&nbsp;One point is added to the systemic score if at least 3 of the following 5 facial features is present: dolichocephaly [reduced cephalic index or head",
"    <span class=\"nowrap\">",
"     width/length",
"    </span>",
"    ratio], enophthalmos, downslanting palpebral fissures, malar hypoplasia, retrognathia",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Ocular abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ectopia lentis occurs in 50 to 80 percent with MFS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/48\">",
"     48",
"    </a>",
"    ]. It is detected on slit-lamp examination after maximal dilatation of the pupil and the lens is usually displaced upward and temporally (",
"    <a class=\"graphic graphic_picture graphicRef67015 \" href=\"UTD.htm?22/3/22578\">",
"     picture 4",
"    </a>",
"    ). It is caused by failure of the supporting ciliary zonules.",
"   </p>",
"   <p>",
"    Ectopia lentis is the only cardinal ocular criterion for MFS (see",
"    <a class=\"local\" href=\"#H559172\">",
"     'Revised Ghent nosology'",
"    </a>",
"    above). However FBN1 mutations have been identified in some patients with ectopia lentis who do not have MFS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/49\">",
"     49",
"    </a>",
"    ], so the ectopia lentis syndrome should be carefully distinguished from MFS. (See",
"    <a class=\"local\" href=\"#H1950023\">",
"     'Ectopia lentis syndrome'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41557?source=see_link\">",
"     \"Ectopia lentis (dislocated lens) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The finding of myopia &gt;3 diopters contributes one point to the systemic score. Patients with MFS develop secondary myopia due to increased axis globe length. Other ocular findings in MFS include flat cornea (measured by keratometry) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/50\">",
"     50",
"    </a>",
"    ], hypoplastic iris or hypoplastic ciliary muscle causing decreased miosis, retinal detachment, glaucoma, and early cataract formation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/3\">",
"     3",
"    </a>",
"    ]. Retinal tears and detachment are commonly bilateral in MFS and may be associated with proliferative retinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Dural ectasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dural ectasia results from enlargement of the spinal canal owing to progressive ectasia of dura and neural foramina and to erosion of vertebral bone. This abnormality usually involves the lumbosacral spine and was identified in 63 and 92 percent of patients with MFS in case series using computed tomography (CT) and magnetic resonance (MR) scanning [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Dural ectasia is a sensitive but not specific sign of MFS and it commonly seen in Loeys-Dietz syndrome and in the vascular form of Ehlers-Danlos syndrome. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Spectrum of phenotypes and differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Several modalities have been utilized to help identify dural ectasia, including CT scanning, plain radiography, and MR. The last technique appears to be the most sensitive [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/53\">",
"     53",
"    </a>",
"    ]. No correlation appears to exist between the severity of dural ectasia and the degree of aortic dilatation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5438685\">",
"    <span class=\"h2\">",
"     Pneumothorax",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with MFS develop lung bullae (predominantly in the upper lobes), which can predispose to spontaneous pneumothorax (which contributes 2 points to the systemic score) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86855 \" href=\"UTD.htm?33/55/34674\">",
"     image 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/3,14\">",
"     3,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3616954\">",
"    <span class=\"h2\">",
"     Skin striae",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of striae atrophicae contributes one point to the systemic score if they are not associated with pronounced weight changes or pregnancy and if they have an uncommon location such as the mid back, lumbar region, upper arm, axillary region or thigh [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3616976\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent or incisional herniae, joint hypermobility and high arched palate may occur but are not included in the systemic score since these clinical features are considered nonspecific [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SPECTRUM OF PHENOTYPES AND DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As reflected in the above revised Ghent criteria, patients with MFS present with a spectrum of aortic, ocular, cardiac, and systemic features. The differential diagnosis for MFS includes a variety of conditions with phenotypic features that partially overlap the Marfan phenotype including disorders associated with FBN or TGFBR mutations as well as a variety of other genetic disorders (",
"    <a class=\"graphic graphic_table graphicRef59476 \" href=\"UTD.htm?40/50/41773\">",
"     table 1",
"    </a>",
"    ). As noted above, exclusion of MFS is particularly difficult in individuals &lt;20 years old. (See",
"    <a class=\"local\" href=\"#H3616818\">",
"     'Diagnosis in the young'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1950283\">",
"    <span class=\"h2\">",
"     Imaging those at risk for aortic enlargement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis for MFS includes other conditions associated with aortic complications. Patients with Loeys-Dietz syndrome or a genetic mutation known to predispose to aortic",
"    <span class=\"nowrap\">",
"     aneurysms/dissections",
"    </span>",
"    (TGFBR1, TGFBR2, FBN1, ACTA2, or MYH11) should undergo complete aortic imaging at initial diagnosis and six months thereafter to establish if enlargement is occurring, as recommended in the 2010",
"    <span class=\"nowrap\">",
"     ACC/AHA/AATS",
"    </span>",
"    guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/41\">",
"     41",
"    </a>",
"    ]. Monitoring is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/51/5945?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of Marfan syndrome and related disorders\", section on 'Aortic monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As noted above, individuals under 20 years of age with systemic findings suggestive of MFS but without cardiovascular involvement should also have annual echocardiograms due to the potential risk of rapid development of aortic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/14\">",
"     14",
"    </a>",
"    ]. Adults with repeatedly normal aortic root measurements can be seen at two- to three-year intervals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     FBN phenotypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;To date, no correlation between the specific type of FBN1 mutation and clinical phenotype has been recognized. As a general rule, patients with exon skipping tend to have more severe disease, while those showing premature termination causing reduced levels of a shortened mutant transcript tend to have milder disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/54\">",
"     54",
"    </a>",
"    ]. Some families have members with both classic MFS and a milder but related phenotype without aortic involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/55\">",
"     55",
"    </a>",
"    ]. These differences may be due to different genetic alterations rather than single FBN1 mutations.",
"   </p>",
"   <p>",
"    Some patients with FBN1 mutations have only one major criterion such as isolated ectopia lentis syndrome, isolated ascending aortic aneurysm",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dissection, or isolated skeletal features [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1949901\">",
"     'Conditions related to MFS'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Mutations involving a second fibrillin protein, fibrillin-2 (FBN2), have been linked to congenital contractural arachnodactyly (Beals syndrome). (See",
"    <a class=\"local\" href=\"#H1949862\">",
"     'Congenital contractural arachnodactyly'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     TGFBR phenotypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A spectrum of clinical features and outcomes are seen in patients with TGFBR1 or TGFBR2 mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/17,57\">",
"     17,57",
"    </a>",
"    ]. Some individuals with TGFBR1 or TGFBR2 mutations have clinical features wholly consistent with MFS, while others have features of one of two other syndromes with overlapping clinical manifestations: Loeys-Dietz syndrome or familial thoracic aortic aneurysm syndrome. Some have proposed classifying patients with Marfan phenotype and TGFBR1 or TGFBR2 mutations as LDS2 (rather than as MFS or Marfan syndrome 2) as a means of highlighting the potential for more aggressive vascular disease than seen in MFS with an FBN1 mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/3,14\">",
"     3,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The degree of aortic dilatation in individuals with TGFBR1 or TGFBR2 mutations is highly variable, and aortic dissection in patients with normal aortic diameters has been reported in some series but not others [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/17,57\">",
"     17,57",
"    </a>",
"    ]. Skeletal features are also variable with usually a mild Marfan phenotype.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10004284\">",
"    <span class=\"h3\">",
"     Loeys-Dietz syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with a TGFBR1 or TGFBR2 mutation have Loeys-Dietz syndrome, which is characterized by hypertelorism (widely spaced eyes), a split uvula or cleft palate, tortuous arteries, and aortic aneurysms [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Associated findings may include premature fusion of the skull, structural heart disease and aneurysms affecting other vessels.",
"   </p>",
"   <p>",
"    The prognosis in patients with a TGFBR mutation is variable and appears to depend upon clinical disease expression as well as treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/17,57\">",
"     17,57",
"    </a>",
"    ]. The following findings were noted in a series comparing the clinical manifestations and outcomes in 71 patients with a TGFBR2 mutation with 50 age- and sex-matched unaffected family members (controls) and 243 patients with FBN1 mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/57\">",
"     57",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The frequency of aortic dilation was similar in the TGFBR2 and FBN1 groups (78 and 79 percent).",
"     </li>",
"     <li>",
"      The two groups also had a similar incidence and average age for both thoracic aortic surgery (31 versus 27 percent and 35 versus 39 years) and aortic dissection (14 versus 10 percent and 38 versus 39 years).",
"     </li>",
"     <li>",
"      The TGFBR2 group had a lower rate of mitral valve disease (myxomatous, prolapse, or regurgitation).",
"     </li>",
"     <li>",
"      The mortality rate was higher in TGFBR2 than FBN1 families if patients who were not treated were included; the difference in mortality rate disappeared if only treated patients were included.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1949901\">",
"    <span class=\"h2\">",
"     Conditions related to MFS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ectopia lentis syndrome, MASS phenotype, and mitral valve prolapse syndrome each include some features of MFS but do not meet diagnostic criteria for MFS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/14\">",
"     14",
"    </a>",
"    ]. These should be distinguished from MFS with care since emerging MFS may include similar features.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1950023\">",
"    <span class=\"h3\">",
"     Ectopia lentis syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;An autosomal dominant form of familial ectopia lentis syndrome (ELS) is caused by FBN1 mutations and recessive forms are caused by LTBP2 and ADAMTSL4 mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/14\">",
"     14",
"    </a>",
"    ]. The revised Ghent criteria for ELS are ectopia lentis with or without systemic features",
"    <strong>",
"     and",
"    </strong>",
"    either an FBN1 mutation not known to be associated with aortic",
"    <span class=\"nowrap\">",
"     dilatation/dissection",
"    </span>",
"    or no FBN1 mutation.",
"   </p>",
"   <p>",
"    Thus, the syndrome includes some skeletal features of MFS as well as ectopia lentis but does not include aortic aneurysm. MFS rather than ELS should be diagnosed if the patient has an aortic aneurysm, family history of aortic aneurysm, or an FBN1 mutation previously associated with aortic aneurysm [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/14\">",
"     14",
"    </a>",
"    ]. It can be difficult to distinguish ELS from emerging MFS since aortic aneurysm may emerge later, so vigilance for aortic aneurysm is required and the diagnosis of ELS cannot be made before the patient is 20 years of age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1393996\">",
"    <span class=\"h3\">",
"     MASS phenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;MASS phenotype is familial disorder which includes the following features partially overlapping with MFS:",
"    <strong>",
"     m",
"    </strong>",
"    itral valve prolapse, mild",
"    <strong>",
"     a",
"    </strong>",
"    ortic dilatation,",
"    <strong>",
"     s",
"    </strong>",
"    triae atrophica, and at least one",
"    <strong>",
"     s",
"    </strong>",
"    keletal feature [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/58\">",
"     58",
"    </a>",
"    ]. The revised Ghent criteria for diagnosis of MASS are an aortic diameter Z&lt;2",
"    <strong>",
"     and",
"    </strong>",
"    systemic score &ge;5 including at least one skeletal feature",
"    <strong>",
"     and",
"    </strong>",
"    absence of ectopia lentis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The MASS phenotype is most difficult to distinguish from emerging Marfan syndrome in a young individual without a contributory family history and careful follow-up is required for appropriate diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/2\">",
"     2",
"    </a>",
"    ]. FBN1 mutations have been found in some patients with the MASS phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/59\">",
"     59",
"    </a>",
"    ] but the potential risk of progression to aortic complications has not been characterized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1950373\">",
"    <span class=\"h3\">",
"     Mitral valve prolapse syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The revised Ghent criteria for mitral valve prolapse syndrome (MVPS) are mitral valve prolapse",
"    <strong>",
"     and",
"    </strong>",
"    systemic features (&lt;5)",
"    <strong>",
"     and",
"    </strong>",
"    aortic diameter Z&lt;2 and absence of ectopia lentis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/14\">",
"     14",
"    </a>",
"    ]. Some common systemic features are pectus excavatum, scoliosis and mild arachnodactyly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1949855\">",
"    <span class=\"h2\">",
"     Homocystinuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Homocystinuria is associated with a Marfanoid body habitus and severe myopia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ectopia lentis, although the lens is typically dislocated downward rather than upward as in MFS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/14\">",
"     14",
"    </a>",
"    ]. Distinguishing features of homocystinuria include mental retardation and thrombosis. The diagnosis of homocystinuria can be excluded by testing for hypermethionemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41557?source=see_link&amp;anchor=H7#H7\">",
"     \"Ectopia lentis (dislocated lens) in children\", section on 'Systemic causes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1949862\">",
"    <span class=\"h2\">",
"     Congenital contractural arachnodactyly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in the FBN2 gene, the gene encoding the extracellular matrix protein fibrillin-2, have been described in patients with congenital contractural arachnodactyly (CCA, MIM# 121050, Beals-Hecht or Beals syndrome), which is an autosomal dominant disorder characterized by a marfanoid habitus with arachnodactyly,",
"    <span class=\"nowrap\">",
"     kyphosis/scoliosis,",
"    </span>",
"    contractures of knees and ankles, flexion contractures of the proximal interphalangeal joints of the fingers and toes (camptodactyly), and crumpled ears (folded upper helix) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/14,48,61,62\">",
"     14,48,61,62",
"    </a>",
"    ]. Some individuals with this syndrome have mild enlargement of the sinuses of Valsalva.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1394003\">",
"    <span class=\"h2\">",
"     Certain Ehlers Danlos types",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of forms of Ehlers Danlos syndrome (EDS) are associated with joint hypermobility. Arterial aneurysms and dissection are seen particularly in EDS vascular type. EDS is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/56/2953?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical manifestations and treatment of the hypermobility syndrome\", section on 'Ehlers-Danlos syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1394010\">",
"    <span class=\"h2\">",
"     Stickler syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type II and type XI collagen mutations have been identified in the Stickler syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1394017\">",
"    <span class=\"h2\">",
"     Additional disorders in the differential diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Congenital bicuspid aortic valve disease with associated aortopathy. Aortic dilation may involve primarily the aortic root or the mid-ascending aorta.",
"     </li>",
"     <li>",
"      Aortic coarctation with associated ascending aortic enlargement",
"     </li>",
"     <li>",
"      Familial thoracic aortic aneurysm or aortopathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SCREENING RELATIVES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for screening relatives are also included in the 2010",
"    <span class=\"nowrap\">",
"     ACC/AHA/AATS",
"    </span>",
"    guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/41\">",
"     41",
"    </a>",
"    ]. First-degree relatives of patients with a gene mutation associated with aortic aneurysms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dissection (FBN1, TGFBR1, TGFBR2, COL3A1, ACTA2, MYH11) should undergo counseling and genetic testing. Those found to have the genetic mutation should then undergo aortic imaging. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24602?source=see_link\">",
"     \"Genetic counseling and testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of MFS in the siblings of an individual with MFS depends upon whether a parent has MFS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/3/20538/abstract/3\">",
"     3",
"    </a>",
"    ]. If a parent has MFS, the risk of MFS in a sibling is 50 percent. If neither parent has MFS, the risk of MFS in a sibling is far less than 50 percent (since the mutation in the proband is likely de novo) but greater than the baseline population risk since there are rare cases of somatic and germline mosaicism which could lead to MFS in siblings without manifestation of MFS in the parents.",
"   </p>",
"   <p>",
"    For patients with aortic aneurysm",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dissection without a known mutation, aortic imaging is recommended for first-degree relatives to identify those with asymptomatic disease. If one or more first-degree relatives are found to have thoracic aortic dilatation, aneurysm, or dissection, then imaging of second-degree relatives is reasonable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/11/25778?source=see_link\">",
"       \"Patient information: Marfan syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of Marfan syndrome (MFS) in familial and sporadic cases is based upon the presence of characteristic manifestations particularly aortic root",
"      <span class=\"nowrap\">",
"       dilatation/dissection",
"      </span>",
"      and ectopia lentis, as well as other systemic features including skeletal findings, mitral valve prolapse, dural ectasia, pneumothorax, and skin striae. The presence of a likely causal fibrillin 1 (FBN1) mutation lends strong support to the diagnosis in combination with certain clinical features. (See",
"      <a class=\"local\" href=\"#H559172\">",
"       'Revised Ghent nosology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      MFS is caused by a variety of mutations in the FBN1 gene. FBN1 mutations have been identified in over 90 percent of patients with MFS. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'FBN1 mutations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      About 10 percent of individuals with suspected MFS have no FBN1 mutation. Some of these individuals have TGFBR1 or TGFBR2 mutations.",
"      <span class=\"nowrap\">",
"       TGFBR1/TGFBR2",
"      </span>",
"      mutations cause Loeys-Dietz syndrome (LDS) and familial thoracic aortic aneurysm (FTAA) syndrome. We suggest categorizing individuals with the Marfan phenotype with a TGFBR1 or TGFBR2 mutation as LDS2 since they may be at risk for more aggressive vascular disease than seen in MFS. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'TGFBR mutations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some patients with FBN1 gene mutations do not have MFS and instead have a related disorder such as ectopia lentis syndrome or other diseases such as Shprintzen-Goldberg syndrome or Weill-Marchesani syndrome. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'FBN phenotypes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Application of diagnostic criteria to individuals &lt;20 years old requires special care since some clinical features may have not yet emerged. (See",
"      <a class=\"local\" href=\"#H3616818\">",
"       'Diagnosis in the young'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The aortic root Z-score is used to identify aortic dilatation since aortic size varies with body size. However, use of Z-scores may underestimate aortic size, particularly in individuals with large body surface area. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Aortic disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3616851\">",
"       'Critique of the revised Ghent nosology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis for MFS includes a variety of conditions with phenotypic features that partially overlap the Marfan phenotype, including disorders associated with FBN or TGFBR mutations, as well as a variety of other genetic disorders (",
"      <a class=\"graphic graphic_table graphicRef59476 \" href=\"UTD.htm?40/50/41773\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Spectrum of phenotypes and differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      First-degree relatives of patients with a gene mutation associated with aortic aneurysms",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      dissection (FBN1, TGFBR1, TGFBR2, COL3A1, ACTA2, MYH11) should undergo counseling and genetic testing. Those found to have the genetic mutation should then undergo aortic imaging. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Screening relatives'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with aortic aneurysm",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      dissection without a known mutation, aortic imaging is recommended for first-degree relatives to identify those with asymptomatic disease. If one or more first-degree relatives are found to have thoracic aortic dilatation, aneurysm, or dissection, then imaging of second-degree relatives is reasonable. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Screening relatives'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Ramirez F, Godfrey M, Lee B, et al.. Marfan syndrome and related disorders. In: The Metabolic and Molecular Basis of Inherited Disease, Scriver CR, Beaudet AL, Sly WS, et al. (Eds), McGraw Hill, New York 1995. p.4079.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/2\">",
"      Judge DP, Dietz HC. Marfan's syndrome. Lancet 2005; 366:1965.",
"     </a>",
"    </li>",
"    <li>",
"     Dietz HC (Updated June 30, 2009). Marfan syndrome. In: GeneReviews at GeneTest: Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. 1997-2011. Available at file://www.genetests.org (Accessed on April 20, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/4\">",
"      Hilhorst-Hofstee Y, Rijlaarsdam ME, Scholte AJ, et al. The clinical spectrum of missense mutations of the first aspartic acid of cbEGF-like domains in fibrillin-1 including a recessive family. Hum Mutat 2010; 31:E1915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/5\">",
"      Sakai LY, Keene DR, Glanville RW, B&auml;chinger HP. Purification and partial characterization of fibrillin, a cysteine-rich structural component of connective tissue microfibrils. J Biol Chem 1991; 266:14763.",
"     </a>",
"    </li>",
"    <li>",
"     Dietz HC, Ramirez F, Sakai LY. Marfan's syndrome and other microfibrillar diseases. In: Advanced Human Genetics, Harris H, Hirschorn K (Eds), Plenum Press, New York 1994. p.153.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/7\">",
"      Akhurst RJ. TGF beta signaling in health and disease. Nat Genet 2004; 36:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/8\">",
"      Smallridge RS, Whiteman P, Doering K, et al. EGF-like domain calcium affinity modulated by N-terminal domain linkage in human fibrillin-1. J Mol Biol 1999; 286:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/9\">",
"      Sinha S, Nevett C, Shuttleworth CA, Kielty CM. Cellular and extracellular biology of the latent transforming growth factor-beta binding proteins. Matrix Biol 1998; 17:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/10\">",
"      Reinhardt DP, Keene DR, Corson GM, et al. Fibrillin-1: organization in microfibrils and structural properties. J Mol Biol 1996; 258:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/11\">",
"      Zhang H, Hu W, Ramirez F. Developmental expression of fibrillin genes suggests heterogeneity of extracellular microfibrils. J Cell Biol 1995; 129:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/12\">",
"      Collod-B&eacute;roud G, Le Bourdelles S, Ades L, et al. Update of the UMD-FBN1 mutation database and creation of an FBN1 polymorphism database. Hum Mutat 2003; 22:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/13\">",
"      Milewicz DM, Michael K, Fisher N, et al. Fibrillin-1 (FBN1) mutations in patients with thoracic aortic aneurysms. Circulation 1996; 94:2708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/14\">",
"      Loeys BL, Dietz HC, Braverman AC, et al. The revised Ghent nosology for the Marfan syndrome. J Med Genet 2010; 47:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/15\">",
"      Mizuguchi T, Collod-Beroud G, Akiyama T, et al. Heterozygous TGFBR2 mutations in Marfan syndrome. Nat Genet 2004; 36:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/16\">",
"      Loeys BL, Chen J, Neptune ER, et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet 2005; 37:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/17\">",
"      Loeys BL, Schwarze U, Holm T, et al. Aneurysm syndromes caused by mutations in the TGF-beta receptor. N Engl J Med 2006; 355:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/18\">",
"      Loeys B, De Backer J, Van Acker P, et al. Comprehensive molecular screening of the FBN1 gene favors locus homogeneity of classical Marfan syndrome. Hum Mutat 2004; 24:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/19\">",
"      Schlatmann TJ, Becker AE. Histologic changes in the normal aging aorta: implications for dissecting aortic aneurysm. Am J Cardiol 1977; 39:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/20\">",
"      Schlatmann TJ, Becker AE. Pathogenesis of dissecting aneurysm of aorta. Comparative histopathologic study of significance of medial changes. Am J Cardiol 1977; 39:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/21\">",
"      Hirst AE, Gore I. Editorial: Is cystic medionecrosis the cause of dissecting aortic aneurysm? Circulation 1976; 53:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/22\">",
"      Trotter SE, Olsen EG. Marfan's disease and Erdheim's cystic medionecrosis. A study of their pathology. Eur Heart J 1991; 12:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/23\">",
"      Collins MJ, Dev V, Strauss BH, et al. Variation in the histopathological features of patients with ascending aortic aneurysms: a study of 111 surgically excised cases. J Clin Pathol 2008; 61:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/24\">",
"      Dietz HC, McIntosh I, Sakai LY, et al. Four novel FBN1 mutations: significance for mutant transcript level and EGF-like domain calcium binding in the pathogenesis of Marfan syndrome. Genomics 1993; 17:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/25\">",
"      Judge DP, Biery NJ, Keene DR, et al. Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome. J Clin Invest 2004; 114:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/26\">",
"      Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006; 312:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/27\">",
"      Brooke BS, Habashi JP, Judge DP, et al. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med 2008; 358:2787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/28\">",
"      Ahimastos AA, Aggarwal A, D'Orsa KM, et al. Effect of perindopril on large artery stiffness and aortic root diameter in patients with Marfan syndrome: a randomized controlled trial. JAMA 2007; 298:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/29\">",
"      Ng CM, Cheng A, Myers LA, et al. TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. J Clin Invest 2004; 114:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/30\">",
"      Ahimastos AA, Dart AM, Kingwell BA. Angiotensin II blockade in Marfan's syndrome. N Engl J Med 2008; 359:1732; author reply 1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/31\">",
"      De Paepe A, Devereux RB, Dietz HC, et al. Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet 1996; 62:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/32\">",
"      Radonic T, de Witte P, Groenink M, et al. Critical appraisal of the revised Ghent criteria for diagnosis of Marfan syndrome. Clin Genet 2011; 80:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/33\">",
"      Roman MJ, Devereux RB, Kramer-Fox R, O'Loughlin J. Two-dimensional echocardiographic aortic root dimensions in normal children and adults. Am J Cardiol 1989; 64:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/34\">",
"      Adams JN, Trent RJ. Aortic complications of Marfan's syndrome. Lancet 1998; 352:1722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/35\">",
"      Bruno L, Tredici S, Mangiavacchi M, et al. Cardiac, skeletal, and ocular abnormalities in patients with Marfan's syndrome and in their relatives. Comparison with the cardiac abnormalities in patients with kyphoscoliosis. Br Heart J 1984; 51:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/36\">",
"      Jeremy RW, Huang H, Hwa J, et al. Relation between age, arterial distensibility, and aortic dilatation in the Marfan syndrome. Am J Cardiol 1994; 74:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/37\">",
"      Adams JN, Brooks M, Redpath TW, et al. Aortic distensibility and stiffness index measured by magnetic resonance imaging in patients with Marfan's syndrome. Br Heart J 1995; 73:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/38\">",
"      Groenink M, de Roos A, Mulder BJ, et al. Biophysical properties of the normal-sized aorta in patients with Marfan syndrome: evaluation with MR flow mapping. Radiology 2001; 219:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/39\">",
"      Jondeau G, Boutouyrie P, Lacolley P, et al. Central pulse pressure is a major determinant of ascending aorta dilation in Marfan syndrome. Circulation 1999; 99:2677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/40\">",
"      Roman MJ, Devereux RB, Kramer-Fox R, Spitzer MC. Comparison of cardiovascular and skeletal features of primary mitral valve prolapse and Marfan syndrome. Am J Cardiol 1989; 63:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/41\">",
"      Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation 2010; 121:e266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/42\">",
"      Januzzi JL, Isselbacher EM, Fattori R, et al. Characterizing the young patient with aortic dissection: results from the International Registry of Aortic Dissection (IRAD). J Am Coll Cardiol 2004; 43:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/43\">",
"      Mehta RH, O'Gara PT, Bossone E, et al. Acute type A aortic dissection in the elderly: clinical characteristics, management, and outcomes in the current era. J Am Coll Cardiol 2002; 40:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/44\">",
"      Rybczynski M, Mir TS, Sheikhzadeh S, et al. Frequency and age-related course of mitral valve dysfunction in the Marfan syndrome. Am J Cardiol 2010; 106:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/45\">",
"      Faivre L, Collod-Beroud G, Loeys BL, et al. Effect of mutation type and location on clinical outcome in 1,013 probands with Marfan syndrome or related phenotypes and FBN1 mutations: an international study. Am J Hum Genet 2007; 81:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/46\">",
"      Alpendurada F, Wong J, Kiotsekoglou A, et al. Evidence for Marfan cardiomyopathy. Eur J Heart Fail 2010; 12:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/47\">",
"      Erkula G, Jones KB, Sponseller PD, et al. Growth and maturation in Marfan syndrome. Am J Med Genet 2002; 109:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/48\">",
"      Tsipouras P, Del Mastro R, Sarfarazi M, et al. Genetic linkage of the Marfan syndrome, ectopia lentis, and congenital contractural arachnodactyly to the fibrillin genes on chromosomes 15 and 5. The International Marfan Syndrome Collaborative Study. N Engl J Med 1992; 326:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/49\">",
"      Edwards MJ, Challinor CJ, Colley PW, et al. Clinical and linkage study of a large family with simple ectopia lentis linked to FBN1. Am J Med Genet 1994; 53:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/50\">",
"      Heur M, Costin B, Crowe S, et al. The value of keratometry and central corneal thickness measurements in the clinical diagnosis of Marfan syndrome. Am J Ophthalmol 2008; 145:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/51\">",
"      Abboud EB. Retinal detachment surgery in Marfan's syndrome. Retina 1998; 18:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/52\">",
"      Pyeritz RE, Fishman EK, Bernhardt BA, Siegelman SS. Dural ectasia is a common feature of the Marfan syndrome. Am J Hum Genet 1988; 43:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/53\">",
"      Fattori R, Nienaber CA, Descovich B, et al. Importance of dural ectasia in phenotypic assessment of Marfan's syndrome. Lancet 1999; 354:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/54\">",
"      Putnam EA, Cho M, Zinn AB, et al. Delineation of the Marfan phenotype associated with mutations in exons 23-32 of the FBN1 gene. Am J Med Genet 1996; 62:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/55\">",
"      Pereira L, Levran O, Ramirez F, et al. A molecular approach to the stratification of cardiovascular risk in families with Marfan's syndrome. N Engl J Med 1994; 331:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/56\">",
"      Faivre L, Collod-Beroud G, Callewaert B, et al. Pathogenic FBN1 mutations in 146 adults not meeting clinical diagnostic criteria for Marfan syndrome: further delineation of type 1 fibrillinopathies and focus on patients with an isolated major criterion. Am J Med Genet A 2009; 149A:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/57\">",
"      Attias D, Stheneur C, Roy C, et al. Comparison of clinical presentations and outcomes between patients with TGFBR2 and FBN1 mutations in Marfan syndrome and related disorders. Circulation 2009; 120:2541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/58\">",
"      Glesby MJ, Pyeritz RE. Association of mitral valve prolapse and systemic abnormalities of connective tissue. A phenotypic continuum. JAMA 1989; 262:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/59\">",
"      Rybczynski M, Bernhardt AM, Rehder U, et al. The spectrum of syndromes and manifestations in individuals screened for suspected Marfan syndrome. Am J Med Genet A 2008; 146A:3157.",
"     </a>",
"    </li>",
"    <li>",
"     Picker JD, Levy HL (Updated [March 29 2006]). Homocystinuria caused by cystathionine beta-synthase deficiency. In: GeneReviews at GeneTests: Medical Genetics Information Reseource (database online). University of Washington, Seattle. 2006. Available at file://www.genetests.org. Accessed [April 18, 2011].",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/61\">",
"      Putnam EA, Zhang H, Ramirez F, Milewicz DM. Fibrillin-2 (FBN2) mutations result in the Marfan-like disorder, congenital contractural arachnodactyly. Nat Genet 1995; 11:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/62\">",
"      Callewaert BL, Loeys BL, Ficcadenti A, et al. Comprehensive clinical and molecular assessment of 32 probands with congenital contractural arachnodactyly: report of 14 novel mutations and review of the literature. Hum Mutat 2009; 30:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/63\">",
"      Wilkin DJ, Mortier GR, Johnson CL, et al. Correlation of linkage data with phenotype in eight families with Stickler syndrome. Am J Med Genet 1998; 80:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/3/20538/abstract/64\">",
"      Sirko-Osadsa DA, Murray MA, Scott JA, et al. Stickler syndrome without eye involvement is caused by mutations in COL11A2, the gene encoding the alpha2(XI) chain of type XI collagen. J Pediatr 1998; 132:368.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8150 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-00FF42CD0A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_3_20538=[""].join("\n");
var outline_f20_3_20538=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      FBN1 mutations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14548416\">",
"      - Causal FBN1 mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TGFBR mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Prenatal genetic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18272484\">",
"      Role of genetic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      HISTOPATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5437793\">",
"      CRITERIA FOR DIAGNOSIS OF MFS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Older criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H559172\">",
"      Revised Ghent nosology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14548408\">",
"      - Systemic score",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3616818\">",
"      - Diagnosis in the young",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3616851\">",
"      Critique of the revised Ghent nosology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1393404\">",
"      CLINICAL MANIFESTATIONS OF MFS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Aortic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cardiac disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Skeletal findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5438518\">",
"      - Arachnodactyly",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5438657\">",
"      - Pectus deformity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5438665\">",
"      - Hindfoot valgus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5438598\">",
"      - Abnormal US/LS and arm span/height",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5438605\">",
"      - Scoliosis and kyphosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5438612\">",
"      - Protrusio acetabuli",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3616747\">",
"      - Facial features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Ocular abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Dural ectasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5438685\">",
"      Pneumothorax",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3616954\">",
"      Skin striae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3616976\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SPECTRUM OF PHENOTYPES AND DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1950283\">",
"      Imaging those at risk for aortic enlargement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      FBN phenotypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TGFBR phenotypes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10004284\">",
"      - Loeys-Dietz syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1949901\">",
"      Conditions related to MFS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1950023\">",
"      - Ectopia lentis syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1393996\">",
"      - MASS phenotype",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1950373\">",
"      - Mitral valve prolapse syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1949855\">",
"      Homocystinuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1949862\">",
"      Congenital contractural arachnodactyly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1394003\">",
"      Certain Ehlers Danlos types",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1394010\">",
"      Stickler syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1394017\">",
"      Additional disorders in the differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SCREENING RELATIVES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/8150\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8150|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/9/21648\" title=\"diagnostic image 1\">",
"      PLAX echo Marfan aorta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?32/38/33378\" title=\"diagnostic image 2\">",
"      Aortic root enlargement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?33/55/34674\" title=\"diagnostic image 3\">",
"      Chest x-ray Marfan syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/55/29553\" title=\"diagnostic image 4\">",
"      CT scan Marfan aorta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8150|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/2/26659\" title=\"picture 1\">",
"      Wrist sign in Marfan syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/17/36127\" title=\"picture 2\">",
"      Thumb sign in Marfan syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/42/31398\" title=\"picture 3\">",
"      Marfan syndrome skeletal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/3/22578\" title=\"picture 4\">",
"      Marfan syndrome dislocated lens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8150|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?31/57/32656\" title=\"movie 1\">",
"      Aortic root aneurysm parasternal long axis echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8150|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/50/41773\" title=\"table 1\">",
"      Differential diagnosis of Marfan syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=related_link\">",
"      Clinical manifestations and diagnosis of aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/56/2953?source=related_link\">",
"      Clinical manifestations and treatment of the hypermobility syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41557?source=related_link\">",
"      Ectopia lentis (dislocated lens) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24602?source=related_link\">",
"      Genetic counseling and testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/51/5945?source=related_link\">",
"      Management of Marfan syndrome and related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6649?source=related_link\">",
"      Natural history of chronic mitral regurgitation in mitral valve prolapse and flail mitral leaflet",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/11/25778?source=related_link\">",
"      Patient information: Marfan syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25207?source=related_link\">",
"      Pectus carinatum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18071?source=related_link\">",
"      Pectus excavatum: Etiology and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20262?source=related_link\">",
"      Pregnancy and Marfan syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_3_20539="Segmental Na reabsorption";
var content_f20_3_20539=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F62655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F62655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sodium reabsorption in different nephron segments",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Tubule segment",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent filtered NA reabsorbed",
"       </td>",
"       <td class=\"subtitle1\">",
"        Determinants of reabsorption",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Proximal tubule",
"       </td>",
"       <td>",
"        60-65",
"       </td>",
"       <td>",
"        <p>",
"         Na+-H+ exchange",
"        </p>",
"        <p>",
"         Na+-glucose cotransport",
"        </p>",
"        <p>",
"         Angiotensin II and norepinephrine",
"        </p>",
"        <p>",
"         Peritubular capillary hemodynamics",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Loop of Henle",
"       </td>",
"       <td>",
"        25-30",
"       </td>",
"       <td>",
"        Flow-dependent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Distal tubule",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        Flow-dependent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Collecting tubules",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        <p>",
"         Aldosterone",
"        </p>",
"        <p>",
"         Atrial natriuretic peptide",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Anatomic distribution and determinants of segmental NaCl reabsorption.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Bennett, CM, Brenner, BM, Berliner, R, J Clin Invest 1968; 47:203.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_3_20539=[""].join("\n");
var outline_f20_3_20539=null;
var title_f20_3_20540="Dosing novel beta lactams II";
var content_f20_3_20540=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F51241&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F51241&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Adjusted maximum dose in renal failure for novel beta-lactams",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        GFR, mL/min",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Removal by dialysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        &gt;50",
"       </td>",
"       <td class=\"subtitle2\">",
"        10-50",
"       </td>",
"       <td class=\"subtitle2\">",
"        &lt;10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ampicillin-sulbactam (1 g:0.5 g)",
"       </td>",
"       <td>",
"        NC",
"       </td>",
"       <td>",
"        3 g Q 12h (of combination)",
"       </td>",
"       <td>",
"        3 g Q 24h",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ticarcillin-clavulanate (3 g:0.1 g)",
"       </td>",
"       <td>",
"        NC",
"       </td>",
"       <td>",
"        3.1 g Q 6-8h (of combination)",
"       </td>",
"       <td>",
"        2 g Q 12h",
"       </td>",
"       <td>",
"        Yes (H)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Piperacillin-tazobactam (3 g:0.375 g) or (2 g:0.25 g)",
"       </td>",
"       <td>",
"        NC",
"       </td>",
"       <td>",
"        2.25 g Q 6h (of combination)",
"       </td>",
"       <td>",
"        2.25 g Q 8h (of combination)",
"       </td>",
"       <td>",
"        Yes (H)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Imipenem-cilastatin (1:1)",
"       </td>",
"       <td>",
"        NC",
"       </td>",
"       <td>",
"        500 mg Q 8-12h",
"       </td>",
"       <td>",
"        250-500 mg Q 12h*",
"       </td>",
"       <td>",
"        Yes (H)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meropenem",
"       </td>",
"       <td>",
"        NC",
"       </td>",
"       <td>",
"        500 mg-1 g Q 12h",
"       </td>",
"       <td>",
"        500 mg-1 g Q 24h",
"       </td>",
"       <td>",
"        Yes (H)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ertapenem",
"       </td>",
"       <td>",
"        NC",
"       </td>",
"       <td>",
"        0.5 g-1 g Q 24h",
"       </td>",
"       <td>",
"        0.5 g Q 24h",
"       </td>",
"       <td>",
"        Yes (H)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Doripenem",
"       </td>",
"       <td>",
"        NC",
"       </td>",
"       <td>",
"        250 mg Q 8-12h",
"       </td>",
"       <td>",
"        Inadequate data for use",
"       </td>",
"       <td>",
"        Yes (H)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aztreonam",
"       </td>",
"       <td>",
"        NC",
"       </td>",
"       <td>",
"        1g Q 8h",
"       </td>",
"       <td>",
"        500 mg Q 8h",
"       </td>",
"       <td>",
"        Yes (H, P)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     H: hemodialysis; P: peritoneal dialysis.",
"     <br>",
"      *&nbsp;Substantial caution should be used, particularly if hemodialysis has not begun.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_3_20540=[""].join("\n");
var outline_f20_3_20540=null;
var title_f20_3_20541="OI clinical features";
var content_f20_3_20541=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78737&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78737&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical features of OI by type",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type",
"        <br/>",
"        (MIM#)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Inheritance",
"        <br/>",
"        (gene)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Severity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Fractures",
"       </td>",
"       <td class=\"subtitle1\">",
"        Bone deformity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Stature",
"       </td>",
"       <td class=\"subtitle1\">",
"        DI",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sclerae",
"       </td>",
"       <td class=\"subtitle1\">",
"        Hearing loss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I",
"        <br/>",
"        (#166200)",
"       </td>",
"       <td>",
"        AD (COL1A1 or COL1A2)",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"       <td>",
"        Few to 100",
"       </td>",
"       <td>",
"        Uncommon",
"       </td>",
"       <td>",
"        Normal or slightly short for family",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Blue",
"       </td>",
"       <td>",
"        Present in about 50 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        II",
"        <br/>",
"        (IIA - #166210, IIB - #610854)",
"       </td>",
"       <td>",
"        <p>",
"         AD (IIA - CO1A1 or COL1A2)",
"        </p>",
"        <p>",
"         AR (IIB - CRTAP)",
"        </p>",
"       </td>",
"       <td>",
"        Perinatal lethal",
"       </td>",
"       <td>",
"        Multiple",
"       </td>",
"       <td>",
"        Severe",
"       </td>",
"       <td>",
"        Severely short stature",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        <p>",
"         IIA - Dark blue",
"        </p>",
"        <p>",
"         IIB - Light blue",
"        </p>",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        III",
"        <br/>",
"        (#259420)",
"       </td>",
"       <td>",
"        AD; (COL1A1 or COL1A2)",
"       </td>",
"       <td>",
"        Severe",
"       </td>",
"       <td>",
"        Multiple",
"       </td>",
"       <td>",
"        Moderate to severe",
"       </td>",
"       <td>",
"        Very short",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        Blue at birth, becoming normal with age",
"       </td>",
"       <td>",
"        Frequent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IV",
"        <br/>",
"        (#166220)",
"       </td>",
"       <td>",
"        AD (COL1A1 or COL1A2)",
"       </td>",
"       <td>",
"        Moderate to mild",
"       </td>",
"       <td>",
"        Multiple",
"       </td>",
"       <td>",
"        Mild to moderate",
"       </td>",
"       <td>",
"        Variably short stature",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        Normal to grey",
"       </td>",
"       <td>",
"        Some",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        V",
"        <br/>",
"        (#610967)",
"       </td>",
"       <td>",
"        AD (IFITM5)",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        Multiple with hypertrophic callus",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        VI",
"        <br/>",
"        (#610968)",
"       </td>",
"       <td>",
"        AR (FKBP10); rarely AD with parental mosaicism",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        Multiple",
"       </td>",
"       <td>",
"        Rhizomelic shortening",
"       </td>",
"       <td>",
"        Mild short stature",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Normal to faintly blue",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        VII",
"        <br/>",
"        (#610682)",
"       </td>",
"       <td>",
"        AR (CRTAP)",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        Multiple",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Mild short stature",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Normal to faintly blue",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        VIII",
"        <br/>",
"        (#610915)",
"       </td>",
"       <td>",
"        AR (LEPRE1)",
"       </td>",
"       <td>",
"        Lethal/severe",
"       </td>",
"       <td>",
"        Multiple",
"       </td>",
"       <td>",
"        Moderate to severe; bulbous \"popcorn\" sepiphyses",
"       </td>",
"       <td>",
"        Short-limbed dwarfism",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Not reported",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IX",
"        <br/>",
"        (#259440)",
"       </td>",
"       <td>",
"        AR (PPIB)",
"       </td>",
"       <td>",
"        Lethal/severe",
"       </td>",
"       <td>",
"        Multiple",
"       </td>",
"       <td>",
"        Moderate to severe",
"       </td>",
"       <td>",
"        Short-limbed dwarfism",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        Blue",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AD: autosomal dominant; AR: autosomal recessive; DI: dentinogenesis imperfecta.",
"    </div>",
"    <div class=\"reference\">",
"     Modified and updated from: Steiner RD, Pepin MG, Byers PH. Osteogenesis Imperfecta. GeneReviews at GeneTests: Medical Genetics Information Resource, January 2005.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_3_20541=[""].join("\n");
var outline_f20_3_20541=null;
var title_f20_3_20542="Alligator forceps extraction";
var content_f20_3_20542=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/73259/alligatorfbe_conv.mp4?title=Alligator+forceps+extraction\" style=\"width:352px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Alligator forceps removal of a metallic FB",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 254px; height: 176px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles Marquette, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_3_20542=[""].join("\n");
var outline_f20_3_20542=null;
var title_f20_3_20543="Differential dx mood disorders";
var content_f20_3_20543=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F74999&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F74999&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of primary mood disorders",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 446px; height: 373px; background-image: url(data:image/gif;base64,R0lGODlhvgF1AdUAAP///4CAgH9/f7+/vwAAAD8/P0BAQD+MZr/YzMDAwH+yme/v79/f3y8vL19fX5+fn8/Pz09PTwBmMx8fHyAgIK+vr6CgoPDw8N/r5W9vb8/i2O/18o+Pjy+CWTAwMODg4J/Fsl+ff8DZzRAQENDQ0E+VckCMZq/Pv2BgYA8PD2+ojHBwcB95TFBQUI+8pYCzmbCwsA9vP5CQkODs5vD286DGs9Dj2XCpjSB5TVCWc2CggJC8pjCDWbDQwBBwQAAAACH5BAAAAAAALAAAAAC+AXUBAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaZHCQGqq6ytrq+wsbKztAEJp2okFrW8va8WJLh/AQUCxsfIycrLzM3Oz88FAcJlHysUExHQ29zOERMUKx/UegECjQLT5GEBBA4QdRAOBOrrdebo9fZbFx4NDHkYNPBwYd8cfIzSWUnlq6HDh7BuiennoI8DggbjIFyksAqxbiBDioym74uHin4uZoSzUVFHKi0TvfwSoEGgBiXj6ILIExYw/zoxEc2UEvTQUC4fCAAExIDAuDjWsGkbSbXZt3BP3xQ1dBTK1kJdtaxAGcjBCo3u4NGRR4/luYQ5vb7lGFcLBbWBIFB40+9fwIEF23yFggHBkMJINGwYE9bJ4EFhEwS+IBEKiQlMkC3tIqDAAyIVBAxYMiFYEslCKHehaBFjlARPP2QlOteKAgmGARyQgESFBsZ1HdeWWXcFCiEogiexEIEJgQHQF0QhwORBc+lCMjgYUICDkggWlBhHrnzKyT8qp3sQosrjcCoKQhwAgCEE7/oHSvwGoQADffkgCAGCBi7kZkVjTTwmSFgXjCAbBQUFYAAKBZHQggF1KUjdEQt0Jv+AdNAJcc4ABAjw2RAdFiNdAcVsloJ0DGCWBIINPhjhhBVeWN4RNd20YxH0hNfeBRIGEFiC702hgAL6haDBfb9pwAIAGnRgGAsIbFBCgAewoICBVSDIhIKBNGaBAQbAAMAK08BgAAAjkHCBDEhoWEAEoxHhwDkCVGSMENQ1NQBeAOwJQJ+FbocdAC8CqoSYZ6a5ZptvxjlnFElt5kdTsznXDwDtJQfqccJlsSQCB8zHGwAgyLfqAQhoMB8ACJSgG5gH/pjEVqEJQOgRGfyaRQFhKmdAC0KMsAp14aDGY5JFADTABJqmMIS1fwKw4YZEWCsEtsNx0ECf3B4hJgDHJrv/LADNHunEWIOYBQV1AewyzQhD4FsqFkveCgBvKoTg36sIoCqEwbBqca4SRWWA5wMF5IlExF6UGwWC7WmbwMa3zNnCCO4OQaYQFA/BLXXZbmvEyYe+x8CgNs24Y8YEcNyxDB+HvMRdg+g1LwD9tMfyvlf0OwRvB5xAH8EAxLCYAi74m8XCuyZZrnQZsFiBEANE8I3EADDwQGcPQOA1QCl+CEDa2EE8TxFsAwDdAycSgbE6BtAJQDASeVAZEY8xgHajQ0SwddcAcJBB2NsuKoThcjeXrRER1G3uzHjrzbcQfj9xmRLQDeC4EBCMDgbYRZT2xIYBUDBNC2omgCzRtilA/wRvUh6gAtMndNBBCIslPLWudSZ5ZwWbbb0AtQIxsEADYE8r+gQfclCRoYhiX1EFESzQVBHaH5pCBpaLqFzGF7TggQfIqu/BWc8uIVABDZQPAYsFwLN8ARlsKEADixvC/VgEj8lxjUXQGsK50Oe+9q0Pfk5gjhJKJIAJ/CpYZSAWEsCzutQoa29oMoBpkIQGKwHHCkVZAAe+0QAQZS0FA1AcyaKnQYpxh1HXwuG3AAA5bRXBWzg0oN2IF4WR3YFqXBjMhipALAEwwIkPkJbX8uREJ9qNiRlYgANsGIECOABGY+uOiITAxB4eiohaMOIVXNCBWYkBifFTwp4q0AB4RP8sWyU74AzlRiyWsaxkFmOZEBWIxieosQ5wTGMCfQgA62irRRGLkeCo9UgrmuwzZ4MAZiAAEOvJbQLTAwh16Oi9uiUyC4fkwykBlyTvPG5si3veAJgoBOgR4YYAsCGxIIc4XjYnA+dYgMV82TIkrJKEhDgmChdZogxYkJG5jOFbBOAdizmqmD5UYQQaQCxcUow6ZiSkGlK5B2WCKkkOmAD9gsnNbY4mAw1wgC2H4M3R3HCA+QMAPvWHQIvtE5tGMCfDFlnOQmJBiSG6ZjSz9SdrMjJlAGgABxZww3r6MI/iTIMa3fiFDfzmCuYkpx6OOYIWyGCERRBpHAR6hJKetHj/EwTSECIGgZjl06H+ewt1CCAdiPFxjyhDCV5YagSXopSVUFgVGDSgAiyElKALMqi2CEBVCqDAArNRKRQG6VSpTpCqBLAqVpGahEDOdDT/G5dCiZBTRz1AnVv8aTSzKc9iZJQLYA3rVbMKVVYdwD5C0EAJkiYEBZxAd4XFQH8AoIC/LuawhBXsAWyHARBswHaF3cAG5IPZJTy1EQXA0EPymtf3qWkwTCxABTqkQIpWYIsQYCJKHsC97uWyRQzY4olmCVvZklFrExNtT1xBWrCa9pyFCO1wX1Fcqh5XQScowQYwcJ8OYGADCZOA0koQNQlMFgMqsN1hpTTdAMVAMVEz/xgLojQlE4Y3M15FLiOUO9rmYigYX9FkKSNqT5t0hgEQSAEmP8O/xDXHAYoC5QIqd6gCAFjAPCzbBPZ7BPoulxXNJcB95SuIB2j4wq3I8IYVVAKl/QsALphsY223KoMpNQZLug0GYlAgIbBABVmi1XxcEAIAhGBAXooPR40Z38FoMAqCa8MxS7sCNZH1CAxIAQfy9IDrfQaixQRkMe/HNcnpVEROlDLqhlgx4zY5pX3FwwTiiwQmO1lkUBUeb+JTMAQM7GCqOlqdDaPYNgJgAy4ogdMMtgEWFHoDCLBSwT76qCIzcwp0OwIureBQMk9BrJ2CsxKeyM1vBRjM1/yTlv//hMsbYvlPnD5yEYhaBEzDNJl76YKr46iE926ANwgwdGBPDAAVdHcIB4galTDgn1vTSgiKnpV8eryB8+7as46OaSO9CJAoyg0eCeXaaGh7tkNRD61eBNEAIl1G/W3xiyQykczA8JUkC1NE1AP1Q89BMe4dKoCNoiY2c+ruSrNaLl0o3RMibQQIGENYdiNAeNCgIOxOdlUgaGMHlObd3y1GqVryXQkwIPEAlcB3TTUYlSTgHypJvLPrdk9MrUNRzIi6IhgVdRY9+QDoMQCYAKClAMbHbe9NOALeqQAnn4Nw87E7gfOrnxCagp1T05ub+ZxfbBsQT+k4Penlu+sZtAr/rKKbq5UVoOOYFUiBWG89zUtQKhw+W1Ye5il/3MmtTYAIal3KNQXHQNlbIrCnCg7AAYZbSqW1nkS0N5IsSsAoGP5tSMPrs4tbOxQWhWDtzkQAHrn1zNK3aNcGf9FuCUwHBRZuBq4LQe1vYHub5zpXKVcgA7QE/VwrqsHnhA6b3QldTx0AQ2gS+ehQoCQTFP8FxtOOCc1bwDe3BvRorlCfW1Mwg21pKJzHPmx+IbIFzF4G0yMy2m2X4fIeR6yaDkfU9uymTV1ZwGk2Z20vy845eNpo4CeTzVNQIweK4SFG3jBiNVc2+qRBXVNToIZ3xrBEl1d/o3d2+bBMMaVFVBd5/54EAKC0avSWfiTjGQtGdV42BPBEP6lWAFYHQCnnBd7HBsaHTE7QJ6EjSnpkQ84kGgQYMRrUUKFDRWNHZtvngFXgG1SyGFLAVJwBfnRhf2mwAGPzAKbzBCvIBBL0BNOCHfCwIRngHTQlHbSUbxPVKDgnRvr0BBzELqQ3BlqVMEAoBSK3BarnEvj3amkAAVPWGcWSCzIycNzUAFtDAPTzeRFDR/QDD3RUdY3UAF4TTNtkiPKWBKoDAD3YfY53MCVQAljCKv7RWPrxHwcQIKxCIFmCibNyWJlYWQiAci1ohG6IhFTAbRGwFG5TbdKCbWAzePC1BjxTBbQoBj4zBA1IBv+pxHHXZUKwEmhUojRYoiVc4iUI8F4gMB/RNV2GhgAxUAKm2ARtSByqOAX8o0IVwXLTkmUwJzECEEBT8IRMAC+4yAbyMgSPaIaR6AJN5S+wEnEDQiWzUitS4zQ6BgAlEAJLgiVreDGoiI00EYlFYHd4QjIQEHfypEM8ZJCEZwaZEgic0mplmI1NYDQJkzDLqIz3OB9yhme6USAFg2hD5oQDKRRvSGtUYHclQzGuB3tHpmrluJJEETN/gBNG0I7sEImHhWyGASuKAQA/qY9QIzUm9JNMIgTTFZBblZJGYZNFEIVVYHfiJyNdpE9qpQVjuAbnkRLrcQS92JNToAK/I4z/CNA7B9ABv9E7Fic1VdKPs2KWa1kYJ3mKEAgXYPA5VmB3EqiHQlCBF7hWU9CIa8AafHAROiMEPFmQD6hyegkGt5gX3HeY/qApdSAQroEEY+mYkQkTEJkH5rgmiIceEOQG7fAO8TAPO9KYXZCCc3CNKhkGE8kUTiEHUZENVbGbynAV4uAEnfmaoYkHIcV/vHmcyHkM0iAGPQIIOlkHOwFiPfETUOCaWwCbcmBODCGd3NkTf2MSpakH6bESO3OR1zmcRySV+4CYe6CY5AmFlXmej/meVtAXmEkHmrmY9GmRnnmE+3kFqel1bMAW6lkK1nlQ6GkHo2kPuTkVVYFAvOmb/5n2n5xpngdlnMmZoQ9aoO8ZnTyBJstFnRQaQfGJBdvZnSjaEN85ooLBoSyqBMH5ojKKgi46oztZojaaoyhUozrKixbao0BqSDwKpAcapEbKMEMKpDF6pEzKI0nao0XapFKaMVLKBUtapU1KpViaBVG6pUCqpV56BVcapj0KpmRKBUXqLKpxpv9ppmwqBVc6HgAgKm9Kn24qBLAhBLJRp0dwoDXyARACKjiyNzrCp8Jwp9oSloj6plcaKWrCJgDgJnAiJ3pjqKaAqEECKtNAJBiin15apOkCJ+vSLpZ6Cpj6KaEyDQFAKnx6pTRjM0CDMyBTqqWAqaBiL3CSL5Z6oP8ZkzdCsDkA0Dm0Ogq2GjTTMDSGuqQMtD4O9D7DSgq2CiquAwCwAwCyU6pd+qz2EK0NMg0kEEJHVadjqq3b+qRNmq3keqjm2qTjmq7q6q7ViaPw+q7zCpw/Wq+Xuq7nKq/4Cq36yq732q+isKgCy5j8WrCdQAF5pS8IK5YB27CagAJ5NTsQO5UHW7GXYAF5VakY66Md+wlJAVbhirHo+rGS4AFVZbL8qbKbsAJUxaosW7Is2wgwQFUPC7HtOrOPQFUT+rEyq7OKYABhCbRkSLSWEACnqbM/a7SFQAJvRrQ5y7RSmwhLO7Vn4KEp2gsi+qxRa7USeQ26qaFUIaHPWrX/XksTabGabTGsXXu2X2Cff7GZhmq2bosF7CmectuqP3qiWdu3srCiR/qVrUGrvIqhYnu43LCcVdqcOfmvTYC1fjsLW3sGypqg31eltfkHFQkVYOugiNsNZHsG1omdK+W4noCOZZG0bBCgaquvMUq6a2e6CSugLWMM9zk1mjcEobGDpHOxYwC3eJCfZuCasJt6srsJfDlBujcd1XEdILgdYIgEhqkGd5sH7lkGwVm8brCgBvp+0mYEcZNQI1IilhM3COQiMHKHR9CVqDAZgGsFgpuYQ3sa7oumsfYU2qtkx6sJdpKQesInfvJlgkIo4YNgonMt2EGLCCKndJpGOOkH/8+ZBAzsVa4jsexhuXTAvdAKVdIifDu0Q1hmTUAELkUgLuRSf0nwp4EqIRRCqBiCKUpBkbeZwg4CqDfSwhbywknwAQYAVreQvyq4v5lgRBglSF/mewqld0bwMgZ4gkjgqJMSqZVCqVGAuoCwjsuBJo9KKZN6KUhQsxvLYamYpQTlboTzOIfTHDL0PdoyOsTEVRGGwkoQqsqiCsyyAs7yBJNpBMtbBAJHBju4i3M8O3XcDuyCx57aD3l1HFpVZyV3bE1wl8MzpWWch/aDP/qjTv0jIiYoQJgMUAfUeU5cJ+pQMxwTqznjOeq7MsbwTESAQWRAk0QwvU4KKLDqMbOKBP+K7FxiLAUSsCQdIGySbASox4ZCjAlAfEJL0KuaY62c87596r1HsERN9ERiI0X+W0WaIgBYpEVcFG5hE0au9BZlFHk89LDM/KvOHKzQDAAfMAJg1ctR0GKzYjtpKR8f1YwCc3qaOIogUIp1SMZggTmp0UDU+kAA13aN1Bx86ESRxDyU1NCaQgCY1IqapE+dVBHSszwwSEpiE5EppQ7pw6wH7axLQALwXDNahRu1YmJzdgAeFQOsIl25xs8YwF60Mo3ViJKUPNDjxEzj+EzcEjEcME3VNM3yRh3a1GkWBU7mDNJfAMYysNJLIh/8rJG1khsH8BsQ5yr7mCs9fX8/rbz/EjPUA8BQ84fU+xZRE0V7QMV6llYGGtsCKz0EJjRnmAUrwpNdvbbPuDbMeCnQepBklzPWCm0yZ9XEN6XWEEV/PtXUhyJUUM1urjOcq1Jod9YvzYZiTVVo/ExY1PXVAc2kxZuLUEBwAVWgRgWHao3Ye5RWRyxTa/1WXtRNNTQaSl1Xc7GCq20EyWHZqdIBnDhnLLCWSrNZvuPSVFLcuyPaVKDBxFoblgcBEHAiDOAdrJgi4zx56fYZXZPN3bxFo+HNn0dP21ZbS7GCeTVrF+zTXbDee/VkXGA0agDdAzsXzxdbC5Bvi7ON4hJK2sJ8HDDAkiRJ2lLRAIYZzSd0suff/yhhYdKZYc+FwWsA4SAm4WdWvPSdBvYdChsRgGrhAJ9BSXY3VxtyQxtS1CJy1GsNeMiDgbNXQ8IV4fYVAPhF4WngYTN+4TV+4/N5pC0xADOoTxNgbzH+1j/VVsWk5BtSZb2nQBkoV+ptZk8rz39QAKqLBW6GZj9upBshcLFXAINZ4t+UHdUkHYpdhUktN/LX4Bp4Rl7A3lzOBX/cBKhNBAbnK4+Sy1sg5/ItBUA4lEMYj8Yc1jmXh2pRc2clV9/UhyW4OLAdal/2PyziOOgn5Y5LurBsjWAndjOytj5IBWjIaFDglF1l6Ecg4k1g2sWX6Y5nNqolIpPXSAAx3WGjW/+bh0AiAs5QPiMS27MY2QS1QomGAQKXmB+/gR+cOCAFcln5EYrITh//vNPQhurRssqHjQYdrmlPkHzLx0NYGEPNEVsWKDrTNxrVdw7X1zwygwIw64uRCIwbgJbEqAHGmCVbohvKyIzOKF0YEI06LQXb/gnJ/EauDgX7Zwx2deLEAoD1Aw9cFjlN/CcIKAAKKKDp0CAjG+xLAI9CsJEIQI9Rco+2Ijz6aDD9+I8FA9hyDOQ4zuEH74TbAR0w+FMy+G01iEs4eHuHwrtGJyGh/gRY7S8d+SUfKTX0PJJ1ZpLPfcyXcEiy7AWhMeDVrlGGN4Wkw0hXGE1gTixcuN9YQ2//7MfTDdLOhScFPwkAaDmURfk0USM8STkfS/lndtn01r56hLkFJZMB4zZhLT+80mznebiHjh5NgFhHh06INXeIa5OI7wfHhbNwdEsbZXmWQZmWEteWvgM8cNkBcikEdGldph7YpA1V3R3gXiQE3jwcYkM22QFcDXZ5MWIoiz7KZZC8VMDqYGCYbZuX/ln6yEd0Bx7HtoRz9GRByyOIa0Mt+b1aEiUxA/DAha0GeywFuu8FgmytgeqOXR6kZDI0B0c9faJqOj8iLzRuD79HIlLetl8GVmyaRaDDzPnysXv3rZ1T0R86hFL+dAQEEEBhABhkJoJhETBsPqFQQSBatV6x/9cPgZH1fsHhKIPwiSZGF/EaGlCy4XF5czq33/F5uRtMWDQJ6AQWUoQADJsGCpoaIAQyABYaBiD+KhYLKtjq9NgCGjpDsxqoqlBQRKv4UlnFOFthY2MtIsAEGiADAQSUIBoKGt4SU4CVJAsiJit+GwGWF5e+IixkszwcqjsdPLTKYlezw1/DycvFSCZaFWUnSMyhLq7f47bVrlZavoXnWcf5/+dRQBRqHSwIFAACiNegS0IsDBp4sHflwogEsMA51ONPY8dWK7B5FONghcYABBwM1AjBAYFSXgIYwLhP5ByONXHe2dIw5xUyZjR+WEFhQgReR5EmVbqUadOkESZQWP8BFAwFaqwy9tz0UmvXOJ+8ViGFk4SFAGfRplW7lm1bt2ktuGNjASHWAk7x5tW7ly+vAlzDBgYjT/A2wYebeJDBKsFbx48hR5ac9iJiyxQJe613OTCaiZxBh563kCdOiBJFezUAOHVr11hRqnTI0uVrrR9GULW9m/ccoUSN9lVa4K5wpVCl6u7t8dRy58/PmZ281sDq6WvjQseJW65279/znAXPO+Z48+fFiEffumLl9e/hq4cf2gI3LwmAflA+n/9l+f0vs8oLAuz7D8ADAzMQwcBgoOCzKlyiRrwLYgrgwQUxdEjBDLtaLQsC4gFAPBSoCAAVDlEEaMMm8GtCvxT/AfIMi0ACkA6AEZ7AEcYdy1kRAAKb8JFHWVoo6YpA4hFPlx+HbFIWHyMUkQoKV7vQSVG22A+QICmgogUYAEggnyvJDAXKEEcs8cQyWcHnyCYqooKE6gzojs0792DtCRpt1PFGPFNpD9BBY6GAgEMJ8BMKJD1Qck9CzZQJ0kk7QQFRAsaMQpcAugTgyzAzpdSOCygAU9RT5bDg0sUghHMEOem0E9U46JrVVjG2QFTWW2Xx4CpegbXCg0PrCrYaGY1NFoAVDl1TWVg8hKOx66it1lr3nk0FhkN/zZYVEnKDI4DijCvXXOP+8raVQ7VUV4/mPKGptZvcvcMA++pNBbd2/7HIal49850jACMDFqW8NfxNjd6C4SDBVIY7ETQ9eRUGGOKLAZIBXzASFm3hbElIQOSRSS7Z5JNRTpnkXRkWMIyOQ/vYWAtaIGAC4nDOWeedee7ZZ50nwLTbgmt9mWKPLQ62wQkeKC0hBh6I6uGCo/0CZtBkvhWFFB7Q6oEUnM0XWZiOZgMDBJ44+woNNpAla1QX+qMrSVAruEiOy15DAQnQBuAACa5QQQO3k7YVhQbk9kqSsN3N0uq8xVAghAMAwCAEwC0/oITBQVAAg8onB6EJEDRwoW873hZVhgkSD2uBCVh9xwI6aa/d9ttxz1333XEf+g54s7g6cgU2D0EDzP8H14AFADToAG0WENigBNEPYEGB020q/NSKmDhsgDTmMVHl8ckv3/yUSQxF4n4hD0OB6w+gHHAAQJh8/gMQ0IByABAowW/sUac91UHDMgWIXY8E2BMhfUVS7MvD+/4HAMCpIASfux8CELC/DEYwD6mbFAU0IYtKiKICxUJgaBYIB1JhSxXtAwMEnwC4A5ygchcEQAzapgAXcBAPHiTUB1IQhQJwoAkLKEDX5NC0JhBBDrdoQARaB4AU8AsjCcxJCuFQtCsIz30KgALglHcAFdjwBB3oQAjahr+NWJFQMCAgIBAHAA4koYgDiOITKFEFJi4BAoiAwABKw4DuPcEQDiD/IhQKMLVwYFGBbBSDy6zAxVA4j3DKygoBHqCE4jgjGA3QhACgUgAjZsABIWkCBFLwiyEUIAMN6BoHHHCLTzbAAREwZRQyQBMf6oGRV3RkGMYWBUnmwQUd2F8sdgmoS0oik7wAAEMAAJFdiBIAGUBiM56wRyYW5BAcWIQzmVSF1zktmXjoJU7OuYaqCdOFiCnnnS65ixQswJlLCgQ4gYGzgWizCOt4AC4c8M03LOkJzKzCO+2QTpEoNAzgstIwD4PQMsVzAZ9UwgS68LpdvCECSNQjE7a5CD8YQaBbgoJBD/pLc6o0DzagwR0YGgbgtaGdTTgmKzYwuDtIlEzxfIIz/0E5AKNs9JRMO8IgHZABTYT0mRyoQARKGs4n0HIAeZQCSxOawB3wwAQ80EEcbmADKJhABDDF6hccx841zK8VGlBBD8/aU11CoaqJEAAT6toEBnBAACEsKAeIqESoRUIAHIBA1/Kqy6N4lA5JS4A9LsBCgQlwBzl4KQB20AQaiOCymuWsZ8UKAJc2wQY2IGsTZvBZT8QVJpKiiiRBcIDLNUEDJZhhExRwAjHiFgOeA4ACZNs23d62tgfwIgZAsAEv4nYDG5jccr3A0ytBFCcfW8GJ0hceAeIgtE/oAQ9ewIMeAEAEOMjBDXAgWhy8IAeZPW0OdHADH5S1BiYIr1hNoP8DH7zAaqzNQkVkYAA/cfEEJdgABjDXAQxsQI0SoGEJdigB42JABV7UrfIOLLoYsG2HG2RB8pZHyQp/QbpOom5NPlYR/ThIRAZAgRpI0IJ19hcMbH0CD2YAgBnwgLwmaAJZX3ADzQKArD3IwY85m14AGJnIQuaYf7HwgWEdSi5cLAENJQgAFxgXuF6c3wbZGoP37Q0DMTBdE1iggujxj3IuCAEAQkA660nuplcocZNOLBKZzc4AYFoBFWAgkxGQ4AIHpPEXJNDZJrAVcCLwMZFFMAMTmBe/IngBfyEtAh+YgNNCPu2TYbGtVQWpfWrMsuQwiAALNgHMMUw12nprTAD/bMAFJcDhBjfAglxvAAHOw6BOs3DnIeVZhIMMtvYMMKZXnSUQUnkswgSYgxo84aU4yDEN0utoJGuWvZDegZPJagMlP+HTh2ZFPC41Ji6OeAOAQ4CuaZtlAKggwk84wA6Zh4HPtZt/TfD1/ib35g1sON7RhfKwa5qNDEQAErbQnnoIQDKFyKAF4HuZAMX9AhHUIL3sFUEO+Kttb2s8vpCeAQ56wPGy6iAHG/d0WUENC3QfSkdcZLBx5wcCY3aAhhI+Y9vYKj0zlgADOxddCcz41g0yTwKfY97OoYsFYfOI2ITs3gLyWoWsQ6GPj3LFw0thAFa5ozIekGy/EkiDGryg/wY5Jq/GUTttALRd7WxvQtt1rHG8L/kFO8jx3s3dipkTwB1Vj4KNEzL1HQ1zAKBwxiJKmQFqBqOVgMgAAZZBylsOoZSLeAABWBmGrKnnAi3wgAfyYXoPECzmnInpGsB1qMUY/oseUTyMIDoBIXS0AiHJwCGxPokfaaLxRYRC75vgAE0QlMQHT4/zzfF62I+AAKigfU5unyKIPsABDEiHAG5GnAcY0SgTKMKSHEAMvxKVqMw3+Dukn5D4n2MECLl+daGP+5oSIpdyvOUjluj8oqACgugJuK8JrEmqHA7+ME7RvmC0niT/sABcPoC6NEgOQEB0woBt4CD7UIS6MmCeIv8hGAYAsJZhAMBPAI3AAUrQ8YqIaaLmD9zv2BgQDMoNC/buBtfg0VovG0KGuu5HDmAIDASnAyXwAxPuAIsok8bPGe5KiYShAgorihYAsOQm4W5vNc4uSAqntHQQtLYN0korC1KrCSLNDJ9ABLorko4weFwotmbrt2Yt4Nqmf0qgbzzHczLHuHAruPgHATIQCkDgc3JLthYwWagLo2wv/xBlBFpABpRDSOBLvkRABHhsyUwg49rLBnyAq4jMBG6AB2qABnzgpUiRBsKL5VjuBXwgxwCHBnjgBnTgq7aoDR3ICwrswOYHcCAMAE5AAzCABfRNGCVowigpBLxoxHTrt2L/QAU00KbQRgKO7hmlzhYxBKIGy/ZQ4HzO51IQhQJQwALUwEeYDNIAgLsAQNqCbMg+7bS0TQcyawe+6tIWrQnoEXBuANMcsA2sMZLa58rqMctC4Mo+xwWWS4fkrXlwy4vE7H0AZwjtLRoXsvksKeFQjAB4JyNrxxsb8RGlBAvo0RxrQAdOTscmLQcqbdu0rSStDQBCcn7u0Rxhoh9b6AtMbRdHJwRiAAFgCIK+bH988tV+K+qgUd4g0s5o8kDu7x8EgPBEwRu1kB+x4Nu2jRTzkdq6rR3LSuRA8dFe0h75C3CkLfAWqX3YDSf7psIU0m8GZ34Grm1G7N7i7SgjaH7o/zKlKrIV3uinxECJgq36nnL1YOChLObkUg4HYE6+XmoHSE7I4mu83PHRekACYO4rXTIsyQvlesDJ2BD+2ufm9qYeFcCYDiCHzGi52ErnSqAEvEjoOsB/6LLBJvL9ELF9BImuZCMSrIoJBKkhCOqPogCQAjC6LMVKfGMmyVDv3G4kNWvt5I4GdiCz8G4G5K4kzbAyr9MlUavv3K4zo88iw8IDOeRqbmHhsGGUSskIfoEAICAJIoCIAuGfbuGwQA8SIo+aCMAoUoABUEmVqtEjySGdWhIOdEDuOmH+xAU8vUI8M4Q83wCjEvCZ/kj3dqHhZHAIQuhCncH34FMQouHYGv/khMSAOuUA08wkKWmKNxj0GvMGnxThF4jjj6CBAQqgKIQgEAZgAmhJQ8EPZ7pGF5xpj6oRAEolQFE0FRA0XlT0SPnDQZsAozqKrt6InmphSRjgPcMJljTFQ4UUKUUkVCIQDiBQDmhgDSfLM/kBgGjrrQIoL6WOCARgEdrzAY6qIPhqAJKKSRyATj0JAIxKEu4KsMLJmZJq/fDyArwhGxTqtMIqDkTOrNCUHNiqzliNUrfCTe0sljxqr/oqmpBoAZiQDqLpTvWqU0FVAJrwDeqqCg/JSwEgu6rhnLywrEZrs7qrDK1gs3qAB9UwTyJ1DhDgBCZncDJncyoHBHgSAST/QAFE57gmx1iXLnsw1QrACftKAQ0WyYomcb7EcL3ayyVBEceITL80Drw4DQBoABRnkby4CvHQ7leFsDQ1IAYqB8T4JwZYE8HyJ8swwF6jtYmYdD6uZutQ7CV8RVETqBxPC8icjAaw7e48zcl4QKy07QbkbmLLy0yDJ2CvD4bUqH7+hs1iaGTpx35Etk1rM2ZeYnYQNgxCcmEj7SRtQOS07dPmp2a5itNmlgd7sCzvwGMRgIJWLVoZbd4qKMv+NQ5WdEGWkh9eoSJYxmC0CtzK6tNQMQesswe+6tNKscfS0UC99vngNQ4gaOD8hoYQ7GQlqG2y7LbSNmmNcFpFIRvn/+CfgEE2xuG6YjWBDFPlRk4ESs6+vqtqE1MHANfHxK0GROAGKpFnyVJRFRQKFIAFDoDnmIdyx0htR/OtwAhz3c1S12BpESRh/uiOCsqODmEgbpOkTrd1sO4Puu6UUFdungovnwA3jPNArWgGlHPuZqDuDHTtlrM7a2AHbKA6GXO8SFRsv/NniTLxAjY+5KWWKi8TGKGqiqKVMqCVuqY8bQkA0u+IlkGWjCB7cYF7wZfhXBAAlPCqokDswhQ0khRhIvcJ7pIpo/c9/GWk/uABaqE9WTca1gGcMKogoEmaCoKp+PcJvOmO/CFEvyF/tWts/0Vu5YgYHpQB9jSAmcpFC//Cnji4nxaBAzA4ETbvp1iDAraQlyR4pSi4Yiy4qIRAAByAdUKYdQlYkKBBETUqgUWYkCh0dW23DRjnRFGIY+t3A9kWC/StE0T3QGhBjyqgAniYAFQVGjoYTheBAVKAEoJqqHyYdTOBiruAbqMgAgwNANIKK1oYUps3FoowCwJxjZQlAdIhChxBAHhCET21CQSrezUVjwRACFCQN5Hojw+BFxrCjKFgAs4OVpG0jbPqha+AdM5Mt6BVWA9AA3TrzeiHEDVncIaLhjAIdA5AA0GgwIju655lBJymCto32JKYDRhAUaAgAUxIao+Ykq2geq4nF4NRuQ6gX2NgGv+n1pj/5xd1DbmGEgCgR3qoRwVozZMPMVlQAHL80gsIFpmKuAkgSZflF4nFwNRKABknlydRcyLxR+dIp3LMDA8VQH9YzX/UCG6HVFlIQAQRgxCiFgBYlo13+Y3BwNTuLdWUK52buZ5VwHoqZzQp532WboPqGXSpVZLPAwVqATEioJtdhYoEhgI0MqRFeqRvp1ME2ibx0H9mrbcQGoLwhwN1q4n5DYJw6Ld2aKJZ+VkqgrG84gEsDgtmqhM+gBuJuqiNukVO2gtMbd52jqUD0qWDdeeA0eiauYx+LoLs2VWfBVx4uid8up9v96fzpWkXUV3AJQNMtyMWIAMGLQwMwHfUhaw7/+KJM+QDDIBp0vofQHUCDMCjoaA+GEauNYKuOSQBDCA/+6qqFHuxGbuxHfuxIVuxpTACMHKFscAiCkawHYKwUeQDzIKkQZt3asSvt4ijYxhpMCY1tiB3U3Y3ODu1U6EFLFpgZxn/YFs0cDlgNBt6b1s0irRedhsgXru3OyHA7iM/SHu6yOVcmLu5mSJdiJszVOxDCmS2bWNarCW7tdsxLDu6uwIFWA9CauQjqcRCvPu8ncShZgRNqCB9TAS94ZtH3npGRKRPciS+8RtFAPtNkoQKQDi/AXxB2toKNqVTPkVMAjzBAURvCdxVYKU6wFrBJVw7VnvCLXxIAPTCNZxDIP94wz18QX77w0WcPyhuxE0cPhA1uU98xW0DvFn8xb8DXGB8xqHjYGn8xnfjn3F8x1MDamkltIE8yIV8yGkHrnmcTRjcE1gwspm8yZ38yaE8yqVcsR3Auo9cNHA3Qa9kuK+8N+BXSZ2Ey7t8Nzp8YrbcysccNFQYzJtEzNP8NQIATB/nzN8cUFKcfum8zvEEkuccDlQgfqZHFtxKFJhZadFczxEDW80cDtTIcqhZAwBI1ayA15zuD58A0tsmp5qA15a4ctS0CdTmCSRdbS8V0e/ExvEmDpb6GEPgz4EOGT/Mb3QynjsAuJKrAyjozQZSBTpAZMtoNGloNAeSmnHrjMr/uXJwnQ918pTj1tTZRMf7nA2W+n2EtQnoTd7qx2/YVMFmbSd7fdbWFtw3iNuLrpnlzX7T2RnRjNcomjadnUymO9UZ/XR0aHLjh9l/koMk7N7hLAZuywX83YtaTTQRGt3rkaAxqN1p8N3LJKhvUdr7JtcwwM0OLyc5KAYq/QlOgF5p68M8bN+WB4YQT+ThTAMVLKspkuHJJMujfQ0Kmp1nrdYRwAUiLJUpydR07gQKDAFCYOZ7fYZOQBg3iHj6x4tIXnLTuddOALjceV9LXeWvZL5bXgw6R4cqfQM6J7kkqHOcbhAv/X1EWYfaRgPe53MKPVlZDQ+joJTlsKGfkSeB/y2nod5JtMgNYcFdK3jur2TNyQYWnjfv9R7PTJvU8jzwh2SNt6i24UDTOcPNDd8y+Lwms+HsFf4L5tgcHP/xDyO37R4WRj2iS3PNaOvTr6CJLR3URb8fDl3zeyLE/bEViu7PvWjZkZUFSmChmyAEWr00JWiMQGB5yqxyQl4BNgDXdZ9+jKsD4j4UMp/1A8O4H14U1N2Z2b1SobHa5y3CsEwYi0nn3wyiv725lscXVToVmt/5vSLeX58VEB70odHe40d02CoELqzCmnX2/f0EEMDf4wcIVIAhsWg8IouCQLLpfEKj0im1ar1is9ott6tFrZoBgfcYAg07GMRhyB4eEP+ukFFCBKnohwMGoFAQncRosJQ1LRkmKi4yNjo+Qi6SjFwkjTEidJwotGHEIGi8AcRtdCjIuQDYDW1InACodAz9IYTIyYaUIOAxIkb+AgcLDxMDG1hYkjFiKKC5KWhgOIP0bYA0b/gVpQJIuyEAbLpkhyu49C36Fq+zt7u/A1t4JMPXP6nb5+vv87uPJCC51E8fvoEGDyJMWCUAioDKFLYrCHEixYr6PhCoZESgwQ0I0DkB50iixZImT/5qwWTjQ30ahGBgoeBEGyerGpFEqXMnzywJKBzhyMijhiIairL6SMRjtaJ/3BABVeTjzV4re2LNqvUJBRgsHRFSUCLVHgX/HdBoMHUArcyxb1iwOKDBzoYDeeiUylM13dWtfv9ildHiayMFQgBki9OtkBrEMQB0EOmxzVNVsJx1eMltr6KcgD+DVniBwIciQhVhOMCiRFHFliXs2WM5KmVAlg90iK3BNedEnkMDD64PBYoAI0gAOL1og9hR4GICiAEyOsg3le2UcDakxKvZOPsKDy/+HQwDBM4DVG7IxakQQuwiKAEIhKYTJfzEAeHCum07hEAgoAICJ0TmQm+G/Daeggs2YsF5D8qQXEuKWNMMHLQQocEfSCGAjTcIiGQbBux11yEzjyTIoIorctHCgwQwoV4jrlmUIos34ijFBRQ8aICEwVBj/5KNORJZpBGTnOejjEYOaaSTRDp43o9WMAABFAtYyQWWZWyJRZNPgskiCuddsGQTC0yQpRMDFNAFm2W86SV4YdJp5AUeEJCAmUkI8AARAwyQBJsLDLDAEISqiQQEahJaQZtHLGrEAAwAwECgQ1iaZZxXfFmnp+F9MAIMeyLRwKENZOCAAwAUEOibA6SQQQYNYDmBABFwMICpADjKagGz+qmrAAW0qWsBBLCq6qMERCCArQ5EsOoAzUaQAQCbWtHpp9uGNiqpRkCw6rW7GtrqtcU+6sADAlgLgKFpAhCBn+a+2YCVr8JbgbgOVAAAsgAIoMy/lQ6ALLZVaMutwn+VOf8hFAM85EAKBfRLL7pDBMxAARNEYOUDDjAwwRAW+zvEq48GjDEZ/6ZcMgQNOCCAwY9yOufCN4v3bREQG1FBCqy6ejEA6h56q7uxKkNyCoaePMTHQ2TgJ8sCs9pvyQdTkTDOW++kcxG7DuDAAByYKgC/ERQ7QQUPTLAABwKE3W4GS48cNACphi00mg+wbejUQyCLdwYzu0uAoVnbzLXif3lNhNhDVCAAB4a6zQEEfjLAgeaUr+un0+IC8AClDHj+gOWYe+7u5hibfKkybzNABum8gj6F1ovjPlHjmNLaxQSUEpPBpYjnXrxfu0NutRazF5Oo7YkbH31JyC94u/TX20P/vT3DU2Hp4cRjH75F2gfjcBEDH8E3EhU0IIDzUVgvvvzEkO/upEQQCvwU+RdhKRHoH8Fg+iMCA4DnvbrJaX4KRMjuCiAx97WvAH6CgK1w1bJ/EWBwbHrgy4blJwHALFqhI8CvkkCAmMHLgSkIGBkeUAAQLioFDaAZ+BZow300sF0NoNQCftaASy3ggoCzWgkBsMOjAYxqJWvCv55WxIChCXIRAFoCb2jF7JnPCebyF7GItUSVAS6MCORiF5MoRgAa4V9v2mLAYNVFa20xW9C7Ih2D0cBLpWCAeSSCEL+4xT3yUYloPN/nqJhEChohjgibYx0b+Yg7Oq0BFajAFIc1/wDT6WoAgxOjIR8gSUqacYkTeECgJJnGB7AvUGwkA7QuCcdAyWqRjpylMHYnOiJAIGCa6pOh1hU71jlNf7l037VchykBVCCKRuiTAIB3y2JCTnKUuuURa0jLazqifsKIHJdoKIX4YTOcTtBmMBjwPS0N8JuMFCc7rUDO4ICznfKc0me6pIV4zpOd72yCNxPRzzX9U5b5HKg7s2iFSBHqcMNLKAG59wSEFspkSeDfoQbQqy3gk6DXJCexZnWrDIjsahwDKcZ+dUQVOqyj7atWSJGlKgBQcFERDFYEA2pNjeJUDAadAsmoSDigKfMBcGzXEXpqrn81wJP9OmIPjXgvm/8+L6dS1SkXjBqon7YqTmt0KBGsusQFEEBgXWyTGqGqzqmilTBa8CpWJxVSfRmyqHbzqdMK0DtADoFuWJNjWvtKzyyw9VwIfGEqqRjLIgSWgkGcolJBiTcHmBV+6/RrO8l5S+bdUnalc2Yzg2nEdF52swADgOWGUNphZsl0l+NCRim7wH12YQGRjchkXRtO2KLTIK21rfxw+5nd8jZ8vq1Cogr4jogiAbjBvd47M/C+0TbBdErYKRecGwUX8qm2y3Wkegjl0Psp6nAQGN4giRABA0JMGRTFFFeHMF78DUBNgHKveJ0XqSE87gjK3a7x1NO+WQGuWXmM6dBWZS5VZaD/AAt4AAkTbLUfVmqKpH2hrWA6U4ChSoTGcqkDElyrW00OVS81lwMhOzKTeo4BEl6mdvlLRxkRCsJ/Y58n6wbXu3FgiQ+YIiJJ66emmpGpP2vZ7waQL3Fl4G3tivGhgHZjflFxU7tisYvzqRzZNmsCVwXj3egGNGd1UWpE+B3RjGgylK1srKHMKsomEGaNccxKEqPYl5WRsp6yKrktrvINlcMuBP5tATP0XKs4ULsvmq1tMBXXy8CI11AW+VGGPsJiieAzoD3tbvOaa571u2c+v9ZhqXTWls2Iqx5aqVWChpvmADDKQIFVGdYdQgM44KgWfrKSrRqWYN3VvrFpDm4dzA7b2Eyl6lH2LcqPkq2eQV1Z80XukpRSBqAgkGOY5viWC+ZlpZA5hN/RughuI+WlUAuwmKU4ddt+wALWHc3JhY6Hq4t3pTzXp2Y7W5zDTUKmuWk76iai0fjONzb3jYRnWmG+wCjtwAlOS4NvZb8OXxjEtSLxiXOr4lm5OMY/pXGscLzjdfp4T0Iu8jAF4EUqXznLW+7yl8M85jKfOc0/ffKb4zznOt85z3vu858DPehCHzrRi270oyM96UpfOtOb7vSnQz3qUp861fcRBAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from US Dept of Health and Human Services. Depression in Primary Care: Volume",
"     <br>",
"      1. Detection and diagnosis. AHCPR Publication No. 93-0550, Agency for Health Care Policy and Research, Rockville, MD 1993, p. 20.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_3_20543=[""].join("\n");
var outline_f20_3_20543=null;
